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1. Introduction and aims of this thesis
1. History of PsoriAsis
Hippocrates (circa 400 B.C.) was one of the first to describe a group of dry and scaly skin dis-
eases including psoriasis, eczema, red flat lichen, tubercular lupus and leprosy. In the times 
of Hippocrates, psoriasis was known under the names of lepra and psora, as well as alphos 
and leichen. Consequently, society believed psoriasis was like leprosy, mange (scabies) and 
vitiligo and psoriasis patients were isolated, did not receive medical aid, wore specific cloth-
ing and had to carry a rattle or a bell.
One of the first historical mentions of psoriasis dates back to the Holy Bible in the Old Testa-
ment, in the books of Leviticus ad Deuteronomious where reference is made to the “Tharaath” 
as a skin condition and leprous disease.
Herodotus and Plato united the group of the skin diseases, characterized by peeling, 
dryness and itch with the Greek term psora. The Greek philosopher Celsus was the first to 
clinically describe psoriasis (40 A.D.). Around 200 A.D. Roman physician Claudius Galen used 
the words psoriasis vulgaris (common psoriasis) for the first time and from then the term was 
used to refer to all skin conditions accompanied by itch.
Beginning of the 19th century, the English doctor Robert Willan described psoriasis, its 
manifestations and complications and distinguished two diseases: discoid psoriasis, called 
Lepra Graecorum (Lepra Vulgaris, Lepra Willani), and Psora Leprosa. In 1841, Ferdinand Von 
Hebra and Moritz Kaposi definitely set psoriasis apart from leprosy. Other dermatologists of 
the 19th Century such as Polotebnov, Pospelov, Gebr and Koebner studied psoriasis in depth 
and considered it to be a systemic disease. The association between psoriasis and arthritis 
was described for the first time by Jean Louis Alibert in 1818 and he named psoriasis Dartre 
squameuse centrifuge of Alibert. Pierre Bazin described psoriasis arthritique in 1860. In 1937 
Seghers and Robinson considered psoriatic arthritis as a clinical entity.
2. EPiDEMioloGy
One of the first epidemiological studies on psoriasis was conducted on the Faroe Islands 
in the 1960s reporting a prevalence of psoriasis of 2.8% in the general population.1 This 
prevalence has been confirmed in studies conducted in other western countries.2-4 A recent 
systematic review mentioned that a total of 53 studies to date have reported the prevalence 
and incidence of psoriasis in the general population and concluded that it varied according 
to age and geographic region (psoriasis being more frequent in areas more distant from the 
equator), the case definition of psoriasis used in the studies, environmental factors, ultra-
violet exposure, genetics, historical migration patterns and regional variations in antigen 
exposure.5,6 The prevalence in children ranges from 0% (in Asia) to 8.5% in Norway with an 
incidence of around 40 per 100.000 person-years in the United States. In adults, the lowest 
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prevalence has been observed in the United Kingdom (1.3%) and the highest values were 
seen in North-East and Southern Europe (5.2% in France) (Figure 1). Several studies show a 
first peak at age 30 and a second peak around age 50, suggesting the existence of an early 
and a late onset form of psoriasis.5,7-10
3. PAtHoPHysioloGy
Psoriasis is a T-cell mediated inflammatory condition of the skin. A combination of environ-
mental factors such as stress, specific drugs, trauma or smoking and genetic factors trigger 
a series of cascades in the skin involving the innate and adaptive immunity, which interact 
together to form the process of inflammation in psoriasis. Plasmacytoid dendritic cells 
and keratinocytes produce pro-inflammatory cytokines such as interferon-α, interleukin-1, 
interleukin-6, Tumor necrosis factor-alpha (TNFα) and chemokines. These activate the my-
eloid dendritic cell, which in turn present antigens and secrete interleukins leading to the 
differentiations of Th-1 and Th-17 helper cells. The T cells then secrete mediators that activate 
keratinocytes and induce the production of antimicrobial peptides, proinflammatory cyto-
kines and chemokines. These processes maintain inflammation in psoriasis (Figure 2).11
Continuous research on mediators of inflammation in psoriasis, such as IL-12, IL-23, IL-17, 
Janus kinases (JAK) and phosphodiesterase 4 (PDE4) has become important for the develop-
ment of new targets for antipsoriatic therapy.12
 
figure 1. studies providing information on prevalence of psoriasis in adults.5
Circle: period prevalence; square: lifetime prevalence; triangle: point prevalence.
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3.1 Genetics
The fact that genes could be involved in psoriasis was first mentioned by Farber who ob-
served that the incidence of psoriasis is higher amongst relatives of psoriasis patients than 
among the general population.13 The lifetime risk of getting psoriasis if no parent, one parent 
or both parents have psoriasis is 0.04, 0.28 and 0.65, respectively in a questionnaire survey of 
more than 3000 families in Sweden.14 Early onset psoriasis has been associated with HLACw 
allele encoding for a MHS protein.15 To date, 36 genes have been shown to be associated 
with psoriasis in European individuals.16 Many loci overlap with those associated with other 
autoimmune disease like Crohn’s disease and ankylosing spondylitis.
figure 2. schema of the evolution of a psoriatic lesion from initiation to maintenance of disease.
Reproduced with permission from Nestle et al11 Copyright Massachusetts Medical Society.
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3.2 Microbiome
In the past years much research has been done on skin and gut microbiome and exploring the 
role of imbalance of bacteria in contributing to skin diseases such as psoriasis.17-19 Staphylococci 
and Propionibacteria have shown to be significantly lower in psoriatic skin compared to healthy 
skin.20,21 Future psoriasis therapies could include treatments that modify the microbiome.
4. CliniCAl AnD HistoPAtHoloGiCAl fEAtUrEs
The most common form is psoriasis vulgaris and accounts for more than 90% of all cases.23 It 
is characterized by thick, red plaques with white to silvery colored scales, predominantly on 
the elbows, knees and lower back (Figure 3). The disease severity can vary from a few plaques 
to involvement of the entire surface of the skin. The scales on the plaques are a result of 
hyperproliferation of the epidermis due to multiplication of keratinocytes which multiply so 
rapidly that they move to the upper epidermis without losing their nucleus (parakeratosis). 
This results in thickening of the epidermis referred to as acanthosis and also elongation of the 
rete ridges. The activation of dendritic cells, neutrophils, T cells and macrophages leads to an 
inflammatory infiltrate in the epidermal and dermal layer. The accumulation of neutrophils in 
psoriatic epidermis is referred to as Munro microabscesses, named after William Jon Munro 
(1829-1908) an Australian physician.
The skin of psoriatic patients is prone to develop lesions after local trauma, characterized 
as Koebner phenomenon, after Herry Koebner (1834-1904), a German dermatologist and a 
student of Von Hebra. The vessels within the papillae are dilated and tortuous and when pso-
riasis scaling is scraped off, this leads to bleeding spots, called Auspitz’s sign, after Heinrich 
Auspitz (1835-1886).
 
figure 3. « Psoriasis nummulaire sur le poignet, en nappe sur l’avant-bras, avec arthropathies psoria-
siques de la main et des doigts » (original title from Précis de Dermatologie).22
The description of psoriasis according to J. Darier, A. Civatte, A. Tzanck:
« L’élément du psoriasis est typique. Sous sa forme moyenne et commune, c’est une tâche d’un rouge vif, 
bien circonscrite, couverte de squames sèches, nacrées, lamelleuses, friables, abondantes, tache non infil-
trée de base, et non prurigineuse. »
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The other types of psoriasis are less common and include guttate psoriasis which typically 
occurs after a streptococcal throat infection, inverse psoriasis involving the body folds, eryth-
rodermic psoriasis and generalized pustular psoriasis including the acute form referred to 
as Zumbusch and the generalized pustular psoraisis of pregnancy.23 The localized pustulosis 
palmoplantaris, which is characterized by sterile pustels on palms and soles can be accompa-
nied with psoriatiform lesions on the body, although this presentation is often considered a 
separate entity, related to smoking.24
Psoriatic arthritis can be considered as its own entity but is also often seen in combination 
with psoriasis vulgaris. Its prevalence among patients with psoriasis ranges from 6 to 39%.25,26 
The diagnosis was based on criteria established by Moll and Wright, Vasey and Espinoza and 
Bennett. Moll and Wright described five subgroups of psoriatic arthritis on the basis of clinical 
observations: distal interphalangeal arthritis, symmetrical polyarthritis, mono- or asym-
metrical oligoarthritis, spinal disease and arthritis mutilans. The recent CASPAR (ClASsification 
criteria for Psoriatic ARthritis) criteria were developed for the purpose of clinical research.27 
In patients with psoriasis, this seronegative arthritis manifests itself as asymmetrical inflam-
mation of the joints, which can become symmetrical when arthritis persists. In more than 
three-quarter of patients, psoriatic arthritis develops on average 10 years after the onset of 
psoriasis of the skin.28 In the remaining patients, psoriatic arthritis occurs prior to or at the time 
of skin involvement. In psoriatic arthritis, the distal inter-phalangeal joints and nails are often 
affected, which enables physicians to distinguish this joint disease from rheumatoid arthritis.
Nail involvement is caused by psoriasis lesions in the nail bed and includes pitting, oil 
spots, onycholysis, subungual keratosis and red spots. The prevalence varies between 10 and 
80% but a recent survey among patients of a psoriasis association indicated a prevalence of 
nail psoriasis of 66%.29
5. tHErAPy
There are very few skin diseases where the therapy has changed so dramatically during the 
past 25 years. Psoriasis and other skin diseases were originally treated with arsenic and coal 
tar. It is only beginning of the 20th century when more tailor made treatments such as the 
Goeckerman regime (combination of tar and UV) were developed to treat psoriasis patients. 
However most patients were very much encouraged by their physicians to seek the sun well 
into the mid-1950s. Figure 4 depicts a timeline of the different psoriasis treatments.
Presently the choices for anti-psoriatic therapy are numerous and depend on several factors:
- Psoriasis related factors: type, disease severity, localization, disease duration, presence of 
psoriatic arthritis.
- Treatment related factors: previous therapies, effectiveness, side effects, contra-indica-
tions.
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- Patient related factors: age, gender, comorbidities, physical and mental health, patients’ 
preference and compliance to therapy.
5.1 topical therapies
Topical corticosteroids have been used for more than half a century in psoriasis patients. They 
are more eff ective than placebo, however their long-term use is limited due to the possible 
side eff ects such as skin atrophy, hypertrichosis, hypopigmentation and striae.31 They can be 
used as monotherapy or in combination with phototherapy and other systemic therapies.
Topical vitamin D3 analogues, developed in the early 1990s, aff ect keratinocyte growth 
and diff erentiation and inhibit T lymphocyte activity.32 Vitamin D products are more eff ective 
than placebo. For body and scalp psoriasis, vitamin D and corticosteroid combination treat-
ment was signifi cantly more eff ective than vitamin D alone or corticosteroid alone. When 
applied to the scalp, vitamin D alone was less eff ective than both potent and very potent 
topical corticosteroids. Vitamin D derivatives cause local adverse events such as burning and 
irritation. However the combination with corticosteroids seems to be tolerated as well as 
potent corticosteroids alone.33
Head to head studies with topical corticosteroids have shown that Vitamine D3 analogues 
such as calcipotriol are as eff ective,34,35 except for when calcipotriol is compared to a combi-
nation of potent corticosteroids and calciptriol.36
Coal tar and anthralin have been used for several decades in psoriasis patients, however 
they are less commonly used due to side eff ects such as skin irritation and staining and to the 
superiority of other topical treatments. They are often used in inpatient setting.
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Science is finally getting to grips with this enigmatic autoimmune 
disease. By James Mitchell Crow.
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Science is finally getting to grips with this enigmatic autoimmune 
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Topical retinoids such as tazarotene modulate keratinocyte proliferation and differentiation37 
and are anti-inflammatory38 but also cause irritation and erythema at the site of application and 
are therefore not commonly used (tazaroten is not available in the Netherlands).
5.2 Phototherapy and photochemotherapy
Traditionally patients with psoriasis were encouraged to seek sunny holiday destinations. 
In some countries, healthcare insurance would remunerate a stay at the dead sea. This was 
considered as balneotherapy. The use of UV phototherapy was derived from this practice. 
Narrowband UVB and PUVA cause depletion of cells involved in the pathogenesis of psoriasis, 
including lymphocytes, macrophages and dendritic cells.39,40
Narrowband UVB has proven to be more effective than broadband UVB.41 The dose de-
pends on the minimal erythema dose (MED) and patients are treated thrice-weekly. PUVA 
monotherapy refers to the use of 8-methoxypsoralen which sensitizes the cells to the effects 
of longer-wavelength UV light and can be administered topically or orally.42 Exposure to 
more than 350 PUVA treatments greatly increases the risk of squamous cell carcinoma and 
basal cell carcinoma.43
5.3 systemic therapies
In the Dutch treatment guideline for psoriasis, fumaric acids are the first choice for the treat-
ment of moderate to severe plaque type psoriasis. However methotrexate is more favorable 
with joint and skin involvement. Ciclosporine can be administered as monotherapy for 
periods up to 2 years, however long-term treatment is challenging due to adverse events.
Fumaric acids inhibit the proliferation of keratinocytes and mediators of inflammation in 
psoriasis.44,45 The treatment is only registered in Germany and used as first choice in patients 
without joint complaints. Fumaric acids are used off-label in the Netherlands. A randomized 
controlled trial showed that fumaric acids are as effective as methotrexate in the treatment 
of moderate to severe plaque psoriasis.45
Methotrexate (MTX) inhibits the dihydrofolate reductase enzyme. This results in the in-
hibition of thymidylates and purine synthesis, leading to the impairment of RNA and DNA 
synthesis. Originally used in rheumatoid arthritis, it has proven a very effective treatment 
in psoriasis and psoriatic arthritis with a PASI 75 (reduction in baseline score for the PASI of 
more than 75%) of 60% and a PASI 90 among 40% of patients after 16 weeks of treatment.46 
Side effects are mostly dose-dependent. The most important adverse drug reactions associ-
ated with MTX are hepatotoxicity and myelosuppression and can lead to dose-reduction or 
discontinuation of the treatment.42
Ciclosporine is a calcineurin inhibitor and immune modulator and inhibits the production 
of interleukins and activity of T lymphocytes. Due to its nephrotoxicity and the possible 
increase in blood pressure, it should be reserved for short-term therapy (induction therapy) 
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until satisfactory response is achieved, generally requiring 10 to 16 weeks. The efficacy is 
dose-dependent and the PASI 75 response is 50% at 8 weeks with a daily dose of 3mg/kg.42
Oral retinoids such as acitretin have antiproliferative and anti-inflammatory properties. 
They have teratogenic properties and therefore cannot be administered in women of child-
bearing age. The most common side effects are mucocutaneous dryness and hyperlipidemia. 
Acitretin is not recommended as first choice monotherapy in plaque psoriasis, however its 
use in combination with topical calcipotriol or phototherapy (Re-UVB or Re-PUVA) has been 
proven effective.47
The first biological to be approved by the Food and Drug Administration for the treat-
ment of moderate to severe psoriasis was alefacept in 2003. Efalizumab was approved in 
2003 and was withdrawn from the market in 2009 due to the increased risk of progressive 
multifocal leukoencophalopathy. Many other biologicals followed: the TNFα antagonist 
adalimumab, etanercept and infliximab and the interleukin-12/23 antagonist ustekinumab. 
These therapies attain PASI 75 response varying from 30 to 80% at 12 weeks. A recent study 
has been published showing no significant difference in drug survival, mean PASI change and 
Skindex-29 response between etanercept, adalimumab and ustekinumab at weeks 12 or 52.48 
As these drugs are being administered to patients, new biologic treatments emerge aiming 
at inhibiting novel and already known pathways involved in psoriasis. Recent examples are 
the anti-interleukin-17A receptor antibodies secukinumab, brodalumab, and ixekizumab.49-51 
Two small molecule drugs are currently in phase III trials: tofactinib (an inhibitor of the Janus 
kinases) and apremilast (inhibitor of the phosphodiesterase 4 (PDE4)). These are promising 
therapies and are cheaper to manufacture than biologic drugs.52,53
Biologic therapies are very expensive however studies show promising results. The next 
step is the approval of biosimilars for psoriasis.54 A biosimilar is a biological product that is 
highly similar to the reference product notwithstanding minor differences in clinically inac-
tive components. Approval is based on an assurance that there are no clinically meaningful 
differences between the biological product and the reference product in terms of the safety, 
purity, and potency of the product. The European Medicines Agency (EMA) have approved 20 
biosimilar medicines since 2006, based on an abbreviated clinical development programme 
which includes a thorough assessment of efficacy and safety according to high EMA demands 
of equivalence criteria but not repeating proof of benefit in every indication.55,56 Physicians 
administering biosimilars, will play an important role in contributing to pharmacovigilance 
of biosimilars by their cooperation in post-marketing surveillance and patient registries. 
Particularly dermatologists, since use in psoriasis of the first European Union approved bi-
osimilar monoclonal antibody infliximab (Remsima or Inflectra) in October 2013 depends on 
extrapolation to psoriasis from phase 3 studies in two other indications (rheumatoid arthritis 
and ankylosing spondylitis).57
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6. DisEAsE sEvErity AnD HEAltH rElAtED qUAlity of lifE
In the past decades several tools have been developed to measure disease severity in pso-
riasis. These range from instruments used by physicians to patient administered question-
naires. Some only give an indication of the extent of the lesions (Body Surface Area [BSA]), 
while others also take into account the character of the lesions (Psoriasis Area and Severity 
Index [PASI] and the self-administered PASI [SAPASI]). A recent systematic review showed 
that the Physician’s Global Assessment (PGA) was very reliable and correlated well with the 
PASI.58 The PASI is the most commonly used clinical measure in research. It’s response distri-
bution is low because only half of the scale is used, however due to its widespread use, this 
severity measure enables to compare outcomes between trials. Newer simplified scores, 
such as the Simplified Psoriasis Index, attempt to overcome the limitations of the available 
instruments.59 Finally, the choice of instrument depends on the nature of the study; an 
Internet survey would request patients to report the number of palms (BSA) or the SAPASI, 
whereas a clinical study would more likely require the use of the PASI or the PGA.
In order to address the impact of psoriatic disease on patients, it is inevitable to evaluate 
patient reported outcome measures (PROMs) such as those measuring the impairment of 
health related quality of life (HRQoL). Mild disease could have a profound impact on patients’ 
HRQoL.4 A large number of instruments have been developed to measure HRQoL in psoriasis 
patients including dermatology specific questionnaires such as the Dermatology Life Quality 
Index (DLQI),60 the Skindex-2961 and the Psoriasis Disability Index (PDI)62 and generic instru-
ments such as the Short-Form-36 (SF-36)63 and the Euro Qol 5D.64 The former instruments al-
low comparison between skin diseases and the latter generic instruments allow comparison 
between all diseases. Commonly, the combination of a dermatology specific and a generic 
instrument is recommended.65 In psoriasis, PROMs are a cornerstone of systemic treatment, 
giving treating physicians tools to assess treatment satisfaction and QoL in their patients.
7. PsoriAsis CoMorbiDitiEs
The first comorbidity to be studied in psoriasis was joint manifestation, described by Jean 
Louis Alibert in 1818.66 A large Scandinavian cohort followed more than 150,000 Swedes over 
a decade (1970-1979) with regard to inpatient hospitalization for all diagnoses, showing that 
psoriasis patients had higher rates of alcoholism, hypertension, infections, pneumonia, liver 
cirrhosis, urticaria, and rheumatoid arthritis.67 In the 1980s a number of landmark studies ap-
peared: the PUVA follow-up study noted a dose-dependent risk of cutaneous squamous-cell 
carcinoma in 1,380 patients treated for psoriasis with oral methoxsalen (8-methoxypsoralen) 
and ultraviolet A photochemotherapy (PUVA).68
A landmark paper on patients with rheumatoid arthritis showed that cardiovascular deaths 
were reduced by 70% in individuals treated with methotrexate and that this treatment 
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decreases systemic inflammation.69 The mechanisms involved are partly due to traditional 
cardiovascular risk factors.70
An association between cardiovascular disease and psoriasis was found in the early 70’s.10,71,72 
In 2004, a Swedish cohort study investigated cardiovascular mortality and showed that inpa-
tients were significantly at a higher risk than outpatients.73 A study using GPRD data concluded 
that the risk of myocardial infarction was greatest in young patients with severe psoriasis.74 The 
interest in the study of cardiovascular comorbidity in psoriasis patients resulted in multiple 
research groups investigating this association in population-based cohorts based in different 
countries.75-90 The results of these studies are inconsistent, possibly due to difference in case 
definition of exposure, outcome and psoriasis disease severity, the study setting and design, 
the methods used to adjust for cardiovascular risk factors, residual confounding and statistical 
power. The discrepancy in the results obtained in these studies has led to controversial discus-
sion in the literature of the past decade.
Further relatively well-studied possible comorbidities in psoriasis are malignancies,91-95 
infections,67,96 non-alcoholic fatty liver disease,97,98 osteoporosis,99 inflammatory bowel dis-
ease100,101 and COPD.102
The concept of comorbidity in psoriasis is based on the hypothesis that psoriasis not only 
leads to skin inflammation, but also causes systemic inflammation mediated by inflamma-
tory markers such as interleukins and TNFα circulating in the serum.103 These may alter the 
function of hepatocytes, endothelial cells, atheroma and thrombus risk, leading to increasing 
cardiovascular risk factors. This so-called “psoriatic march” can eventually lead to atheroscle-
rosis and finally to cardiovascular events.104
Another hypothesis is that components of the metabolic are risk factors for psoriatic 
disease,105 This has been confirmed in the Nurses’ Health Study, where smoking, obesity and 
high wait circumference increase the risk of incident psoriasis.106,107
Most of the studies investigating the association between psoriasis and other diseases are 
observational in nature and are based on large secondary or routine databases using different 
case definitions for exposure and outcome, and it is therefore often a challenge to compare 
their results. These databases are mostly limited by residual confounding (the datasets were 
not primarily designed to study the association and many of the potentially relevant confound-
ers are missing or incomplete), or detection bias (patients seek medical aid when visiting their 
dermatologist, and other medical conditions other than those involving the skin are more likely 
to be diagnosed). Furthermore, disease severity in psoriasis patients in these studies is often 
defined using proxies, such as psoriasis medication (topical versus systemic medication).88,108,109
However, observational studies can aid in generating a hypothesis and establishing an 
association between exposure and outcome. This does not necessarily imply a causal asso-
ciation. In 1965 Sir Austin Bradford Hill established a number of criteria describing in what 
circumstances we can pass from an observed association to causation, some of which were 
also mentioned in “A treatise of human nature” by the Scottish philosopher David Hume:110,111
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- Strength of an association.
- Consistency showing that the association has been repeatedly observed by different 
persons, in different places, circumstances and times.
- Specificity, meaning that the same cause always produces the same effect.
- Temporality, indicating that the cause must be prior to the effect.
- Presence of a biological gradient or dose-response relationship.
- Biological plausibility.
- Coherence of the association with generally known facts of the natural history and biol-
ogy of the disease.
- Confirmation in experiments.
- Analogy assuming that like effects imply like causes.
8. AiMs of tHis tHEsis
Figure 5 depicts the complexity of the association between psoriasis and its comorbidities. 
The goal of this thesis is to attempt to explain a number of the links in this chart by using 
various datasets.
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figure 5. Complexity of the association between psoriasis and comorbidities.
Adapted from commentary by Nijsten and Wakkee.112
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We addressed the following topics in this thesis:
- Characteristics of psoriasis, disease severity and health related quality of life
- Depressive symptoms, clinical depression and antidepressant use
- Inflammation, atherosclerosis and cardiovascular disease
Firstly, we described the characteristics of psoriasis patients and the impact of this chronic 
skin condition on their quality of life using a Belgian database with patients diagnosed 
with psoriasis by a dermatologist (chapter 2.1). We investigated healthcare consumption 
in psoriasis patients compared to patients without psoriasis by analyzing data on all drug 
prescriptions in the Dutch General Practitioner database (chapter 2.2).
After concluding that psoriasis has a significant impact on the health related quality of 
life of patients, we were interested to know whether these patients also experienced more 
symptoms of depression. We therefore summarized the available data on depression in 
psoriasis by means of a systematic review and meta-analysis (chapter 3.1) including studies 
assessing depressive symptoms according to questionnaires, clinical depression according to 
the International Classification of Disease codes (ICD-codes) and the Diagnostic and Statisti-
cal Manual of Mental Disorders, 4th edition (DSM-IV) and also antidepressant use. Estimates 
were given of the prevalence of depressive symptoms and depression according to the dif-
ferent assessment methods. In this meta-analysis, psoriasis patients showed high prevalence 
of depressive symptoms according to questionnaires. We were therefore interested to know 
whether an increased questionnaire score also implies clinical depression as diagnosed by 
the DSM-IV. We were able to investigate this using data from the population-based Rotterdam 
Study, where all participants were asked to complete the Center for Epidemiologic Studies 
Depression score (CES-D) and patients with an elevated score were referred to a psychiatrist 
for an interview to determine whether they had clinical depression (chapter 3.3). We were 
also interested whether psoriasis patients use more antidepressants and have more depres-
sive episodes than controls without psoriasis. This was investigated in a population-based 
study, using the Dutch hospital and pharmacy linked databases (PHARMO RLS) (chapter 3.2).
In recent years there has been a lot of controversial discussion in the literature on whether 
to consider psoriasis as a systemic disease. Numerous research groups have investigated the 
presence of markers of inflammation in the serum of psoriasis patients. We therefore con-
ducted a meta-analysis of the available studies to determine whether inflammatory markers 
are elevated in psoriasis patients compared with healthy controls, taking into account the 
influence of age, gender and disease severity (chapter 4.1). Finally, we investigated the as-
sociation between psoriasis and cardiovascular disease in the population-based Rotterdam 
Study, where atherosclerosis, myocardial infarction, stroke and heart failure were studied in 
psoriasis patients and controls, adjusting for known cardiovascular risk factors (chapter 4.2).
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AbstrACt
background: Although several large observational studies have reported on psoriasis 
characteristics, very few have included severity assessments by dermatologists and validated 
health related quality of life measures.
objective: To describe psoriasis characteristics, clinical severity and its impact on quality of 
life of patients diagnosed with psoriasis by a dermatologist.
Methods: From 2006 to 2007, 192 Belgian dermatologists examined psoriasis patients. 
Demographics, type of psoriasis, body sites affected, Psoriasis Area and Severity Index (PASI), 
Body Surface Area (BSA) and Physician’s Global Assessment were assessed. Patients answered 
questions concerning their psoriasis and completed the Dermatology Life Quality Index 
(DLQI), Skindex-17 and European Quality of Life-5 Dimensions (EQ-5D).
results: Of the 3,629 psoriasis patients, more than three quarters had plaque psoriasis for 
more than 16 years. One fifth had nail involvement and 16% had affected genitals. 15% suf-
fered from severe joint pain and 6.4% reported psoriatic arthritis diagnosed by a rheumatolo-
gist. Despite therapy in 83% of patients, clinical psoriasis severity was relatively high (mean 
PASI 8.5 and %BSA12). 40% of patients reported a substantial impact of psoriasis according 
to the DLQI and Skindex-17 and the mean EQ-5D score was 0.76.
Conclusion: Psoriasis patients consulting dermatologists present with relatively severe 
disease and often report a high impact on their physical and psychological well-being.
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introDUCtion
Psoriasis is among the best studied dermatological diseases. Nevertheless, most of the 
descriptive studies assessing psoriasis prevalence and its clinical characteristics in samples 
of the general population were published in the 60’s and 70’s.1-4 One of the landmark epide-
miological studies on psoriasis was conducted on the Faroe Islands where the prevalence of 
psoriasis at the time of examination was 2.8% among 11,000 subjects.5,6 These observational 
studies provided important data on age at onset and prevalence of disease, family history, 
common sites affected by psoriasis and the influence of climate, stress and pregnancy on 
the disease. Other studies suggested the existence of different variants of psoriasis based 
on the age at onset of disease among hospitalized patients in Germany and members of a 
Swedish psoriasis advocacy group.4,7 A population based survey in the United States showed 
that psoriasis occurs in about 2% of the population and that the majority of patients have 
mild disease that nevertheless may have a profound impact on patients’ lives.8
A European patient membership survey including 17,990 patients who stated having been 
diagnosed with psoriasis by a physician showed that 75% of respondents had chronic plaque 
type psoriasis with a mean age at onset of 30 years. About 60% of the members had more 
than 3% of BSA involvement and 30% reported psoriatic arthritis (PsA).9 The basic clinical 
characteristics of psoriasis of more than 28,000 newly diagnosed Japanese patients who con-
sulted a dermatologist were accurately described in 2003.10 In this dataset, no information 
on clinical disease severity and patient reported outcomes was presented. 86% of patients 
had chronic plaque psoriasis and 1% had PsA. The mean age of onset was about 40 years and 
two peaks were noted, in the twenties and forties. The scalp, back and extensor sides of the 
extremities were most commonly affected by psoriasis.
The objective of the present cross-sectional study is to describe clinical characteristics and 
clinical disease severity assessed by dermatologists and impact of psoriasis on patients’ lives 
using validated questionnaires among a large sample of Belgian psoriasis patients visiting a 
dermatologist in an open access healthcare system.
MAtEriAls AnD MEtHoDs
Participating dermatologists and patients
The BELPSO survey is a 1-year open label, cross-sectional epidemiological point prevalence 
study in psoriasis patients treated in dermatologic clinical practice in Belgium. Of the 518 
members of the Royal Belgian Society of Dermatology and Venerology, 192 dermatologists 
agreed to include patients for this study (response rate 37%). From January 2006 to February 
2007 participating dermatologists were asked to screen all psoriasis patients seen at their 
practice. Patients were eligible if they were 18 years or older, were diagnosed with psoriasis, 
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had provided written informed consent and were able to complete Dutch or French Health 
Related Quality of Life (HRQoL) instruments.
Patients who had participated in an interventional clinical trial in the 3 months prior to the 
study were excluded. The survey targeted to enrol a maximum of 5,000 patients diagnosed 
with psoriasis or the total number of psoriasis patients enrolled during one year, whichever 
came first.
The study was approved by the research ethics committee in Belgium and all participants 
gave written informed consent.
questionnaire
Patient’s and investigator’s questionnaire were used to collect patient data. The investiga-
tor’s case report form (CRF) contained information such as age, gender, age at diagnosis of 
psoriasis, duration of disease, type of psoriasis (i.e., chronic plaque, guttate, erythrodermic, 
pustular, palmoplantar and inverse psoriasis) and the localisation of the lesions at the time 
of clinical examination. The investigators were asked to only report the most dominant form 
of psoriasis.
Clinical psoriasis severity was assessed using a 5-point static Physician’s Global Assessment 
(sPGA) for all psoriasis patients. The percentage of affected Body Surface Area (%BSA) and 
the Psoriasis Area and Severity Index (PASI) were also estimated. Joint involvement was 
evaluated by means of 5 questions derived from existing diagnostic criteria (namely the Moll 
and Wright, the Vasey and Espinoza and the Bennett criteria),11-13 but without laboratory and 
imaging studies. The psoriasis treatment history was assessed by checking medical records of 
the participating dermatologists for photo(chemo)therapy, topical, systemic and biological 
treatment.
In the questionnaire given to patients, demographic data, family history of psoriasis, treat-
ment for joint pain (regular intake of non-steroidal anti-inflammatory drugs [NSAIDs]) and 
consent for participation in a follow-up study were recorded. Patients were asked to score 
a subject global assessment (SGA) for clinical psoriasis severity, itching and joint pain in 
the past week on a 6-point Likert scale. The impact of psoriasis on the patient’s HRQoL was 
measured with the SGA, the Dermatology Life Quality Index (DLQI), the Skindex-17 and the 
generic Euro-Qol 5D (EQ-5D). The scores of the DLQI and Skindex-17 were categorized as 
previously suggested.14,15
Basic data concerning each investigator were recorded: gender, the spoken language (Dutch 
or French), originally from North or South of Belgium, year of graduation from medical school, 
university where dermatology training was completed and type of dermatology practice 
(private and/or [academic] hospital).
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statistics
Results were generally expressed as means ± standard deviations (SD) or median and range 
for continuous variables as appropriate. Frequency tables were used for describing categori-
cal variables. Mean values from two groups were compared by the Student t-test (corrected 
for unequal variances if necessary) or by the Mann-Whitney test when the variable was not 
normally distributed. Analysis of variance (ANOVA) or the non-parametric Kruskal-Wallis test 
was applied for the comparison of several groups. The classical chi-square test for contin-
gency tables was used for comparing categorical variables.
P-values were two sided and considered significant if <0.05. Calculations were always done 
on the maximum number of data available and missing data were not replaced. All statistical 
calculations were performed using the SAS (version 9.1 for Windows) and S-Plus (version 6.2) 
statistical packages.
rEsUlts
Participating dermatologists
Of the 192 participating dermatologists, 61.5% resided in the Northern part of Belgium and 
74.5% were female. The mean age was 43.2 years (± 9.98) and they practiced dermatology 
for an average of 17.3 years (± 9.91). Almost half of the dermatologists combined work in a 
private practice and hospital, 15.6% was affiliated to a hospital and 35.9% worked exclusively 
in private practice. On average, each dermatologist included 17 patients (± 30), however half 
of the investigators included less than 10 patients.
study population
A total of 3,269 patients were willing and eligible to enter this study. This population is de-
scribed in Table 1. Of the included patients, 99.3% had used or was currently using topical an-
tipsoriatics, 62.0% phototherapy, 30.3% a conventional systemic drug and 5.9% a biological. 
The majority of patients (40.6%) received a combination of two types of psoriasis treatment.
Psoriasis type
The most frequent type of psoriasis was plaque psoriasis (77%) followed by guttate (13%), 
palmoplantar (5%) and inverse psoriasis (3%). Gender differences were more pronounced for 
pustular and palmoplantar psoriasis than for plaque and guttate psoriasis. Guttate psoriasis 
affected younger patients more significantly than palmoplantar, inverse and plaque psoriasis 
(p<0.0001). Patients affected by plaque and guttate psoriasis were diagnosed earlier than 
palmoplantar and inverse psoriasis patients. Patients with chronic plaque, erythrodermic and 
guttate psoriasis were affected significantly longer by their disease compared to those with 
palmoplantar and inverse psoriasis (p<0.0001) (Table 1).
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localisation of psoriasis
At the time of clinical examination, the most frequent localisation of psoriasis was the elbow 
followed by the scalp, the lower leg, knee and back (Table 2). On average, 6.3 different body 
sites were involved. Of the 698 patients with only one localisation of psoriasis, the scalp 
(56.7%), elbow (47.3%) and lower leg (29.0%) were most commonly affected.
table 2. the frequency of body sites affected by psoriasis (n=3,269).
localisation number of patients (%)
Elbow 2,152 (65.8)
Scalp 2,027 (62.0)
Lower leg 1,853 (56.7)
Knee 1,621 (49.6)
Back 1,496 (45.8)
Upper leg 1,477 (45.2)
Lower arm 1,442 (44.1)
Chest 1,429 (43.7)
Buttock 1,337 (40.9)
Upper arm 1,328 (40.6)
Back of hand   881 (27.0)
Nail   691 (21.1)
Face   687 (21.0)
Back of foot   612 (18.7)
Genitalia   522 (16.0)
Palm   405 (12.4)
Foot sole   328 (10.0)
Neck   270 (8.26)
Other    98 (3.00)
Clinical psoriasis severity
According to the sPGA scale, approximately one quarter of patients had no lesions or was 
almost clear of psoriasis, more than one third of the patients had mild psoriasis (36.1%) 
and 35.6% had moderate to severe disease (Table 3). In 2,528 patients with chronic plaque 
psoriasis the mean %BSA was 12.3 (SD 14.8; range 0.3-95.0) and the median PASI score was 
6.25 (Interquartile Range 9). In patients with plaque psoriasis 31.6% had a PASI >10 and 32.9% 
had a BSA >10%. Both PASI and %BSA scores were significantly higher in men than in women 
(9.49 ± 8.08 vs. 7.34 ± 7.48; and 13.3 ± 15.1 vs. 10.8 ± 14.5, respectively; p<0.001).
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Evaluation of joint involvement
Of the total study population 26.9% patients complained about the presence of joint pain, 
7.0% scored their joint pain as (very) severe and 6.4% reported PsA diagnosis confirmed 
by a rheumatologist. Patients with pustular psoriasis complained significantly more about 
joint pain than those affected by other types of psoriasis (p= 0.036), but only one reported a 
confirmed diagnosis of psoriatic arthritis.
In this population, 14.1 % of the patients used NSAIDs regularly for joint pain. The use of 
NSAIDs was more frequent in women than in men (16.1% vs 12.4%, p = 0.004) and those with 
longer duration of psoriasis (18.9 ± 15.4 vs 15.2 ± 14.1; p<0.0001), and differed across dif-
ferent types of psoriasis (p=0.048); patients with erythrodermic and pustular psoriasis more 
frequently used NSAIDs (24% and 27%, respectively) compared to patients with plaque type 
psoriasis (14%).
family history of psoriasis
Of the 3,166 patients where information on family history of psoriatic disease was available, 
36.8% reported a positive family history of psoriasis (Table 4). These patients were slightly 
younger than those without a family history (46.6 ± 15.0 vs 48.4 ± 15.6; p=0.002) and their 
duration of disease was longer. Patients with early psoriasis onset (< 30 years) or those with 
erythrodermic or guttate psoriasis were significantly more likely to report a positive family 
history than others (p <0.0001 and p=0.006 respectively).
table 3. Disease severity: distribution of the 6-point physician’s global assessment (PGA) scale for all 
patients and according to the type of psoriasis.
type of psoriasis1 n Absence 
of lesions, 
discoloration
(%)
Almost 
exempt of 
lesions
(%)
Mild
(%)
Moderate
(%)
severe
(%)
very 
severe
(%)
All psoriasis types 3269 38 (1.16) 832 (25.5) 1,179 (36.1) 812 (24.8) 353 (10.8) 55 (1.68)
Plaque 2528 29 (1.15) 647 (25.6) 914 (36.2) 638 (25.2) 265 (10.5) 35 (1.38)
Guttate 419 4 (0.95) 98 (23.4) 163 (38.9) 107 (25.5) 43 (10.3) 4 (0.95)
Erythrodermic 26 1 (3.85) 3 (11.5) 2 (7.69) 3 (11.5) 9 (34.6) 8 (30.8)
Pustular 31 2 (6.45) 12 (38.7) 7 (22.6) 5 (16.1) 4 (12.9) 1 (3.23)
Palmoplantar 166 0 (0.00) 38 (22.9) 55 (33.1) 42 (25.3) 24 (14.5) 7 (4.22)
Inverse 98 1 (1.02) 34 (34.7) 38 (38.8) 17 (17.4) 8 (8.16) 0 (0.00)
1 The distribution of PGA differed significantly (p<0.0001) between the various types of psoriasis.
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Patient reported outcomes
Subject global assessment
Of the 3,269 psoriasis patients, 25.9% self-reported having no disease or mild disease and 
28.5% indicated having severe psoriasis (SGA≥4) in the last week prior to consultation (Fig-
ure 1).
Of all patients, 39.8% reported little to no itching due to their psoriasis, but almost a quar-
ter reported suffering from a (very) severe itch.
Dermatology specific HRQoL
The mean DLQI was 8.68 (SD 6.73; range 0-30) among all psoriasis patients. For 34.6% of the 
patients psoriasis had a large effect on their life (DLQI >10). Patients with moderate to severe 
psoriasis (PGA≥3) reported higher DLQI scores than those with milder disease (10.8 ± 7.2 vs 
7.2 ± 6.0; p<0.0001). Women presented slightly higher DLQI-scores than men (9.04 ± 6.71 
vs 8.37 ± 6.71; p=0.014). The patients in whom psoriasis was diagnosed before the age of 
30 years presented significantly higher DLQI-scores than others (9.54 ± 6.93 vs. 7.70 ± 6.33; 
p<0.0001), but disease duration did not affect DLQI scores (p=0.34). Erythrodermic patients 
presented a higher DLQI-score than those with other types of psoriasis (p=0.002).
table 4. A comparison of the distribution of demographic and disease characteristics between 
 patients with and without a family history of psoriasis.
variable n family history of psoriasis p-value
yes
n (%)
no
n (%)
All patients 3,166 1,165 (36.8) 2,001 (63.2)
Gender 3,164
Male 592 (35.1) 1,096 (64.9) 0.032
Female 572 (38.8) 904 (61.2)
Age (years) 3,166 46.6 ± 15.0 48.4 ± 15.6 0.002
Age at time of psoriasis diagnosis (years) 3,121 28.3 ± 15.7 34.2 ± 17.4 0.0002
Age at time of psoriasis diagnosis 3,121
≤ 30 years 679 (43.0) 902 (57.1) <0.0001
> 30 years 473 (30.7) 1,067 (69.3)
Duration of psoriasis disease (years) 3,221 18.4 ± 15.3 14.0 ± 13.5 <0.0001
Type of psoriasis 3,165
Plaque 911 (37.2) 1,535 (62.8) 0.006
Guttate 166 (40.4) 245 (59.6)
Erythrodermic 11 (44.0) 14 (56.0)
Pustular 6 (20.0) 24 (80.0)
Palmoplantar 41 (25.3) 121 (74.7)
Inverse 30 (33.0) 61 (67.0)
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The mean total Skindex-17 score was 13.2 (±8.32; range 0-34). The impact of psoriasis on the 
psychological dimension was considered high by 40.1% of the patients. More than half the 
patients scored the impact of the symptoms on their daily life as high. Patients with moder-
ate to severe psoriasis reported higher Skindex-17 scores than those with milder disease 
(16.0 ± 8.7 vs 11.3 ± 7.5; p<0.0001). For both subscales of the Skindex-17, women presented 
significantly higher scores than men (p<0.014). The patients who were diagnosed with pso-
riasis before the age of 30 had higher scores of the psychosocial and symptom dimensions 
of the Skindex-17 compared to the remaining patients (p<0.0001). Erythrodermic patients 
presented the highest Skindex-17 scores.
Generic HRQoL
The mean EQ-5D score was 0.76 (SD 0.61; range -0.59 – 1.0). (A score equal to 1 corresponds 
to the utility of being completely healthy and 0 corresponds to the utility of being deceased.) 
This observation was supported by a mean self-related health state (using a Visual Analogue 
Scale) of 71.3 (SD 18.4). Patients with moderate to severe psoriasis reported higher impact 
than those with milder disease according to the EQ-5D (0.71 ± 0.30 vs 0.80 ± 0.22; p<0.0001). 
Concerning the five dimensions of the EQ-5D, the majority of patients did not have any real 
problems, with the exception of moderate to extreme pain and discomfort in 54.1% of the 
patients and moderate to extreme anxiousness or depression in 45.1% of patients. Men 
showed slightly, but significantly higher EQ-5D scores than women (0.79 ± 0.24 vs 0.72 ± 
0.28; p <0.0001). Erythrodermic patients presented significantly lower EQ-5D scores than all 
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figure 1. subject global assessment of joint pain, itching and psoriasis severity in the past week on 
a 6-point likert scale (n=3,269).
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other patients (0.42 ± 0.44; p<0.0001). Patients with inverse and palmoplantar psoriasis had 
lower scores than those with chronic plaque and guttate psoriasis. No relevant associations 
were detected with age and disease duration.
DisCUssion
As expected more than three quarters of the psoriasis patients visiting a dermatologist had 
plaque psoriasis.16-18 However, guttate psoriasis affected more than one eighth of Belgian 
and European psoriasis patients, which is considerably higher than the 2.8% in the study 
from Japan.9,10 We observed less inverse psoriasis than in the EUROPSO study (12% vs 3%), 
possibly explained by the fact that in the latter study the results were self-reported by the 
patients and they could indicate multiple types of psoriasis, whereas in the present study 
dermatologists could only indicate the most dominant psoriasis type. This is illustrated by 
the observation that more than 10% of participants had psoriasis on their palms and soles 
and only 5.8% were classified as palmoplantar psoriasis. As expected, guttate psoriasis af-
fected relatively younger patients19,20 and women were twice as likely to have pustular and 
palmoplantar psoriasis.20 Other population based studies focussed on studying psoriasis in 
general, however they did not differentiate between psoriasis types.1,8
The distribution of body sites affected by psoriasis was driven by plaque psoriasis that most 
commonly involves the scalp, extensor sites of the extremities and lower back.21 In the pres-
ent study, dermatologists observed nail involvement in more than 20% of patients, which is 
much higher than that reported by Japanese dermatologists10 but lower than that observed 
in a cross-sectional survey.1 The genitals were affected in 16% of the study population 
emphasizing the need to examine or discuss the involvement of these sensitive areas and 
their possible consequences. Three population surveys of patients visiting a dermatologist 
reported that involvement of the genitals might occur in 29-40% of patients at some time 
during the course of the disease.1,2,22 In a recent questionnaire-based survey among members 
of the Dutch Psoriasis Society, 46% of the responding patients with psoriasis reported genital 
involvement at some time during the course of their disease.23
To our knowledge, this is the first large observational study documenting clinical psoriasis 
severity assessed in detail by dermatologists. In two studies patients self-reported the ex-
tent of BSA involvement assessing the number of palms affected,8,9 but none of the other 
observational studies included prospective assessments of psoriasis severity by a physician. 
Among more than 2,500 Belgian patients with chronic plaque psoriasis of which more 
than 80% received therapy, the mean BSA involved was 12% and the mean PASI was 8.5. 
According to the PGA, about a quarter were almost clear of their psoriasis and more than a 
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third had moderate to severe disease. These observations suggest relatively severe disease 
among patients visiting a dermatologist, which may be explained by the fact that patients 
with more severe psoriasis and dermatologists with special interest in psoriasis were more 
likely to participate in this study. This results in an overrepresentation of patients with moder-
ate to severe psoriasis. These findings may also suggest that a large proportion of patients 
were not under optimal disease control with their current treatment, which may be related 
to patients’ preferences or physicians’ reluctance to treat psoriasis more aggressively as has 
been postulated previously.24,25
Although we did not use validated diagnostic criteria for PsA, this study suggests that ap-
proximately 5-15% of patients with cutaneous psoriasis have joint involvement. Of all partici-
pating patients, more than a quarter reported joint pain, 15% used NSAIDs to control their 
joint pain and 6% had a diagnosis of PsA confirmed by a rheumatologist. This is in accordance 
with other studies.10,26 Interestingly, patients with pustular psoriasis were more likely to have 
joint complaints.
Among the included patients, 30-50% reported high levels of HRQoL impairment using 
the DLQI and Skindex-17, which is comparable to other hospital-based studies27,28 but as 
expected higher than that observed in psoriasis patients from the general population.8 
Although clinical disease severity and HRQoL impact are different constructs, patients with 
more severe psoriasis reported a higher impact of disease on their lives.29,30 This is confirmed 
by erythrodermic patients reporting the highest score on the DLQI and Skindex-17. Although 
male psoriasis patients had more severe disease at the time of enrolment, women with 
psoriasis reported more impaired HRQoL, suggesting that this latter group of patients may 
benefit from additional psychological care especially at a younger age. In this study, the 
mean EQ-5D was 0.76 for all patients and 0.71 for those more severely affected, which is 
considerably lower than that measured in the general Belgian population suggesting a lower 
HRQoL in psoriasis patients.31 The observed level of generic impairment in psoriasis patients 
is comparable to that observed in other chronic diseases such as asthma, diabetes, rheuma-
toid arthritis, several types of cancer (e.g., prostate cancer and haematological malignancies) 
and dermatological diseases such as severe acne and hand eczema.32-36
strengths and limitations
The major strength of this study is that it includes a large study population and that all pa-
tients were diagnosed and examined by a dermatologist. This also implies that the results are 
specific to patients consulting a dermatologist, which may reduce the generalizability of the 
findings. However, the Belgian medical system allows patients to seek specialised medical 
care freely (i.e., through an open access healthcare system), at low personal costs and without 
long delays, suggesting that the results obtained could be generalised to most psoriasis pa-
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tients in the general population. In contrast to other observational studies on the presentation 
of psoriasis, clinical disease severity was assessed in detail (PASI, BSA and sPGA) and several 
validated HRQoL instruments were used to assess the impact of psoriasis. All patients, regard-
less of their treatment at the time of the survey, were included, and not only newly diagnosed 
patients as in the Japanese survey.10 Therefore, the true clinical and psychosocial impact of 
the disease may be underestimated. An advantage of these less stringent eligibility criteria 
is that we could assess the HRQoL impairment among patients who have been dealing with 
psoriasis for a long time (16 years on average in this study). Comorbidities were not included 
in the questionnaire and therefore patients with skin diseases other than psoriasis and those 
with known mental or physical illness, which could interfere with patient’s HRQoL, could not 
be excluded from the study. Dermatologists were asked to indicate the most dominant type 
of psoriasis and could not indicate different types of psoriasis making these estimates less 
precise and more difficult to compare with other studies. No complete set of criteria for the 
diagnosis of PsA was used and laboratory and imaging studies were not performed, introduc-
ing diagnostic bias. About one third of all dermatologists in Belgium participated and their 
demographics and the sites of inclusion (private practice and hospital) varied substantially. 
These findings suggest a modest selection bias. The cross-sectional design does not enable 
us to describe the longitudinal course of psoriasis, but informed consent was obtained to 
contact participants in the future.
ConClUsion
In the present study, the majority of the included psoriasis patients had plaque psoriasis lo-
cated at the usual body sites. More than one fifth had nail involvement and 16% had affected 
genitals. Approximately 10% of patients seem to suffer from PsA. Despite the use of therapies 
in most patients, the clinical psoriasis severity was relatively high and about 40% of patients 
reported a substantial impact of psoriasis on their HRQoL.
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AbstrACt
The reported prevalence of depression in psoriasis varies substantially. This study aims to 
determine the prevalence and odds of depressive symptoms and clinical depression in 
psoriasis.
A systematic literature search was conducted. Mean questionnaire values and proportions 
for depressive symptoms and clinical depression were pooled according to different assess-
ment methods. In controlled studies, standardized mean differences (SMD) and OR compared 
depression in psoriasis patients with controls using the random effects model.
The majority of the 98 eligible studies were conducted in tertiary centres, without a con-
trol group. The prevalence of depressive symptoms was 28% using questionnaires and the 
prevalence of clinical depression was 12% using International Classification of Diseases (ICD)-
codes, 19% using the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV) and 9% for antidepressant use. Psoriasis patients had significantly more depressive 
symptoms (SMD 1.16; 95% CI 0.67-1.66) and population-based studies showed that they were 
at least one and a half times more likely to experience depression (OR 1.57; 95% CI 1.40-1.76) 
and they used more antidepressants than controls (OR 4.24, 95% CI 1.53-11.76).
More than 10% of psoriasis patients suffer from clinical depression, and twice as many 
have depressive symptoms. The high prevalence of these symptoms is likely to be affected by 
the tertiary study populations and differential misclassification using questionnaires, where 
psoriasis-related symptoms may be detected as depressive symptoms.
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introDUCtion
Psoriasis is estimated to affect 3% of the Caucasian population and is known to have a major 
impact on patients’ Health Related Quality of Life (HRQoL).1-3 The latter captures patients’ 
perspectives and may assist in calculating the burden of disease, treatment evaluation, and 
identifying patients who are in high need of psychological counselling. Psoriasis patients 
often feel impaired by their physical appearance, leading to stigmatization, avoidance of 
social interaction and isolation. It has been assumed that this altered behaviour and impaired 
HRQoL may lead to depression, anxiety, stress-related disorders and even to suicidal ide-
ation.4-8 A study using a structural equations modeling approach, demonstrated the complex 
association between psoriatic symptoms, disease severity, depressive symptoms and quality 
of life, showing that a significant proportion of the variance of depressive symptoms was 
explained by HRQoL.9 However, psoriasis patients may also have other comorbidities that 
increase the risk of developing depression.10,11
The prevalence of depression in psoriasis varies from 6 to 62%, depending mainly on study 
design, study population, sample size, and outcome definition for depression.12-14 Most stud-
ies use validated questionnaires assessing depressive symptoms. Larger population-based 
studies using secondary databases, assess depression with International Classification of Dis-
ease (ICD) codes or measure antidepressant use with Anatomical Therapeutic Classification 
(ATC) codes. Very few studies define depression based on the 4th edition of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV) classification of psychiatric diseases. 
According to this classification, major depression is defined as depressed mood or loss of 
interest for at least 2 weeks, accompanied by 5 of the following symptoms: weight loss or 
gain, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feelings of 
worthlessness or guilt, diminished concentration, recurrent thoughts of death or suicide.15
We were interested to what extent the well-documented impairment of HRQoL in psoriasis 
translates into depressive symptoms (assessed by questionnaires) and ultimately clinical 
depression (assessed by antidepressant use, ICD-codes and DSM-IV). We aimed to provide a 
pooled estimate of the prevalence and odds of depressive symptoms and clinical depression 
in psoriasis patients.
MAtEriAls AnD MEtHoDs
types of studies
No restrictions were made as to the type of study (experimental or observational), publica-
tion date or language.
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types of participants
Studies conducted in adults aged 18 years and older were included. Psoriasis patients were 
defined as those with a confirmed diagnosis of psoriasis by a physician (dermatologist, 
rheumatologist, general practitioner (GP) or other healthcare provider), a self-report of a 
physician’s diagnosis for psoriasis or according to a diagnostic code (ICD9: 696.0-1/ICD10: 
L40.0-9, or OXMIS code). No restriction was made as to type of psoriasis, but a distinction 
was made as to whether studies included patients with cutaneous plaque psoriasis, psoriatic 
arthritis (PsA) or other types.
types of outcome measures
Depression was defined using different methods: (1) diagnosis by a psychiatrist, psychologist, 
GP or other healthcare provider, (2) DSM-IV criteria, (3) self-report of a physician’s diagnosis 
of depression, (4) ICD-codes (ICD-9-CM 296.2-3, 298.0, 300.4, 309.1, 311, ICD10: F32.0-9 and 
F33.0-9), (5) Mini International Neuropsychiatric Interview (MINI),16 (6) antidepressant use 
using ATC codes or self-report, (7) validated questionnaires assessing depressive symptoms 
such as the Beck Depression Inventory (BDI),17,18 Center for Epidemiologic Studies Depression 
Scale (CES-D),19 Hospital Anxiety and Depression Scale (HADS),20,21 Hamilton Rating Scale 
for Depression (Hamilton DS),22 Carroll Rating Scale for Depression (CRSD),23,24 Zung Self-
rating Depression Scale (Zung-SDS)25,26 and Montgomery Asberg Depression Rating Scale 
(MADRS).27 The General Health Questionnaire (GHQ) measured patient’s “general health”.26,28 
These questionnaires and their cut-off values are described in the Supplementary Table 3.
search strategy
The search was performed by a medical librarian in Embase, Medline, PubMed, PsycInfo and 
the Cochrane Database, from inception to August 2012 (Supplementary Table 1).
study selection and data extraction
The titles and abstracts were screened and articles were selected based on the inclusion and 
exclusion criteria. Data was extracted using a standardized form (Supplementary Table 2). 
Baseline values for proportions or mean values according to questionnaires, and the propor-
tion of patients with a diagnostic code for depression or antidepressant use were registered. 
Studies where outcome values were reported separately for subgroups were also included 
(Supplementary Table 2). When several studies reported results from the same population, 
the study with the most complete data was included in the meta-analysis. Participants from 
the same studies were only included once per combined analysis. However in one study by 
Turel Ermertcan et al, the results of psoriasis patients were split into four groups and there 
were only two control groups. We therefore included information on the control group twice 
in order to be able to calculate a standardized mean difference (SMD) for the four psoriasis 
groups.
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The quality of the articles was rated using an adapted version of the NOS (range 0-10; Wells 
et al, 2012)29 (for the score sheet, see Supplementary Material).
These steps were conducted independently by E.A.D. and F.S.v.L. or E.A.D and M.W. Differ-
ences were resolved and consensus was reached through discussion.
statistical analysis
In controlled and uncontrolled studies, pooled mean values and the prevalence of psoriasis 
patients with depressive symptoms according to the questionnaires were calculated. Pooled 
prevalence of clinical depression in psoriasis was calculated according to antidepressant use, 
ICD, and DSM-IV.
In controlled studies, depressive symptoms were compared between psoriasis patients 
and controls by calculating the difference in mean questionnaire values, obtaining a SMD 
and 95% confidence interval (CI). Odds ratio (OR) and 95% CI for depressive symptoms and 
clinical depression between psoriasis patients and controls were obtained according to 
questionnaires, antidepressant use, ICD and the DSM-IV .
The analyses were performed using a random-effects model according to the method of 
DerSimonian and Laird,30 taking into account within-study and between-study variance.
Heterogeneity between studies was quantified using I² statistics.31 Publication bias was 
assessed graphically with funnel plots and statistically with Egger’s regression.32 The trim and 
fill method provided an estimate of the number of missing studies and of the pooled effect 
size if these studies had been included.
Meta-regression and subgroup analyses
Sources of heterogeneity between studies were explored by performing meta-regression for 
age, gender, Psoriasis Area and Severity Index (PASI) and Newcastle-Ottawa Scale (NOS) score 
(all determined a priori). Another method used to address the heterogeneous data was to 
conduct subgroup analyses. In this study, the primary subgroup analysis consisted of the dis-
tinction between the different methods of assessment for depression. In addition, subgroup 
analyses were performed for variables which were significant in the meta-regression.
The present study was conducted and reported in accordance with the PRISMA guidelines for 
reporting systematic reviews and meta-analyses.33
All statistical analyses were performed using Comprehensive Meta-Analysis Version 2.2 
(Biostat, Englewood, NJ, USA).
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rEsUlts
study characteristics
The electronic search yielded 1,815 articles, of which 98 were eligible. Twenty-six studies 
compared psoriasis patients with healthy controls (Figure 1).
In the meta-analysis of the 98 studies, data was pooled on 401,703 psoriasis patients. Two 
studies included more than 100,000 patients each5,34 and three studies included more than 
20,000 patients each.35-38 In the 26 controlled studies, data on 264,568 psoriasis patients and 
1,174,612 healthy controls was pooled.
Embase (1747)
Medline via OvidSP (490)
PsychInfo (85)
Cochrane (27)
Pubmed (38)
1815 articles after exclusion of duplicates
Full text of articles were assessed and articles were 
excluded for the following reasons:
- non-validated depression questionnaire
- assessment of depression in dermatological patients 
and not specifically in psoriasis patients (no values for 
psoriasis patients alone)
- duplicate studies
- subjects below the age of 18
132 articles 
98 studies
included in meta-analysis
Reasons for exclusion from meta-analysis:
- missing mean values or percentages for 
depression
- missing standard deviations available for 
mean depression values
- missing confidence intervals reported for 
relative risks
102 articles
selected based on full text 
98 studies
including psoriasis patients
26 studies
including psoriasis patients 
and healthy controls
Titles and abstracts screened 
for inclusion criteria
figure 1. flow chart of search strategy and study selection.
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More than one fourth of studies were conducted in tertiary centres of which 17 were 
restricted to inpatients and 33 to outpatients (Supplementary Table 2). Six studies assessed 
depression among members of psoriasis advocacy groups. Eight very large population-based 
studies derived their data from pharmacy, insurance or administrative databases.5,7,34-37,39,40
In more than 60% of studies, psoriasis was diagnosed by a dermatologist. Approximately 
40% of studies measured disease severity using the PASI, with a mean PASI of 13. The remain-
ing studies either did not measure the severity or used other measures, or failed to report the 
obtained mean PASI values.
The majority of studies assessed depressive symptoms using questionnaires. Several stud-
ies used ICD-codes and only a few defined depression according to antidepressant use and 
DSM-IV criteria (Tables 1 and 2). Only 14 studies measured incident depression i.e., exclud-
ing patients with a history of psychiatric diseases or those taking psychotropic medication 
before psoriasis onset.
None of the studies scored the maximum of 10 points on the modified NOS for quality as-
sessment. The highest score was 7 points, which was reached by 6 studies, while the majority 
of studies scored between 4 and 6 points (n=67) (Supplementary Table 2).
Prevalence of depressive symptoms
Among the 98 studies, the most commonly used questionnaire was the HADS followed by the 
BDI (Table 1). According to the HADS, the prevalence of depressive symptoms was 23% using 
the standard cut-off value of 8, with a pooled mean value of 5.86 (95% CI 5.05-6.67). However, 
the other frequently used instrument, the BDI, showed that 36% (95% CI 26-46%) of psoriasis 
patients were depressed on using the cut-off value of 10 points, with a pooled mean value of 
13.34 (95% CI 11-18-15.51) (Table 1). The other questionnaires Hamilton RS, Zung-SDS, CES-D 
were only used in two to three studies each. The proportion of depressive symptoms was 
highest in the studies using the CES-D score (n=3) with a pooled rate of 55% (95% CI 31-77%), 
and lowest among the studies using the HADS questionnaire (23%). The forest plot in figure 
3a shows the prevalence of psoriasis patients with depressive symptoms for the studies using 
validated questionnaires (n=33), which varies a lot, resulting in a high heterogeneity (I²=97%, 
p<0.001). We notice that there are a few studies reporting prevalence estimates higher that 
50% for depressive symptoms. The pooled results estimated that more than a quarter of the 
psoriasis patients showed symptoms of depression (28%, 95% CI 22-34%).
Prevalence of clinical depression
The proportion of depressed patients decreased when measuring clinical outcomes: 19% accord-
ing to the DSM-IV and 12% according to the ICD (Table 1). Antidepressant use was even lower, 
with a pooled rate of 9% (95% CI 6-14%) in ten studies (Figure 2a). A total of 49% of patients had an 
impaired general health according to the five studies using the GHQ, which is remarkably higher 
than the above mentioned proportions for depression and depressive symptoms (Figure 2a).
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odds of depressive symptoms
Of the 26 controlled studies, 42% used questionnaires. Nine out of eleven questionnaire-
based studies reported mean values for the used questionnaires, showing that psoriasis 
patients were significantly more likely to show depressive symptoms compared with healthy 
table 1. Depression outcomes in psoriasis patients.
questionnaires reporting mean values for depressive 
symptoms
number of 
studies
Pooled mean and 95% Ci ¹
HADS 26 5.86 (5.05-6.67)
BDI 21 13.34 (11.18-15.51)
Hamilton DS 6 6.50 (4.37-8.64)
CRSD 6 13.41 (11.99-14.84)
Zung-SDS 2 31.68 (6.28-57.08)
CES-D 2 23.56 (20.39-26.74)
MADRS 1 6.09 (4.17-8.01)
questionnaires reporting proportion of patients with 
depressive symptoms
number of 
studies
Pooled rate and 95% Ci ¹
HADS, % patients with a score ≥ 8 19 23% (19-27%)
BDI, % patients with a score ≥ 10 10 36% (26-46%)
Hamilton DS, % patients with a score >7 2 25% (22-28%)
Zung-SDS, % patients with a score > 50 2 37% (29-46%)
CES-D, % patients with a score >16 3 55% (31-77%)
All questionnaires ² 33 28% (22-34%)
Clinical outcome measures for depression number of 
studies
Pooled rate and 95% Ci ¹
ICD 10 12% (8-18%)
DSM-IV 4 19% (12-29%)
Antidepressant use 10 9% (6-14%)
MINI interview 2 21% (12-35%)
General health number of 
studies
Pooled rate and 95% Ci ¹
GHQ, mean value 4 4.93 (3.96-5.89)
GHQ, % patients with a score ≥ 2 5 49% (39-58%)
Abbreviations: BDI, Beck Depression Inventory; HADS, Hospital Anxiety and Depression Scale; Hamilton DS, 
Hamilton Depression Score; CRSD, Carroll Rating Scale for Depression (CRSD), MADRS, Montgomery Asberg 
Depression Rating Scale; Zung-SDS, Zung Self-rating Depression Scale; CES-D, Center for Epidemiologic 
Studies Depression Scale; MINI, Mini International Neuropsychiatric Interview; ICD, International Classifica-
tion of Diseases; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders 4th edition; GHQ, General 
Health Questionnaire.
¹ All estimates were calculated using the method of DerSimonian and Laid and the random effects model. 
See Supplementary Figures 1a, b, c and d and Figure 3a for the individual forest plots.
² Meta regression was conducted for this analysis: age: -0.03 (-0.08 to 0.01); gender: -0.004 (-0.02 to 0.01); 
PASI 0.04 (-0.008 to 0.09); NOS score: -0.09 (-0.28 to 0.10).
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controls (SMD 1.16; 95% CI 0.67-1.66; Table 2). In the forest plot (Figure 3b), the two groups 
of individuals with depression confirmed by a psychiatrist from the study by Turel Ermertcan 
showed the highest SMDs for depression (3.39, 95% CI 2.50-4.29 and 4.00, 95% CI 2.99-
5.01).41 The high heterogeneity, with an I² of 91%, decreased to 82% when excluding these 
two groups, but remained high. The majority of the remaining studies had significant SMDs 
ranging from 0.47 to 1.97.
According to the HADS and MADRS, psoriasis patients were six times more likely to show 
depressive symptoms compared with their healthy peers (OR 6.06, 95% CI 0.99-37.04; Figure 
2b), however this result was not significant (p=0.051). The difference between psoriasis and 
controls was greatest when using the HADS questionnaire (n=3 studies) with a pooled OR 
of 8.00 (95% CI 1.42-45.17). Only one study used the MADRS questionnaire and its primary 
objective was to compare depressive symptoms in migraine patients with those in psoriasis 
patients and healthy controls.42 In this study, depressive symptoms were not significantly 
table 2. Depression outcomes in psoriasis patients compared with healthy controls.
questionnaires reporting mean values for depressive 
symptoms
number of 
studies
Pooled sMD and 95% 
Ci ¹
BDI 4 0.86 (0.36-1.35)
HADS 2 0.48 (0.19-0.77)
Hamilton DS 2 2.08 (0.83-3.34)
MADRS 1 -0.06 (-0.45-0.33)
All questionnaires ² 9 1.16 (0.67-1.66)
questionnaires reporting proportion of patients with 
depressive symptoms
number of 
studies
Pooled or and 95% Ci ¹
HADS, % patients with a score ≥ 8 3 8.00 (1.42-45.17)
MADRS, % patients with a score >10 1 2.13 (0.76-3.27)
All questionnaires 4 6.06 (0.99-37.04)
Clinical outcome measures for depression number of 
studies
Pooled or and 95% Ci ¹
Antidepressant use, % psoriasis compared with controls 2 4.24 (1.53-11.76)
ICD, % psoriasis compared with controls 5 1.57 (1.40-1.76)
General health number of 
studies
Pooled or and 95% Ci ¹
GHQ, % patients with a score ≥ 3 1 0.90 (-0.10-1.79)
Abbreviations: BDI, Beck Depression Inventory; HADS, Hospital Anxiety and Depression Scale; Hamilton DS, 
Hamilton Depression Score; MADRS, Montgomery Asberg Depression Rating Scale; GHQ, General Health 
Questionnaire; ICD, International Classification of Diseases; SMD, Standardized Mean Difference; OR, Odds 
Ratio.
¹ Estimates were calculated using the method of DerSimonian and Laid and the random effects model. See 
Supplementary Figures 2a, b, and c and Figure 3b for the individual forest plots.
² Meta regression was conducted for this analysis: age: -0.03 (-0.16 to 0.09); gender: 0.0008 (-0.29 to 2.67); 
PASI -0.72 (-1.39 to (-0.05)); NOS score -0.51 (-0.88 to (-0.14)).
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figure 2. Pooled prevalence and odds ratio of depression according to assessment method.
figure 2a. Prevalence of depressive symptoms and clinical depression in psoriasis.
Abbreviations: CI, Confidence Interval; GHQ, General Health Questionnaire; MINI, Mini International Neuro-
psychiatric Interview; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders 4th edition; ICD, Inter-
national Classification of Diseases. Questionnaires include Hospital Anxiety and Depression Scale, Hamilton 
Depression Score, Beck Depression Inventory, Zung Self-rating Depression Scale and Center for Epidemio-
logic Studies Depression Scale (see Table 1).
“n” represents the number of studies per assessment method.
figure 2b. odds ratio for depressive symptoms and clinical depression in psoriasis patients com-
pared with healthy controls.
Abbreviations: OR, Odds Ratio; CI, Confidence Interval; International Classification of Diseases. Question-
naires include Hospital Anxiety and Depression Scale and Montgomery Asberg Depression Rating Scale 
(see Table 2).
“n” represents the number of studies per assessment method.
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elevated in the psoriasis group compared with the controls (OR 2.13, 95% CI 0.76-3.27) 
(Table 2).
odds of clinical depression
The likelihood of using antidepressant drugs (n=2 studies) was four times higher among pso-
riasis patients (OR 4.24, 95% CI 1.53-11.76), while five studies that used ICD-codes to assess 
depression, yielded an OR for depression of 1.57 (95% CI 1.40-1.76). Figure 2b illustrates that 
the observed OR for depressive symptoms and clinical depression decreases according to the 
following order, depending on the used instrument: from questionnaires, to antidepressant 
use, to ICD-codes.
Meta-regression and subgroup analyses
Heterogeneity between the studies was considerable (I²>90%) when pooling the mean 
scores of the questionnaires and proportions of patients with depressive symptoms and 
clinical depression. Meta-regression and subgroup analyses were conducted to determine 
the possible sources of heterogeneity.
The rate for depressive symptoms in psoriasis patients according to questionnaires was 
independent of mean age, gender, PASI and the quality assessment score (Table 1). No 
subgroup analysis was conducted based on study location, because this was already re-
flected in the analyses including studies using ICD-codes and antidepressants, which were 
all population-based, versus the studies using questionnaires, which were mostly based in 
tertiary centres.
The SMD for studies measuring depressive symptoms in psoriasis compared with controls 
was neither dependent on the weighted mean age, nor on gender distribution in the studies. 
An increase in PASI and NOS score led to a decrease of the SMD for depressive symptoms 
(Table 2). We therefore conducted subgroup analyses for these covariates. Twelve groups 
were included in the subgroup analysis of which the PASI was missing for six groups and was 
below 10 for the rest; there was no significant difference in SMD between the two groups. 
The six groups with a NOS score below 5 (of which four groups were from the same study by 
Turel Ermertcan et al.) had a higher SMD compared with the groups with an NOS score above 
5 (respectively 1.91, 95% CI 1.30-2.52 and 0.47, 95% CI -0.09-1.03).
There is possibly some degree of overlap of participants in studies from two research 
groups. The studies by Gupta and Gupta, which were the only to report mean CRSD, were 
pooled alone and not included in the combined analysis.43-48 The studies published by the 
research group based in Manchester used the HADS, reporting means or proportion of 
depressive symptoms.13,14,49-55 The authors could not exclude some degree of overlap of 
participants between the studies (C.E.M. Griffiths, personal communication). Including all 
four studies reporting proportions in the combined analysis, resulted in a pooled propor-
tion of depressive symptoms of 28%13,14,51,55 and only including the largest study,14 yielded a 
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similar proportion of 30% (95% CI 24-37%), suggesting little impact of the possible overlap 
of participants.
figure 3. forest plots of studies using questionnaires reporting proportions or mean values for de-
pressive symptoms.
 
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
McAleer 2011 0.07 0.04 0.13
Paloma 2011 0.52 0.43 0.61
Richards 2004 0.12 0.05 0.25
Kirby 2008 0.22 0.14 0.32
Hill 2002 0.27 0.19 0.37
Fortune 2003 0.06 0.03 0.12
Fortune 2005 0.16 0.10 0.25
Yang 2005 0.10 0.05 0.18
Richards 2001 0.10 0.06 0.17
Freire 2011 0.12 0.09 0.15
Consoli 2006 0.26 0.18 0.36
Mizara 2012 0.25 0.15 0.38
Scharloo 2000 0.29 0.20 0.41
Langley 2010 placebo 0.31 0.27 0.36
Langley 2010 Ust45 0.24 0.20 0.29
Langley 2010 Ust90 0.25 0.21 0.29
Dauden 2009 ETN paused 0.37 0.32 0.42
Dauden 2009 ETN continuous0.30 0.26 0.35
Schneider 2006 0.21 0.14 0.31
Tyring 2006 placebo BDI 0.35 0.30 0.41
Tyring 2006 etanercept BDI 0.34 0.29 0.39
Ghajarzadeh 2011 0.67 0.57 0.75
Devrimci-Ozguven 2000 0.44 0.31 0.58
Reich 2010 0.21 0.14 0.30
Mercan 2008 0.42 0.24 0.62
Golpour 2012 0.67 0.57 0.75
Zamirska 2008 with itch 0.39 0.25 0.54
Zamirska 2008 no itch 0.19 0.11 0.32
Akay 2002 0.58 0.44 0.71
Taner 2007 0.04 0.02 0.11
Kanikowska 2009 0.22 0.15 0.30
Mossner 2009 HamDS 0.20 0.14 0.28
Tyring 2006 placebo 0.26 0.21 0.31
Tyring 2006 etanercept 0.25 0.21 0.30
Menter 2010 placebo Zung 0.37 0.25 0.51
Menter 2010 adalimumab 0.32 0.20 0.47
Colonna 2004 0.45 0.28 0.62
Esposito 2006 overall CESD 0.62 0.60 0.64
Schmitt 2007 0.80 0.75 0.85
Kulkarni 2004 0.19 0.11 0.30
0.28 0.22 0.34
-1.00 -0.50 0.00 0.50 1.00
Meta Analysis
figure 3a. Proportion of depressive symptoms in psoriasis patients.
The mentioned studies used the Hospital Anxiety and Depression Scale, Hamilton Depression Score, Beck 
Depression Inventory, Zung Self-rating Depression Scale and Center for Epidemiologic Studies Depression 
Scale to measure depressive symptoms.
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Publication bias
In the pooled analysis of depressive symptoms in psoriasis (33 studies), there was no pub-
lication bias based on the funnel plot, Eggers regression or the trim and fill method (See 
Supplementary Figure 1b).
As to the analyses for questionnaire means in controlled studies, there was publication 
bias according to the Eggers regression (9.67, 95% CI 4.15-15.20, p=0.004). However only one 
study was trimmed according to the trim and fill method, yielding an adjusted SMD of 1.37 
(95% CI 0.71-2.03), slightly higher than the unadjusted SMD of 1.16 (95% CI 0.67-1.66) and still 
significantly elevated for the psoriasis group.
DisCUssion
The present study shows that psoriasis patients are at least one and a half times more likely 
to manifest signs of clinical depression than their healthy peers. More than one quarter of 
psoriasis patients show symptoms of depression and approximately one tenth have signs of 
clinical depression.
These results were independent of the mean age and the gender distribution. The majority 
of the studies included patients with plaque psoriasis, and studies including only patients 
with PsA did not seem to have a higher prevalence of depression.
Eight of the studies were population-based and most of them investigated ICD diagnoses for 
depression,5,7,34,36,37,40 showing a prevalence of depression varying from 2 to 10%. These might 
 
Study name Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Lee 2010 0.74 0.34 1.15 0.00
Guler 2009 0.20 -0.25 0.65 0.38
Ak 2011 0.96 0.57 1.34 0.00
Mercan 2008 1.63 1.02 2.23 0.00
Smith 2002 0.49 0.02 0.96 0.04
Richards 2004 0.47 0.10 0.84 0.01
Chaudhury 1998 1.97 1.35 2.59 0.00
Turel Ermertcan 2006 females no dep 1.00 0.38 1.62 0.00
Turel Ermertcan 2006 males no dep 0.29 -0.25 0.83 0.30
Turel Ermertcan 2006 female with dep 3.39 2.50 4.29 0.00
Turel Ermertcan 2006 males with dep 4.00 2.99 5.01 0.00
Kowacs 2003 -0.06 -0.45 0.33 0.76
1.16 0.67 1.66 0.00
-5.00 -2.50 0.00 2.50 5.00
Meta Analysis
figure 3b. standardized mean difference for depressive symptoms in psoriasis patients compared 
with healthy controls.
The mentioned studies used the Beck Depression Inventory, Hamilton Depression Score, Hospital Anxiety 
and Depression Scale and Montgomery Asberg Depression Rating Scale to measure depressive symptoms.
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better reflect depression in the general psoriasis population compared with most of the 
other studies conducted in tertiary centres using questionnaires, which only assess depres-
sive symptoms and are likely to overestimate the prevalence of depression.56 Questionnaires 
are case-finding instruments and may capture somatic symptoms that are not necessarily 
indicative of clinical depression.
Patients from the studies investigating antidepressant use, represented the entire span 
of the psoriasis population: patients from psoriasis associations, patients recruited through 
internet advertisements, inpatients, outpatients and patients registered in large pharmacy 
and healthcare databases. The pooled proportion of 9% therefore reflects antidepressant use 
in the broad psoriasis population, which is in line with the depression rates obtained using 
ICD-codes.
The pooled analysis of studies using the DSM-IV criteria, the gold standard for the diagnosis 
of depression, yielded high rates for depression. This could have several explanations: it could 
be due to the low number of available studies (n=4), the tertiary study setting, the highly 
selective psoriasis population with moderate to severe disease, or the fact that patients with 
an elevated questionnaire score were subjected to the DSM-IV criteria.57-60 Another explana-
tion could be the discrepancies between ICD-10 and DSM-IV related to mental disorders.61 
A recent study showed that the ICD-10 was more sensitive to the mild range of depressive 
symptoms, while the DSM-IV was more sensitive to the moderate to severe range.62 In the 
case of attention deficit-/hyperactivity disorder, the prevalence was more than twice as 
high according to the DSM-IV criteria.63 Finally, diagnosing patients using the DSM-IV is time 
consuming and necessitates a psychiatrist or psychologist, possibly explaining why it is not 
commonly used in a dermatology setting.
Chronic diseases affect the psychological health of patients, and higher levels of psychosocial 
disability decrease treatment adherence, resulting in treatment dissatisfaction which may 
also contribute to depression.8 Depression has been proven to be a common co-morbidity in 
patients with chronic diseases such as diabetes, rheumatoid arthritis and heart failure with 
comparable differences in proportions of depressive symptoms and clinical depression.64-68 
It is challenging to conduct a head to head comparison of the prevalence of depression in 
patients with different chronic conditions because the studies do not always use the same 
case definition for depression.
We observe that the differences between the instruments in the proportion of subjects as-
sessed as having a depression were much larger in patients with psoriasis. In the controls 
there was only a modest difference between the proportion of subjects with depressive 
symptoms according to the HADS score, and clinical depression according to antidepres-
sant use and ICD-code. A possible explanation could be that the psychometric properties of 
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questionnaires assessing depressive symptoms have been extensively studied, but not in a 
population with skin diseases. Therefore, psoriasis related symptoms and complaints may be 
falsely detected by the questionnaires as being depressive symptoms, resulting in differential 
misclassification and an overestimation of the prevalence of depressive symptoms in pso-
riasis patients compared with healthy controls. Furthermore, studies using questionnaires 
predominantly include psoriasis patients from tertiary centers, with severe disease, who may 
therefore also have more symptoms of depression.
A study by Schmitt and Ford demonstrated a high convergent validity of the CES-D in 
psoriasis patients, hypothesizing that HRQoL impairment leads to depressive symptoms. In 
this study a significant proportion of the variance of depressive symptoms was explained by 
HRQoL.9 The fact that QoL indexes correlate with measures of psychiatric symptoms69 was 
also confirmed in a cluster analysis by Sampogna et al. in psoriasis patients, showing two 
distinct groups: clinical severity measurements and another cluster formed by quality of life 
(QoL) and psychological indexes.70
strengths and limitations
This is to date the largest study to systematically summarize the available data on depres-
sion in psoriasis. The broad inclusion criteria for depression instruments enables the study 
of these different tools and their effect on the prevalence and odds of depression. We chose 
to focus on depression as outcome. Nevertheless, antidepressant use may not be necessarily 
indicative of underlying depressive disease as the frequency of off-label use in medically ill 
patients is quite high, moreover antidepressant use could reflect other mental disorders as 
well. Several studies could not be included because they did not use one of the validated 
instruments, possibly leading to reporting bias. However, there did not seem to be consider-
able publication bias, neither for controlled, nor for uncontrolled studies.
There were a large number of uncontrolled studies in this meta-analysis, including a very 
specific psoriasis population, possibly resulting in selection bias. Furthermore, the question-
naires might have been administered in a specific way to individuals from these studies, 
leading to information bias.
Most of the included questionnaires were primarily designed to assess the intensity of de-
pression in psychiatrically diagnosed patients (BDI, Hamilton RS) and were subsequently used 
to detect depressive symptoms in normal populations. These instruments were validated for 
non-dermatological diseases and no validation studies have been conducted in psoriasis. 
The HADS is the most commonly used depression screening instrument in psoriasis due to 
its feasibility, however a review noted that the BDI, CES-D and the Zung-SDS were among 
the most thoroughly evaluated instruments in primary care.71 Only four studies used the 
DSM-IV criteria, and therefore no distinction could be made in the studies between patients 
with major or minor depression and dysthymia. Only two studies used a questionnaire fol-
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lowed by a clinical interview,59,60 in accordance with the case-finding approach to diagnosing 
depression.56
The appraisal of the eligible studies showed that only a small percentage scored high 
points for the NOS score. One point was allocated to the studies with a healthy control group, 
representative of the average community. Therefore, more than 70% of all studies, without 
a control group or with a selected control group (hospital controls or controls with other 
dermatological conditions), did not get a point for this item.
Determining the prevalence of depression was not always the primary objective of the 
studies included; several studies were primarily interested in comparing depression in psoria-
sis patients with depression in patients with other skin conditions, whereas others focussed 
on the effect of psoriasis therapy on depressive symptoms.
Data from different studies was pooled despite the high degree of heterogeneity, which is 
partly a result of the varying prevalence and odds of depression according to studies. This, 
together with the fact that very few studies were available for some of the outcomes, could 
also explain the large confidence intervals. Meta-regression and subgroup analyses were 
conducted to attempt to explain this heterogeneity.
The results of this study, particularly those of the questionnaires, may not entirely be 
extrapolated to the general psoriasis population. The prevalence of depressive symptoms 
was mainly determined in convenient samples of psoriasis patients from tertiary care popula-
tions. On the other hand, the prevalence obtained from population-based studies could be 
generalized to the psoriasis population.
ConClUsion
In addition to the impact on HRQoL, psoriasis patients manifest more signs of depression 
than healthy controls. The prevalence is highest for depressive symptoms in patients con-
sulting tertiary centres. This could be due to misclassification of psoriasis-related symptoms 
as being depressive symptoms when using questionnaires. Approximately 10% of psoriasis 
patients from the general population suffer from clinical depression.
Although we did not identify clear risk factors associated with psychological distress, we 
recommend administering a HRQoL tool or a depression questionnaire to patients that seem 
to be severely affected by their psoriasis. In patients suspected of depression, physicians 
should actively ask for signs of clinical depression, as elaborated in the DSM-IV classification, 
and if necessary refer them to a psychiatrist.
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supplementary table 1. Digital search strategy.
(last update performed on 20th of Augustus 2012)
Database search string
Embase (depression/exp OR ‘antidepressant agent’/exp OR (depress* OR antidepress*):ab,ti) 
AND (psoriasis/exp OR (psoria*):ab,ti)
Medline via OvidSP (exp depressive disorder/ OR depression/ OR exp antidepressive agents/ OR 
(depress* OR antidepress*).ab,ti.) AND (exp psoriasis/ OR (psoria*).ab,ti.)
PsycInfo (exp “depression (emotion)”/ OR exp major depression/ OR atypical depression/ OR 
“Long-term Depression (Neuronal)”/ OR exp antidepressant drugs/ OR (depress* OR 
antidepress*).ab,ti.) AND ((psoria*).ab,ti.)
Cochrane central (exp depressive disorder/ OR depression/ OR exp antidepressive agents/ OR 
(depress* OR antidepress*):ab,ti) AND (exp psoriasis/ OR (psoria*):ab,ti)
PubMed (Depress*[tiab] OR antidepress*[tiab]) AND psoria*[tiab] NOT medline[sb]
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supplementary table 3. Depression questionnaires and their cut-off values.
questionnaire Description Cut-off value
Center for Epidemiologic studies 
Depression scale (CEs-D)
Twenty items with questions on six dimensions 
of depression: depressed mood, feelings of guilt 
and worthlessness, feelings of helplessness and 
hopelessness, psychomotor retardation, loss of appetite 
and sleep disturbance.
This scale is one of the most widely used instruments in 
psychiatric epidemiology.
1619,138
Hospital Anxiety and Depression 
scale (HADs)
A fourteen-item scale with seven items related to anxiety 
and seven items related to depression.
858,59
beck Depression inventory (bDi) Multiple choice survey with 21 questions on depression 
symptoms and also physical symptoms during the past 1 
to 2 weeks. It is one of the most widely used instruments 
for measuring the severity of depression.
1017,18
Zung self-rating Depression scale 
(Zung-sDs)
Twenty-item self-report questionnaire that rates 
the affective, psychological and somatic symptoms 
associated with depression. The scale contains ten 
positively worded and ten negatively worded questions.
5025,26
Hamilton rating scale for 
Depression (Hamilton Ds)
A 21-item questionnaire used to rate the severity of 
depression with questions on mood, feelings of guilt, 
suicide ideation, insomnia, agitation or retardation, 
anxiety, weight loss and somatic symptoms.
The Hamilton DS was not designed to diagnose 
depression but is very commonly used as a screening 
scale for depression.
722
Carroll rating scale for 
Depression (CrsD)
This scale was developed as a self-rating instrument for 
depression, closely matching the items of the Hamilton 
rating scale. The CRSD assess the same 17 symptoms as 
the Hamilton RS. It consists of 52 statements which have 
to be answered by yes or no.
1023
Montgomery Asberg Depression 
rating scale (MADrs)
Based on a clinical interview that moves from broad 
questions to more detailed ones.
It contains 10 questions, and each question has 6 
possible ratings and covers symptoms of depression 
such as sadness, sleep difficulties, changes in appetite 
and concentration and pessimistic and suicidal thoughts. 
It does not assess somatic symptoms.
1027
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supplementary figures 1. Depression outcomes in psoriasis patients.
a. questionnaires reporting mean values.
HADs
 
Study name Mean and 95% CI
Lower Upper 
Mean limit limit
Langley 2010 (Ust 45) 4.90 4.54 5.26
Langley 2010 (Ust 90) 4.90 4.53 5.27
Langley 2010 (Placebo) 5.40 4.99 5.81
Williamson 2004 PNSS<163.50 2.52 4.48
Williamson 2004 PNSS>165.80 4.62 6.98
Maza 2012 5.00 4.28 5.72
Cauli 2011 5.00 4.52 5.48
McAleer 2011 male 3.96 3.23 4.69
McAleer 2011 female 4.67 3.60 5.74
Fortune 2002 Grp1 7.60 6.52 8.68
Fortune 2002 Grp2 8.50 7.58 9.42
Fortune 2002 Grp3 5.00 4.33 5.67
Fortune 2002 5.20 4.72 5.68
Fortune 2003a 5.70 4.79 6.61
Fortune 2003b 5.20 4.42 5.98
Fortune 2005a 6.00 5.58 6.42
Fortune 2005b 5.10 4.48 5.72
Chern 2011 Goekerman 6.30 5.42 7.18
Chern 2011 Conventional 5.31 3.97 6.65
Gniadecki 2011 ETN BIW 6.60 6.19 7.01
Gniadecki 2011 ETN QW 6.40 6.00 6.80
Korsunskaya 2010a 9.20 9.10 9.30
Korsunskaya 2010b 11.0010.77 11.23
Kirby 2008 6.89 5.97 7.81
Hill 2002 6.70 5.83 7.57
Schneider 2006 5.70 4.96 6.44
Consoli 2006 5.40 4.67 6.13
O'Leary 2004 5.26 4.59 5.93
Smith 2002 5.25 4.21 6.29
Richards 2001 4.80 4.12 5.48
Richards 2004a 8.91 7.65 10.17
Richards 2004b 4.55 3.64 5.46
Yang 2005 4.90 4.11 5.69
Schaaf 2009 4.86 4.14 5.58
Freire 2011 5.49 5.14 5.84
5.86 5.05 6.67
-8.00 -4.00 0.00 4.00 8.00
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bDi
 
Study name Mean and 95% CI
Lower Upper 
Mean limit limit
Calikoglu 2001 9.11 5.62 12.60
Hardy 1982 9.10 6.56 11.64
Zamirska 2008 itch 9.60 7.49 11.71
Zamirska 2008 no itch 6.90 5.35 8.45
Kotrulja 2010 type I pso 8.50 6.83 10.17
Kotrulja 2010 type II pso15.4011.28 19.52
Tyring 2006 placebo 8.40 7.45 9.35
Tyring 2006 etanercept 8.10 7.24 8.96
Reich 2010 6.70 5.42 7.98
Harvima 1996 active pso 5.33 3.36 7.30
Harvima 1996 stable pso 2.59 1.53 3.65
Alpsoy 1998 moclo 34.7230.69 38.75
Alpsoy 1998 placebo 31.8027.69 35.91
Karadag 2010 25.0021.28 28.72
Chan 2009 any depr 21.1219.03 23.21
Chan 2009 no psych diag1.37 0.95 1.79
Mercan 2008 20.0715.00 25.14
Akay 2002 17.9615.33 20.59
Ghajarzadeh 2011 17.1014.69 19.51
Devrimci-Ozguven 2000 16.9614.96 18.96
Ak 2011 16.0412.90 19.18
Kilic 2008 14.0012.18 15.82
Gulec 2009 13.9812.16 15.80
Karanikas 2009 13.8310.32 17.34
Guler 2009 12.8110.17 15.45
Lee 2010 11.4710.10 12.84
Taner 2007 9.36 8.98 9.74
13.3411.18 15.51
-30.00 -15.00 0.00 15.00 30.00
Meta Analysis
3. Depressive symptoms and clinical depression in psoriasis
110
Hamilton Ds
 
Study name Mean and 95% CI
Lower Upper 
Mean limit limit
Alpsoy 1998 placebo 8.00 5.82 10.18
Alpsoy 1998 moclobemide 6.55 4.60 8.50
Chaudhury 1998 6.73 5.38 8.08
Mossner 2009 5.10 4.21 5.99
Tyring 2006 placebo 4.50 3.93 5.07
Tyring 2006 etanercept 4.50 3.99 5.01
Turel Ermertcan 2006 female pso without dep 4.58 3.66 5.50
Turel Ermertcan 2006 male pso without dep 3.22 2.17 4.27
Turel Ermertcan 2006 female pso with dep 11.70 10.25 13.15
Turel Ermertcan 2006 male pso with dep 11.06 9.80 12.32
Chan 2009 no psychiatric diagnosis 0.28 0.00 0.56
Chan 2009 any depressive disorder 12.36 10.93 13.79
6.50 4.37 8.64
-13.00 -6.50 0.00 6.50 13.00
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CrsD
 
Study name Mean and 95% CI
Lower Upper 
Mean limit limit
Gupta 1998 pso stigmatized 17.80 15.12 20.48
Gupta 1998 pso control 11.80 10.38 13.22
Gupta 1989 with nocturnal wakening 17.00 14.25 19.75
Gupta 1989 no nocturnal wakening 13.00 10.84 15.16
Gupta 1997 sexually affected 15.30 13.14 17.46
Gupta 1997 sexually unaffected 11.90 10.18 13.62
Gupta 1988 14.10 12.65 15.55
Gupta 1993 11.90 10.85 12.95
Gupta 1994 10.10 8.76 11.44
13.41 11.99 14.84
-20.00 -10.00 0.00 10.00 20.00
Meta Analysis
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Zung-sDs
 
Study name Mean and 95% CI
Lower Upper 
Mean limit limit
Sharma 2011 46.25 45.22 47.28
Menter 2010 placebo 45.80 41.99 49.61
Menter 2010 adalimumab 2.90 -0.76 6.56
31.68 6.28 57.08
-55.00 -27.50 0.00 27.50 55.00
Meta Analysis
CEs-D
 
Study name Mean and 95% CI
Lower Upper 
Mean limit limit
Esposito 2006 female26.70 26.04 27.36
Esposito 2006 male 25.80 25.30 26.30
Schmitt 2007 17.80 16.21 19.39
23.56 20.39 26.74
-30.00-15.00 0.00 15.00 30.00
Meta Analysis
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b. questionnaires reporting proportion of patients with depressive symptoms
(HADs, bDi, Hamilton Ds, Zung-sDs, CEs-D).
See Figure 3a of manuscript for forest plot.
Publication bias
 
-4 -3 -2 -1 0 1 2 3 4
0.0
0.1
0.2
0.3
0.4
0.5
0.6
S
ta
nd
ar
d
 E
rr
o
r
Logit event rate
Funnel Plot of Standard Error by Logit event rate
113
3.1 Meta-analysis on depression in psoriasis
c. Clinical outcome measures for depression.
iCD
 
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Mattoo 2001 0.29 0.21 0.39
Bharath 1997 0.97 0.80 1.00
Bashir 2010 0.50 0.20 0.80
Crown 2004 0.10 0.09 0.11
Pacan 2003 0.17 0.10 0.27
Kimball 2011 0.09 0.09 0.09
Tsai 2011 0.02 0.02 0.02
Schmitt 2010 0.08 0.07 0.09
Zhang 2011 0.09 0.09 0.10
Han 2011 0.09 0.09 0.10
0.12 0.08 0.18
-1.50 -0.75 0.00 0.75 1.50
Meta Analysis
DsM-iv
 
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Golpour 2012 0.09 0.05 0.16
Chan 2009 overall 0.26 0.21 0.32
Biljan 2009 0.19 0.12 0.30
Sharma 2001 0.23 0.12 0.41
0.19 0.12 0.29
-0.50 -0.25 0.00 0.25 0.50
Meta Analysis
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Antidepressant use
 
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Kowacs 2003 0.01 0.00 0.19
Gerdes 2008 0.06 0.04 0.07
Davidsson 2005 0.06 0.06 0.07
Meyer/Feneron 2009 0.18 0.15 0.21
Schmitt 2007 0.16 0.12 0.21
Dowlatshahi 2011 0.18 0.17 0.18
Han 2011 0.06 0.06 0.07
Langley 2010 Ust90 0.11 0.08 0.14
Langley 2010 Ust45 0.11 0.08 0.14
Langley 2010 placebo 0.11 0.08 0.14
Freire 2011 0.09 0.07 0.12
Mossner 2009 0.04 0.02 0.09
0.09 0.06 0.14
-0.25 -0.13 0.00 0.13 0.25
Meta Analysis
d. General Health
GHq means
 
Study name Mean and 95% CI
Lower Upper 
Mean limit limit
Okubo 2011 7.66 6.44 8.88
Bharath 1997 5.03 4.80 5.26
Kotrulja 2010 type I pso 4.40 2.55 6.25
Kotrulja 2010 type II pso 5.90 5.47 6.33
Harvima 1996 active pso 4.14 3.44 4.84
Harvima 1996 stable pso 2.53 1.72 3.34
4.93 3.96 5.89
-9.00 -4.50 0.00 4.50 9.00
Meta Analysis
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GHq ≥2
 
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Mattoo 2001 0.34 0.25 0.43
Harvima 1996 overall pso 0.42 0.28 0.58
Bharath 1997 0.98 0.79 1.00
Sampogna 2006 pso<65years 0.47 0.43 0.50
Sampogna 2006 pso>=65 0.58 0.50 0.66
Sharma 2001 0.53 0.36 0.70
0.49 0.39 0.58
-1.50 -0.75 0.00 0.75 1.50
Meta Analysis
supplementary figures 2. Depression outcomes in psoriasis patients compared with healthy con-
trols.
a. questionnaires reporting mean values for depressive symptoms
(bDi, HADs, Hamilton Ds, MADrs).
See Figure 3b of manuscript for forest plot.
Publication bias
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b. questionnaires reporting proportion of patients with depressive symptoms
(HADs and MADrs).
 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Richards 2004 6.64 0.76 57.77 0.09
Paloma 2011 35.03 7.11 172.48 0.00
Mizara 2012 9.60 2.73 33.77 0.00
Kowacs 2003 0.77 0.28 2.13 0.61
6.06 0.99 37.04 0.05
0.01 0.1 1 10 100
c. Clinical outcome measures for depression.
Antidepressant use
 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Dowlatshahi 2011 2.52 2.43 2.62 0.00
Han 2011 7.15 6.17 8.29 0.00
4.24 1.53 11.76 0.01
0.01 0.1 1 10 100
Meta Analysis
iCD
 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Crown 2004 1.37 1.17 1.61 0.00
Tsai 2011 1.41 1.32 1.51 0.00
Schmitt 2010 1.59 1.29 1.95 0.00
Zhang 2011 1.69 1.57 1.81 0.00
Han 2011 1.81 1.65 1.98 0.00
1.57 1.40 1.76 0.00
0.5 1 2
Meta Analysis
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sUPPlEMEntAry MAtEriAl: qUAlity AssEssMEnt sCorE
MoDifiED nEwCAstlE - ottAwA qUAlity AssEssMEnt sCAlE
CoHort or Cross sECtionAl stUDiEs
Stars indicate the number of points allocated if the item criterion is met. A maximum of 10 points can be 
allocated to each article.
selection
1) Representativeness of the exposed cohort
 a)  truly representative of the general psoriasis population ¯
 b)  somewhat representative of the general psoriasis population ¯
 c)  selected group of psoriasis patients: hospital based, tertiary centre, inpatients, outpatients
 d)  no description of the derivation of the cohort
2) Selection of the non-exposed cohort
 a)  representative of the average community (healthy control, community control) ¯
 b)  selected group of controls (hospital controls, other dermatological condition)
 c)  no control group or no description of control group
3) Ascertainment of psoriasis or psoriatic arthritis
 a)  diagnosed by dermatologist/rheumatologist ¯¯
 b)  diagnosis by physician other than dermatologist/rheumatologist (GP) or use of diagnosis-code in 
database (ICD, OXMIS) ¯
 c)  based on self-report
 d)  no description of psoriasis case definition
4) Assessment of disease severity
 a)  disease severity was assessed with PASI, PGA, BSA SAPASI (self-report) ¯
 b)  disease severity was assessed with or using psoriasis treatments (topical vs. systemic) ¯
 c)  no disease severity assessed or reported
5) Demonstration that outcome of interest (depression) was not present at start of study
 Were patients with prevalent depression excluded at the start of the study?
 a)  yes, only incident depression was measured ¯
 b)  no, patients with prevalent depression were not excluded
 c)  no description: it was not mentioned whether patients with depression at the start of the study 
were excluded
Comparability (Confounding)
1) Comparability of psoriasis and healthy controls on the basis of design or analysis
 a)  study controls for confounding using a multivariate model ¯
 b)  psoriasis patients and healthy controls are matched (for age/gender…) ¯
 c)  no controlling for confounding or matching
outcome
1) Assessment of outcome depression
 a)  clinical diagnosis: psychiatrist (DSM IV), psychologist ¯ ¯
 b)  diagnosis by GP, ICD code, other healthcare provider, questionnaire ¯
 c)  antidepressant use
 d)  not mentioned or self-reported by patients
2) Non-response rate
 a)  difference between responders and non-responders described ¯
 b)  only non-response rate mentioned without further description ¯
 c)  no information

Chapter 3.2
Increased antidepressant drug exposure in 
psoriasis patients: a longitudinal population-
based cohort study.
E.A. Dowlatshahi
M. Wakkee
R.M.C. Herings
L.M. Hollestein
T. Nijsten
Acta Derm Venereol. 2013 Sep 4;93(5):544-50.
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AbstrACt
Psoriasis has a major impact on health related quality of life. The present cohort study investi-
gated the use of antidepressant drugs between psoriasis patients and a reference population, 
using pharmacy and hospitalization data from 1998 to 2008 covering more than 2,5 million 
Dutch residents. Multivariate Cox regression compared the risk of first antidepressant use and 
Poisson regression compared the number of episodes of antidepressant use. 25,691 psoriasis 
cases and 128,573 reference subjects were followed for more than 9 years with an incidence 
of first antidepressant use of 21 and 9 per 1,000 person years respectively and an adjusted 
hazard ratio (HR) of 1.55 (95% confidence interval (CI) 1.50-1.61). Within the psoriasis group, 
the HR of receiving an antidepressant was significantly higher after the first antipsoriatic 
treatment (HR 1.07, 95% CI 1.02-1.12). Psoriasis patients have a twofold increased antidepres-
sant use, the period beyond antipsoriatic treatment being characterized by a further increase 
in antidepressant drug dispenses.
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introDUCtion
In recent years much attention has been drawn towards psychiatric disorders among patients 
with dermatologic conditions, often referred to as “psychodermatology”.1 Reports of suicidal 
ideation among patients with skin disease lead to rising concerns.2,3 In psoriasis, studies have 
demonstrated a significant impairment of health related quality of life (HRQoL) and a higher 
likelihood of developing depression.4 Although the correlation between psoriasis severity 
and impact on the HRQoL is weak,5 the chance of having psychiatric comorbidity seems to in-
crease with psoriasis severity.6 Two previous large healthcare-database studies focussing on 
major psychiatric disorders confirmed a significant and positive association with psoriasis.6,7 
Remarkably, the practical implications of actual antidepressant drug dispenses have only 
received limited attention. Two studies investigated drug prescriptions in general, including 
antidepressants in psoriasis patients, during a restricted time period: one cross-sectional 
study showed that at the time of hospital admission, psoriasis patients had a 1.4 times 
higher risk of using an antidepressant drug compared to healthy individuals,8 while another 
case-control study focusing on the period three years before the date of psoriasis diagnosis 
observed no increased use of antidepressants.9 Furthermore, other studies investigated self-
reported assessment of depressive symptoms, which can bias the outcome definition.4,10-12 
These studies had a cross-sectional study design, a limited sample size or lacked a compara-
tive control group.
The objective of this study was to longitudinally compare antidepressant use and episodes 
in psoriasis patients from 1997 to 2008 to a non-psoriatic reference group from a large 
sample of the general population, specifically focusing on the time before, during and after 
treatment initiation for psoriasis.
MAtEriAls AnD MEtHoDs
Data source
Data was retrieved from the Pharmo Record Linkage system, a large patient-centric data net-
work linking multiple observational databases, including drug dispensing and hospitaliza-
tion data for approximately 2,5 million residents in the Netherlands.13,14 Information on each 
prescription includes product name, Anatomical Therapeutic Chemical (ATC) classification of 
the drug, date of dispense, quantity dispensed, dosage and regimen.
study population
Psoriasis patients were identified using a previously described algorithm based on dispensed 
drugs and hospitalizations for psoriasis and psoriatic arthropathy.15-17 The index date for 
psoriasis patients was the date of the first available active treatment for psoriasis, varying 
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from topical corticosteroids to systemic antipsoriatic therapies. The reference population 
consisted of subjects without psoriasis, who were assigned a random index date. Five refer-
ence subjects were randomly selected for every psoriasis patient using frequency matching 
for the index date.
The eligibility date represents the date of first registration in a pharmacy linked to the 
Pharmo system. Between 1997 and 2008 all subjects were followed from the eligibility date 
to the year of last available prescription, the date when registered subjects moved away or 
the date of death, whichever came first.
Drug exposure
Antidepressants (ATC code N06A) were Selective Serotonin Reuptake Inhibitors (SSRIs), Tricy-
clic antidepressants (TCAs) or other antidepressants. The start of an episode of antidepres-
sant use was defined as the date of dispensing of the first prescription for any antidepressant. 
The length was the number of days for which the prescribed quantity and prescribed dosage 
would suffice and the end of an episode was defined as no new prescription within four 
months after the end date of the last antidepressant prescription. According to the American 
College of Neuropsychopharmacology and other guidelines, recovery from a Major Depres-
sive Episode can be ascribed after at least 4 months of remission have been ascertained.18,19 
An episode of antidepressant use is not equivalent to a Major Depressive Episode, which is 
based on assessment of depressive symptoms, however according to the available recom-
mendations, this seemed the most appropriate way to define an episode.
Covariates
The covariates gender and age at eligibility date included in the multivariate models were 
determined a priori. In order to adjust for comorbidities, we calculated the number of unique 
prescriptions at ATC second level (number of unique therapeutic main groups) during the 6 
months before the index date. This method has been described previously.16 To avoid over-
adjustment, we excluded antidepressants from this count.
statistical analyses
Student’s t-test was used to test for differences between continuous variables and Chi-square 
test for categorical variables. To quantify first antidepressant use we calculated incidence rates 
(IR) per 1000 person years with 95% confidence interval (CI). Multivariable Cox proportional-
hazards analyses compared hazards for the first antidepressant use between the two groups. 
We verified that the hazards for categorical variables were proportional using the log minus 
log function. Poisson regression model compared IRs of number of episodes of antidepres-
sant use, where observation time from eligibility date until the end of follow-up was used as 
an offset. To investigate the pattern of antidepressant use, we calculated cumulative IRs and 
incidence rate ratios (IRR) of episodes of antidepressant use in both groups for the entire 
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follow-up using time windows of 6 months and plotted these rates with their respective 95% 
CI against time since diagnosis of psoriasis (+/- 10 years).
We conducted an internal comparison within the psoriasis group using psoriasis patients as 
their own controls and calculated the hazard ratio (HR) of antidepressant use before and after 
index date using Cox proportional hazards model with robust standard errors.20 We report 
the mean number of episodes before and after the index date and the IRR using Generalized 
estimating equations (GEE) for counts with unstructured correlation matrix, robust standard 
errors and exposure time as an offset.21
sensitivity analyses
We analyzed antidepressant use 7 months before and after the index date (4 months is the 
maximum duration between two prescriptions in the same episode and 3 months is the 
common maximum duration of a prescription in The Netherlands) and also in an analysis 
excluding the time around the index date.
The effect of disease severity was studied, where dispensing of topical antipsoriatic medi-
cation served as a proxy for mild disease and systemic psoriasis medication and hospitaliza-
tion for psoriasis as a proxy for moderate to severe disease.
Statistical analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) 
and SPSS version 17.0 (SPSS inc., Chicago, IL, USA).
The present study was conducted and reported according to the guidelines elaborated in 
the STROBE statement (Strengthening the Reporting of Observational Studies in Epidemiol-
ogy).22
rEsUlts
study population
In this study we included 25,691 psoriasis patients and 128,573 reference subjects. Gender 
distribution was similar in the two groups, while the mean age was six years higher in the pso-
riasis group (Table 1). In both groups the mean follow-up time was approximately 9.5 years. 
Antidepressant use was more than twice as frequent in psoriasis subjects as in the reference 
population (17.8% versus 7.9%, p<0.001). In particular, SSRIs were the most commonly pre-
scribed antidepressants in both populations (Table 1). Multiple episodes of antidepressant 
use were observed in 7.6% of the psoriasis and 2.9% of the reference population (p<0.001).
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Antidepressant use in the psoriasis group compared to the reference 
population
First antidepressant use. The unadjusted IR of antidepressant use per 1000 person years was 
significantly increased in psoriasis patients (21.2, 95% CI 20.6-21.8) compared to the reference 
population (8.8, 95% CI 8.7-9.0). The crude HR was 2.37 (95% CI 2.29-2.45), demonstrating 
that psoriasis patients were about 2.4 times more likely to use antidepressant drugs without 
adjusting for factors that may confound this association (Table 2).
Adjusting for age and gender only had a limited effect on the HR (adjusted HR 2.19, 95% 
CI 2.11-2.27), while adjusting for unique prescriptions dispensed 6 months before index date 
had a remarkable effect since the HR decreased to 1.55 (95% CI 1.50-1.61), but remained 
significant.
Episodes of antidepressant use. Psoriasis patients had more than twice as many episodes 
of antidepressant use than the reference population, 37 versus 15 per 1000 person years 
(IRR 2.54, 95% CI 2.48-2.61) (Table 3). After Poisson regression, the adjusted HR of 1.47 (95% 
CI 1.43-1.51) was comparable to the adjusted HR of the analysis on first antidepressant use.
table 1. baseline characteristics of the reference and psoriasis population.
reference
n=128,573
Psoriasis
n=25,691
p-value
Gender, male, n (%) 62,141 (48.3) 12,494 (48.6) 0.38
Age at eligibility date, years, median (iqr) 33 (18; 50) 42 (28; 56) <0.001
years of follow-up, mean1 9.38 9.46
Antidepressant use, n (%)
Any antidepressant 10,137 (7.88) 4,576 (17.81) <0.001
Selective serotonin reuptake inhibitor2 6,630 (5.16) 3,014 (11.73) <0.001
Tricyclic antidepressant2 3,336 (2.59) 1,650 (6.42) <0.001
Other antidepressants2 2,784 (2.16) 1,359 (5.29) <0.001
Episodes of antidepressant use, n (%)
1 6,326 (4.92) 2,593 (10.09) <0.001
2 2,020 (1.57) 959 (3.73)
3 803 (0.62) 471 (1.83)
4 435 (0.34) 239 (0.93)
5 234 (0.18) 127 (0.49)
≥6 300 (0.23) 167 (0.65)
Abbreviation: IQR, Interquartile Range.
1 Years of follow-up from eligibility date to end of follow-up in Pharmo database.
2 Values do not add up to sum of all antidepressants because patients could have more than one type of 
antidepressant.
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We compared IRs of episodes of antidepressant use in the psoriasis group with those of 
the reference population during 10 years before and after first treatment for psoriasis (index 
date) (Figure 1) and also plotted the cumulative IRRs (Figure 2). The IRRs gradually increased 
from 2.17 ten years before to 2.48 one and a half years before first antipsoriatic treatment. 
The IRRs were highest within the first 6 months after psoriasis treatment, namely 2.79 and 
slowly decreased in the 5 years hereafter to reach a plateau at an IRR of around 2.64 until the 
end of follow-up after 10 years. Looking at the entire period before and after the index date 
and hereby excluding the year around the index date, the IRR for episodes of antidepressant 
use is higher in the years after index date than in the years before. If we adjusted these crude 
rates for age, gender and comorbidity, the risk of dispensing an antidepressant was reduced 
but still remained 50% higher in the psoriasis population. The adjusted risk of antidepres-
sant use followed the pattern of the crude data, by peaking around the index date (adjusted 
HR seven months before index date 1.54, 95% CI 1.39-1.71, adjusted HR seven months after 
index date 1.89, 95% CI 1.70-2.09) and when excluding the seven months before and after 
index date, the adjusted HR were higher in the years after (adjusted HR 1.73, 95% CI 1.65-1.81) 
than before the index date (adjusted HR 1.33, 95% CI 1.25-1.42).
table 2. first antidepressant use in reference and psoriasis groups.
reference Psoriasis
First antidepressant use, n 10,137 4,576
Person years1 1,148,051 215,562
Incidence rate per 1,000 person years (95% CI) 8.83 (8.66-9.00) 21.23 (20.61-21.84)
Crude HR (95% CI) 1 2.37 (2.29-2.45)
Adjusted HR (95% CI)2,3 1 1.55 (1.50-1.61)
Abbreviations: HR, Hazard Ratio; CI, Confidence Interval.
1 Sum of number of person years from eligibility date to date of first prescription for an antidepressant or 
to the end of follow-up in Pharmo.
2 Adjusted for age, gender and number unique prescriptions 6 months before index date.
3 COX regression.
table 3. Episodes of antidepressant use in reference and psoriasis groups.
reference Psoriasis
Episodes of antidepressant use, n 18,070 8,961
Person years1 1,206,416 242,934
Incidence rate per 1,000 person years (95% CI) 14.98 (14.76-15.20) 36.89 (36.12-37.65)
Crude IRR (95% CI) 1 2.54 (2.48-2.61)
Adjusted IRR (95% CI)2,3 1 1.47 (1.43-1.51)
Abbreviations: CI, Confidence Interval; IRR, Incidence Rate Ratio.
1 Sum of number of person years from eligibility date to the end of follow-up in Pharmo.
2 Adjusted for age, gender and number unique prescriptions 6 months before index date.
3 Poisson regression using entire follow-up time of each patient as offset.
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figure 1. incidence rates of antidepressant use in psoriasis and reference group.
Black straight and dotted line: Incidence rates and 95% confidence interval in psoriasis group.
Grey straight and dotted line: Incidence rates and 95% confidence interval in reference group.
Year “0”represents the index date.
figure 2. incidence rate ratio of antidepressant use in psoriasis compared to reference population.
The dotted line represents the 95% confidence interval.
Year “0”represents the index date.
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internal comparison of antidepressant use within the psoriasis group
When restricting the analysis to the psoriasis population and comparing antidepressant use 
before and after the index date, psoriasis patients were about 7% more likely to receive anti-
depressant drugs after the index date, when controlling for within patient variation using the 
GEE model (HR 1.07, 95% CI 1.02-1.12) (Table 4). However, there was no significant difference 
in the mean number of episodes before and after index date, 0.035 and 0.037 respectively 
(IRR 1.03, 95% CI 0.98-1.09, p=0.26).
table 4. Analysis of antidepressant use within the psoriasis group before and after index date 
(n=25,691).
before index date After index date
first antidepressant use in psoriasis patients
Antidepressant users, n 1,977 3,480
Person years1 74,369 148,241
Incidence rate per 1,000 person years (95% CI) 26.58 (25.41-27.76) 23.48 (22.70-24.26)
Hazard Ratio (95% CI)2 1 1.07 (1.02-1.12)
Episodes of antidepressant use in psoriasis patients
Episodes of antidepressant use, n 2,810 6,151
Person years3 78,871 164,064
Incidence rate per 1,000 person years (95% CI) 35.63 (34.31-36.95) 37.49 (36.55-38.43)
Mean number of episodes (95% CI) 0.035 (0.033-0.037) 0.037 (0.033-0.041)
Incidence Rate Ratio (95% CI)4 1 1.032 (0.977-1.090)
Abbreviations: CI, Confidence Interval.
1 Sum of number of person years from eligibility date to date of first antidepressant or to index date (for 
analysis before the index date) and from index date to first antidepressant after index date or to end of fol-
low up in Pharmo (for analysis after the index date).
2 Cox proportional hazard model with robust standard errors.
3 Sum of number of person years from eligibility date to index date (for analysis before the index date) and 
from index date to end of follow up in Pharmo (for analysis after the index date).
4 Poisson regression model using generalized estimating equations with unstructured correlation matrix 
and robust standard errors.
Effect of psoriasis severity on antidepressant drug use
Patients with mild psoriasis had a 2.3-times higher risk (95% CI 2.23-2.40) of using antidepres-
sant drugs compared to reference subjects. In a multivariate COX regression model, the age, 
gender and comorbidity adjusted HR for antidepressant use remained significant (adjusted 
HR 1.55, 95% CI 1.49-1.61) in this subgroup of patients. Patients with more severe psoriasis 
had a crude HR of 2.81 (95% CI 2.59-3.04) and an adjusted HR of 1.57 (95% CI 1.44-1.70) 
compared to the non-psoriasis population. Psoriasis patients with severe disease were at a 
higher risk of having a first antidepressant than patients with mild disease, with an overall 
p-value of p<0.001.
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DisCUssion
Our study shows that dispensing of antidepressants is twofold higher in psoriasis patients 
and that they have twice as many episodes of antidepressant use than the reference popula-
tion. The longitudinal study design enabled us to demonstrate that antidepressant use is 
already increased before psoriasis patients seek medical treatment for their skin and that it 
peaks around the time of treatment initiation but also remains increased hereafter.
Our outcomes are in line with prescription data from German hospitalized psoriasis pa-
tients showing a 1.4 times higher risk of using an antidepressant8 and are also comparable 
to the 1.4 to 1.5 times higher risk of major psychiatric disorders in psoriasis observed in the 
General Practice Database from the United Kingdom and an interdisciplinary administrative 
outpatient database from Germany.6,7
Adjusting for unique number of prescription drugs 6 months prior to the index date, as a 
proxy for the general healthcare consumption pattern, resulted in a considerable decrease 
of the risk of using an antidepressant. This effect could be explained by detection bias, i.e. 
patients with psoriasis visit their physician more often, which equally increases their risk 
of diagnosis and treatment of other diseases including depression.23 This effect was also 
confirmed by other studies, showing that the likelihood of being diagnosed with depression 
increases with the number of physician visits due to psoriasis6 and that on average, pso-
riasis patients with severe disease receive more different systemic drugs than the general 
population.8
The increased risk of antidepressant use after adjustment may be explained by the effect 
of psoriasis on the HRQoL, leading to stigmatization, shame, difficulties in daily activities and 
coping problems,11,24-26 which may result in depressive symptoms.27 An alternative explana-
tion may be reverse causality; depression may lead to self-neglecting behaviour, isolation 
and therefore induces lifestyle changes such as smoking, alcoholism and obesity, which in 
turn can lead to increased inflammation and eventually to psoriasis. However, since the ef-
fects of generalized inflammation mostly become apparent after a long induction period, the 
association between depression, lifestyle changes and psoriasis would take years to manifest 
itself.28,29 Genetics could play a role in the association between psoriasis and depression. 
Genome wide association studies on psoriasis susceptibility loci30-34 and on genes for major 
depressive disorder35 showed no common genes. However, a recent study on inflammation-
related genes in depression identified that the gene PSMB4, critical for T-cell function, was 
associated with susceptibility to Major Depressive Disorder.36 Susceptibility to psoriasis 
has also been associated to the area of chromosome 1q21 (PSORS4) that encodes for the 
PSMB4 gene.34
The pattern of antidepressant use in this study shows three discernable periods (Figure 
2): First, during the years before the index date, antidepressant use gradually increases and 
reaches a maximum in the proximity of the index date. Hereafter, antidepressant use does 
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not decline to its level from before the index date but remains constantly high and reaches 
a plateau until the end of follow-up. The use of antidepressant drugs remained increased 
after the index date, also when adjusting for confounders. Assuming that the index date 
represents the date of first diagnosis of psoriasis, the period of more than one year before 
the index date would represent a period without active psoriasis or where psoriatic disease 
has not yet manifested itself. The risk difference of antidepressant use between the two 
groups in this first period may, therefore, be explained by intrinsic factors at work such as 
unhealthy lifestyle factors, different healthcare consumption attitudes and genetic factors 
leading to higher use of antidepressants than in subjects that do not develop psoriasis. Inter-
estingly, other studies have shown that psoriasis patients are already more obese before the 
manifestation of psoriatic disease,28 which may also lead to depression.37 We then observed 
a deviation of antidepressant use starting one and a half years prior to the first dispensing 
of antipsoriatic medication until one and a half years thereafter in the psoriasis population 
and in the analyses comparing the psoriasis group to the reference population. This increase 
in antidepressant use may not merely be explained by increased healthcare consumption in 
psoriasis patients. Antidepressant use attains a maximum around the index date, whereupon 
the patient seeks medical care due to psoriasis de novo or exacerbation of disease and thus 
the severity of disease in this acute phase may have a more pronounced impact on the psy-
chological condition of the patient.
If there is a causal relationship between psoriasis and depression, then this may be re-
flected in the risk difference of 0.5 comparing the period before and after the index date 
(Figure 2) where the IRR of antidepressant use increases from 2.2 to 2.7. The observation that, 
beyond the index date, the risk of antidepressant use does not return to its level of before 
the index date suggests that it remains difficult to control psoriasis on the long term and that 
disease severity remains relatively stable in time.38 Therefore, the significant increase in risk 
of antidepressant dispensing beyond the index date could be attributed to the impact of 
chronic skin disease on patients’ HRQoL. On the other hand, a study comparing QoL scores 
in a 11 year period demonstrated a significant decrease of approximately 25% in the overall 
psychosocial impact of psoriasis on patients’ HRQoL, suggesting that this group of patients 
accommodate to the impact of their disease over time.39
strengths and limitations
The present study is the largest population based longitudinal study comparing antidepres-
sant prescriptions during an almost 10 year observation period in psoriasis patients to a 
reference population. It is based on prescription data from 2,5 million Dutch residents, and 
is therefore well representative of the Dutch population. The longitudinal study design 
enabled us to focus in detail on drug prescriptions around the time of initiation of psoriasis 
therapy. Besides analyzing unique prescriptions, we also investigated multiple episodes of 
antidepressant use, which resulted in comparable outcomes. The obtained risk estimates 
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confirm the estimates found in studies on the association between psoriasis and major 
psychiatric disorders,6,7 also strengthening our definition of depressive episodes based on 
antidepressant prescription data. We are aware that antidepressant drug use does not imply 
the diagnosis of a depression but may also represent other psychiatric morbidities. In the 
Dutch general practice, 45% of antidepressant users had depression, 17% had anxiety and 
panic disorders, and 9% had sleeping disorders.40
Our definition of psoriasis was based on a drug and hospitalization algorithm; neverthe-
less it had a 98.2% sensitivity and a 80.2% specificity.16 This could result in non-differential 
misclassification of psoriasis cases, which might lead to underestimation of the effect of 
psoriasis on antidepressant use. As also the case in other secondary database studies, 
residual confounding was likely because data on potential confounders such as weight, 
smoking, alcohol consumption, physical activity or socioeconomic status were not available. 
However, the risk estimates were stable across the different analyses including the within 
patient analysis, in which the effect from unmeasured confounding factors between psoriasis 
cases and reference subjects was attenuated. We calculated the exposure to antidepressants 
from dispensed pharmacy prescriptions assuming good drug compliance. However, the rate 
of non-adherence to antidepressant treatment can vary from 40 to 75%,41 especially among 
long term users, which was not the objective of this study. Although the average follow-up 
was almost a decade, it is possible that patients had a depression before they were registered 
in the database, resulting in non-differential misclassification. To minimize the impact of this 
bias, prevalent antidepressant users (n=143) who had changed pharmacists and who had 
an antidepressant drug dispensed in the first pharmacy where they were registered, were 
excluded from the analysis.
ConClUsion
Psoriasis patients use more antidepressant medication than the general population, espe-
cially at the time when they seek medical care for their psoriasis and thereafter. Physicians 
should be aware that patients who seek care for chronic dermatological conditions such as 
psoriasis may have an increased risk of experiencing psychological or psychiatric disorders.
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AbstrACt
background: Studies investigating systemic inflammation in psoriasis use different serum 
markers and report discrepant results.
objective: To determine whether systemic inflammation is elevated in psoriasis patients 
compared to healthy controls and to measure the extent of this elevation, by summarizing 
available data on serum inflammatory markers.
Methods: PubMed, Embase and Web of Science were searched from inception to March 
2011. We included studies comparing the serum inflammatory markers Interleukin (IL)1-beta, 
IL-6, IL-10, C-reactive-protein (CRP), Intracellular adhesion molecule-1 (ICAM-1), E-selectin or 
Tumor necrosis factor-alpha (TNFα) in psoriasis with healthy controls. Difference in serum 
marker levels between patients and controls were pooled as standardized mean differences 
(SMD) (Cohen’s d) using random-effects model.
results: Seventy-eight studies were eligible. Of the 7,852 individuals 3,085 had (severe 
plaque) psoriasis. The pooled SMDs were higher in psoriasis compared to healthy controls 
for IL-6 (d=1.32, 95% CI 0.83-1.81), CRP (d=1.83, 95% CI 0.76-2.90), TNFα (d=1.32, 95% CI 
0.86-1.79), E-selectin (d=1.78, 95% CI 1.32-2.25) and ICAM-1 (d=1.77, 95% CI 1.15-2.39). The 
SMD between cases and controls for IL-1β and IL-10 was not significant. Age had a significant 
effect on the SMD for IL-6 and TNFα. For IL-6 the effect size was higher for plaque psoriasis 
studies (d=1.98). The effect size was not influenced by the PASI, measurement method or 
quality assessment.
Conclusion: The pooled analyses suggest modest, but significantly elevated levels of the 
pro-inflammatory cytokines in the serum of psoriasis patients with predominantly severe 
disease. To what extent this modest increment is clinically relevant could be investigated in a 
synthesis of all studies measuring inflammation before and after antipsoriatic therapy.
149
4.1 Meta-analysis on systemic inflammation in psoriasis
introDUCtion
Psoriasis is a chronic, relapsing, inflammatory skin disease that affects 2% of the Caucasian 
population.1 This skin condition is histologically characterized by abnormal proliferation of 
keratinocytes and infiltration of immune cells, predominantly T-cells and dendritic cells in 
psoriatic lesions.2 The majority of inflammatory cells and cytokines remain in the tissue and 
a relatively small proportion can be measured in the peripheral blood, such as interleukins 
(ILs)3 which have shown to be elevated in patients with cardiovascular disease, metabolic 
syndrome and diabetes.4,5
The search for markers in psoriasis was revived as these were not only found in the skin, but 
researchers also identified a spillover of inflammatory markers into the systemic circulation, 
using them to measure disease severity, to objectively monitor treatment response, find new 
targets for therapy and to explain comorbidities in psoriatic patients.6,7
Much attention has been drawn towards “upgrading” psoriasis from a skin condition to a 
systemic disease as serum biomarkers for inflammation are raised in psoriasis8 and patients 
could therefore have a higher risk of developing systemic comorbidities.6 Data on serum 
levels of pro- and anti- inflammatory cytokines in psoriasis patients compared to controls are 
controversial, with some authors not observing any difference, while others report elevated 
or decreased levels in psoriasis.3 The studies to date have small sample sizes, investigate 
different markers and techniques to assess inflammation; moreover measurement of serum 
inflammation is often not their primary objective.
We conducted the first systematic review and meta-analysis to determine whether six well-
known pro-inflammatory serum markers IL-1β, IL-6, C-reactive protein (CRP), Tumor necrosis 
factor-alpha (TNFα), Intracellular adhesion molecule-1 (ICAM-1), E-selectin are elevated and 
anti-inflammatory IL-10 decreased in treatment naïve psoriatic patients compared to controls.
MAtEriAls AnD MEtHoDs
background to literature search
We investigated whether certain markers of inflammation were elevated in psoriasis pa-
tients compared to controls and were interested in the role of inflammatory markers in the 
development of comorbidities. We therefore conducted an open literature search listing 
inflammatory markers most commonly mentioned in psoriasis and cardiovascular disease 
(CVD) (Supplementary Figure 1). This is the case for IL-1β, IL-6 and TNFα which are produced 
in adipose tissue, are known to be pro-atherogenic but are also involved in skin inflamma-
tion in psoriasis as they are produced by the keratinocytes.2,6 CRP is often used to measure 
suspected inflammatory state in psoriasis patients, whereas high sensitivity CRP is used in the 
prediction of CVD.9-11 The type of CRP measured depended on the objective of the study. We 
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included all studies measuring CRP, regardless of the type. The adhesion molecules E-selectin 
and ICAM-1 expressed on endothelial cells are equally known as mediators of inflammation 
in the prediction of CVD.12
Other than the six above-mentioned pro-inflammatory markers, we chose IL-10 as anti- 
inflammatory cytokine to confirm the hypothesis that IL-10 is below detectable levels in 
psoriasis patients or at the same level as in healthy controls.3,6
Eligibility criteria
Inclusion and exclusion criteria were determined before the search was conducted. We 
included human studies comparing psoriasis patients with ‘healthy’ controls, in which one or 
more of the following inflammatory markers were measured in the serum: IL-1β, IL-6, IL-10, 
CRP, TNFα, E-selectin and ICAM-1. Studies were excluded if psoriatic arthritis (PsA) was the 
main exposure. Case reports and letters were excluded. If several studies reported results 
from the same study population, the most complete report was included.
search strategy
The systematic search was performed by a medical librarian (L.V.) in PubMed, Embase and 
Web of Science from 1988 to March 2011. The search strategy is presented in Supplementary 
Table 1.
Data extraction and quality assessment
Data was collected using a standard data extraction form (Table 1). Information from articles 
in a language other than English, Dutch, French or German was extracted if an English ab-
stract and comprehensive tables were available.
The quality of the articles was assessed using a checklist based on the REMARK guidelines, 
also used in other meta-analyses.13,14 The definition of each checklist item was discussed; two 
points were allocated to each positive item, one point to a partially fulfilled item and no 
points were given if the item criterion was not met. The sum of these points was divided by 
the maximum number of points an article could score.
study selection
Two reviewers (E.A.D. and E.A.M.V.) independently screened all titles, abstracts and full texts 
of selected articles and conducted the data extraction and the quality assessment. Disagree-
ments were resolved by consensus.
Data synthesis and analysis
The primary outcome was the difference in mean serum inflammatory marker levels between 
psoriasis patients and healthy controls for each study. The effect size representing this dif-
ference was calculated using the standardized mean difference (SMD), also referred to as 
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Cohen’s d and we reported its respective 95% confidence interval (CI). In studies where the 
mean was not reported, the median was used. If the standard deviation (SD) was not avail-
able, we assumed that the values lay within three SDs from the mean. SMDs were pooled 
using a random effects-model according to the method of DerSimonian and Laird, where 
within-study variance and between-study variance were taken into account. Heterogeneity 
between studies was quantified using I² statistics. In six studies the serum levels were given 
separately according to psoriasis type, severity or Body Mass Index (BMI), instead of report-
ing an overall mean. These were included as such in the meta-analysis; however, the control 
group remained the same for the studied outcome measures.
Publication bias was investigated graphically by funnel plots and was statistically assessed 
via Egger’s regression. The trim and fill method provided an estimate of the number of miss-
ing studies and an estimate of the pooled effect size if these studies were to be included in 
the meta-analysis.
All statistical analyses were performed using Comprehensive Meta-Analysis Version 2.2 
(Biostat, Englewood, NJ, USA).
Meta-regression and subgroup analyses
Sources of heterogeneity between studies were explored by performing meta-regression 
analyses for age, gender and psoriasis severity. Subgroup analyses were performed based on 
psoriasis type (only plaque psoriasis versus different or non-specified types), laboratory mea-
surements (Enzyme Linked Immuno Sorbant Assay (ELISA) versus other techniques or when 
the measurement method was not specified, and for CRP: ELISA versus immunoturbidimetry 
versus nephelometry versus other or missing method). Subgroups were analyzed for quality 
assessment scores whereby studies above and below the upper quartile were compared to 
each other. For each subgroup the pooled SMD and 95% CI was presented.
We excluded all studies with PsA, however we did not exclude studies with a small number 
of PsA patients alongside other psoriasis patients. In order to ascertain that the impact of PsA 
was limited in the meta-analysis, we conducted subgroup analyses comparing studies where 
PsA patients were excluded to the rest of the studies, showing no significant difference in 
point estimates between these two categories. The interpretation of this analysis was limited 
due to the small number of studies explicitly mentioning that PsA patients were excluded. We 
therefore decided to refrain from further discussing this subgroup analysis in the manuscript.
The present study was conducted and reported according to the PRISMA and MOOSE guide-
lines.15,16
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4.1 Meta-analysis on systemic inflammation in psoriasis
rEsUlts
The search yielded 8447 articles (5385 after exclusion of duplicates), of which 78 were in-
cluded in the meta-analysis. Figure 1 depicts the study selection process.
A total of 7852 individuals (3085 psoriasis patients) were included. Psoriasis patients and 
healthy controls were comparable as to age (Table 1). The psoriasis type was known in 69% 
of patients. Of these, 94% (n=1971) had plaque psoriasis and 3.4% (n=71) had erythrodermic 
psoriasis. A total of 70% of the studies reported a Psoriasis Area and Severity Index (PASI). 
Within this group, 75% of the patients were from studies reporting a mean PASI >10, indicat-
ing that the majority of the studies included patients with severe disease (overall mean PASI 
17.7±10.5).
Search in PubMed, Embase, Web of Science
Duplicates excluded
5385 articles
280 potentially relevant articles reviewed in full text
95 relevant articles
5105 articles excluded which did not fulfill the 
inclusion criteria after review of titles and 
abstracts
185 articles excluded after assessing full text 
- 78 no cytokines measured in serum
- 41 no control group
- 30 not enough information in abstract/article
- 15 duplicate study population
- 12 no psoriasis
- 9 wrong study type
78 relevant articles included in the meta-analysis
missing data for analyses
figure 1. flow diagram of study selection.
interleukin-1β
The SMD for studies analyzing IL-1β was -0.32 (95% confidence interval [CI] -1.05-0.41) in-
dicating that there was no significant difference in serum IL-1β between psoriasis patients 
and controls (Figure 2a). Age and psoriasis severity did not explain the high degree of het-
erogeneity between the studies (I²=93%). When adjusting for gender in the meta-regression, 
we noticed that the higher the percentage of women in the study, the larger the difference 
in IL-1β between psoriasis patients and controls in the study (p=0.001). Regarding the sub-
group analyses, no significant differences were observed between studies including plaque 
psoriasis only and other studies (p=0.90) (Table 2).
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interleukin-6
Twenty two studies provided plasma IL-6 levels in 994 psoriasis patients and 594 controls 
(Table 1). Figure 2b shows a significantly higher level of IL-6 in psoriasis patients, with a 
pooled SMD of 1.32 (95% CI 0.83-1.81). In the forest plot, the study by Galadari et al showed 
high SMDs ranging from 25 to 36 for the three subgroups of psoriasis severity.17 However, the 
point estimate remained significantly higher for psoriasis when excluding this study (d=1.07, 
95% CI 0.65-1.49). Meta-regression for age indicates that the older the age of the patients 
in the study, the smaller the SMD between psoriasis patients and controls across studies 
(β=-0.08, p=0.04). Gender and PASI had no effect on the SMD in IL-6 (p=0.08 and p=0.66, re-
spectively). The SMD for IL-6 was significantly lower in studies including only plaque psoriasis 
(n=13) compared to other studies (n=9) (Table 2), indicating that the difference in IL-6 levels 
between psoriasis patients and controls was larger in studies not restricted to plaque psoria-
sis. These studies did not have a higher PASI score, nor did they include more erythrodermic 
patients (Table 1).
interleukin-10
Pooling of IL-10 levels resulted in a small, positive but not statistically significant SMD be-
tween psoriasis patients and healthy controls (d=0.25; 95% CI -0.90-1.40) (Figure 2c), which 
could not be explained by age, gender or PASI in the meta-regression, or by psoriasis type in 
the subgroup analyses.
figure 2 a to g. forest plots showing standardized mean difference and 95% Ci of individual studies 
and pooled standardized mean difference and 95% Ci in psoriasis patients and healthy controls us-
ing random effects model.
Abbreviations: Std diff in means, Standardized mean difference; CI, Confidence Interval; pso, psoriasis; BMI, 
Body Mass Index; GPP, Generalized Pustular Psoriasis.
a. interleukin-1β
Study Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Anderson 2010 0.79 0.02 1.56 0.04
Jacob 2003 0.22 -0.82 1.27 0.67
Johnston 2008 0.70 0.18 1.23 0.01
Kanda 2010 -1.02 -1.48 -0.57 0.00
Mizutani 1997 0.00 -0.50 0.50 1.00
Bevelacqua 2006 (mild pso) 0.55 -0.07 1.17 0.08
Bevelacqua 2006 (severe pso) 0.54 -0.02 1.10 0.06
Gonul 2009 -0.63 -1.02 -0.23 0.00
Abe 2002 -4.52 -5.58 -3.45 0.00
-0.32 -1.05 0.41 0.39
-6.00 -3.00 0.00 3.00 6.00
 
4. Atherosclerosis, inflammation and cardiovascular disease in psoriasis
160
b. interleukin-6
Study Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Takahashi 2010 2.10 1.75 2.45 0.00
Anderson 2010 1.15 0.35 1.95 0.00
Arican 2005 0.95 0.38 1.53 0.00
Coimbra 2010a 1.83 1.36 2.30 0.00
Jacob 2003 0.03 -1.01 1.08 0.95
Johnston 2008 1.36 0.79 1.92 0.00
Kanda 2010 -1.02 -1.47 -0.56 0.00
Kaur 2008 (BMI>30) 1.13 0.38 1.88 0.00
Kaur 2008 (BMI<25) 0.06 -0.69 0.81 0.88
Krasowska 1998a -0.20 -0.87 0.47 0.57
Martinez-Sales 2010 0.69 0.05 1.33 0.03
Mizutani 1997 2.42 1.80 3.04 0.00
Seishima 1998 (pso) -0.24 -0.68 0.21 0.30
Seishima 1998 (active GPP) 2.96 2.08 3.83 0.00
Szepietowski 2000 0.90 0.32 1.48 0.00
Toruniowa 1995 1.70 0.90 2.49 0.00
Zalewska 2006 0.07 -0.29 0.43 0.71
Bevelacqua 2006 (mild pso) 1.08 0.44 1.73 0.00
Bevelacqua 2006 (severe pso) 1.58 0.95 2.21 0.00
Bonifati 1994 3.11 2.01 4.20 0.00
Deeva 2010 (severe plaque pso) 4.20 2.63 5.76 0.00
Deeva 2010 (mild plaque pso) 0.09 -0.62 0.79 0.81
Deeva 2010 (erythrodermic pso) 0.68 -0.22 1.58 0.14
Gonul 2009 0.33 -0.06 0.72 0.09
Roussaki-Schulze 2005 -0.05 -0.46 0.37 0.82
Galadari 2005 (mild pso) 36.22 27.58 44.86 0.00
Galadari 2005 (moderate pso) 30.27 20.60 39.94 0.00
Galadari 2005 (severe pso) 25.05 16.02 34.07 0.00
Qiu 2005 2.38 1.74 3.03 0.00
1.32 0.83 1.81 0.00
-6.00 -3.00 0.00 3.00 6.00
 
c. interleukin-10
Study Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Takahashi 2010 -6.52 -7.21 -5.82 0.00
Anderson 2010 0.66 -0.11 1.42 0.09
Borghi 2008 -0.35 -0.66 -0.05 0.02
Borska 2008 16.36 14.08 18.64 0.00
Jacob 2003 -6.15 -8.47 -3.84 0.00
Kanda 2010 0.49 0.06 0.93 0.03
McLoone 2004 -0.29 -1.31 0.72 0.57
Reddy 2010 -0.20 -0.61 0.21 0.33
Szegedi 2003 -0.57 -1.36 0.21 0.15
Deeva 2010 (severe plaque pso) 0.00 -0.88 0.88 1.00
Deeva 2010 (mild plaque pso) 0.40 -0.31 1.10 0.27
Jadali 2007 0.41 -0.03 0.85 0.07
Roussaki-Schulze 2005 1.05 0.61 1.50 0.00
0.25 -0.90 1.40 0.67
-6.00 -3.00 0.00 3.00 6.00
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d. tumor necrosis factor-α
Study Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Takahashi 2010 2.30 1.94 2.66 0.00
Anderson 2010 1.06 0.27 1.85 0.01
Arican 2005 1.55 0.93 2.17 0.00
Asadullah 1999 4.71 3.70 5.71 0.00
Borska 2006 -0.13 -0.53 0.28 0.54
Chodorowska 1998 1.45 0.80 2.10 0.00
Coimbra 2010a 1.88 1.40 2.35 0.00
Jacob 2003 0.36 -0.69 1.41 0.50
Kanda 2010 -0.42 -0.86 0.02 0.06
McLoone 2004 0.00 -1.01 1.01 1.00
Mizutani 1997 0.00 -0.50 0.50 1.00
Reddy 2010 -0.37 -0.77 0.04 0.08
Seishima 1998 (pso) 0.00 -0.44 0.44 1.00
Seishima 1998 (active GPP) 7.09 5.65 8.52 0.00
Bevelacqua 2006 (mild pso) 0.90 0.27 1.54 0.01
Bevelacqua 2006 (severe pso) 4.39 3.37 5.40 0.00
Bonifati 1994 0.49 -0.28 1.26 0.21
Corbetta 2006 2.41 1.26 3.57 0.00
Gonul 2009 0.48 0.09 0.87 0.02
Abdel-Hamid 2010 0.42 -0.09 0.92 0.10
Kitamura 1999 0.63 0.05 1.21 0.03
Coimbra 2010c 1.08 0.49 1.67 0.00
Kagami 2010 1.23 0.53 1.92 0.00
Roussaki-Schulze 2005 1.16 0.71 1.60 0.00
Mussi 1997 0.98 0.47 1.49 0.00
Qiu 2005 2.97 2.25 3.69 0.00
1.32 0.86 1.79 0.00
-6.00 -3.00 0.00 3.00 6.00
 
e. C-reactive Protein
Study Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Ardic 2010 0.36 -0.06 0.77 0.10
Chandran 2010 0.08 -0.47 0.62 0.78
Chodorowska 2004 1.20 0.79 1.60 0.00
Coimbra 2009 2.53 1.98 3.08 0.00
Coimbra 2010a 2.98 2.41 3.55 0.00
Coimbra 2010b 2.55 2.04 3.07 0.00
Ctirad 2008 1.39 0.94 1.83 0.00
Kaya 2010 0.36 -0.06 0.77 0.10
Laurent 1981 1.22 0.50 1.94 0.00
Love 2010 9.89 9.53 10.26 0.00
Martyn-Simmons 2011 1.32 0.98 1.66 0.00
Ohtsuka 2008 0.76 0.44 1.08 0.00
Rocha-Pereira 2004 2.81 2.25 3.37 0.00
Serwin 2006 3.33 2.51 4.14 0.00
Yiu 2010 0.89 0.49 1.30 0.00
Bevelacqua 2006 (mild pso) 0.00 -0.61 0.61 1.00
Bevelacqua 2006 (severe pso) 1.55 0.93 2.18 0.00
Balci 2009 0.21 -0.23 0.66 0.34
Vanizor Kural 2003a 0.93 0.40 1.47 0.00
Karabudak 2008 1.90 1.15 2.64 0.00
Vanizor Kural 2003b 0.97 0.47 1.46 0.00
Coimbra 2010d 3.06 2.37 3.74 0.00
1.83 0.76 2.90 0.00
-6.00 -3.00 0.00 3.00 6.00
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f. E-selectin
g. intracellular Adhesion Molecule-1
Study Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Takahashi 2010 6.25 5.57 6.92 0.00
Borska 2006 2.10 1.60 2.60 0.00
Reddy 2010 -0.09 -0.50 0.31 0.66
Vanizor Kural 2003a 0.52 0.01 1.03 0.05
Schopf 1993 1.08 0.36 1.80 0.00
Kowalzick 1993 4.00 2.68 5.32 0.00
Yamamoto 1997 (plaque pso) 3.18 1.30 5.07 0.00
Yamamoto 1997 (GPP) 3.42 1.65 5.20 0.00
Long 2010 4.03 3.37 4.68 0.00
Carducci 1994 1.78 1.22 2.34 0.00
De Pita 1996 1.51 0.74 2.27 0.00
Gangemi 2003 0.96 0.23 1.70 0.01
Groves 1995 2.61 1.54 3.69 0.00
Lecewicz-Torun 1997 1.07 0.33 1.80 0.00
De Pita 1999 2.26 1.50 3.02 0.00
Griffiths 1996 0.75 0.34 1.16 0.00
Kitamura 1999 0.33 -0.24 0.90 0.25
Krasowska 1998b 0.97 0.34 1.61 0.00
Bubl 1994 0.61 0.13 1.08 0.01
Fazio 1994 0.45 -0.32 1.21 0.25
Krasowska 2000 0.87 0.12 1.62 0.02
Ameglio 1994 1.48 0.65 2.32 0.00
1.77 1.14 2.39 0.00
-6.00 -3.00 0.00 3.00 6.00
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tumor necrosis factor-α
The search yielded 24 studies showing an elevated SMD for TNFα of 1.32 (95% CI 0.86-1.79) 
(Figure 2d). Meta-regression showed that the older the age of patients within the studies, the 
smaller the difference in TNFα between psoriasis patients and controls (β=-0.13, p=0.002). 
Gender and PASI do not explain the difference in effect size between the studies.
C-reactive Protein
The mean CRP across studies was significantly elevated in psoriasis compared to controls 
(d=1.83, 95% CI 0.76-2.90) (Figure 2e). The meta-regression for PASI showed a slope of 0.07 
with a p=0.057, demonstrating a trend that an increase in PASI is associated with an increase 
in difference in mean CRP between psoriasis patients and controls. Regarding the subgroup 
analyses, no statistically significant differences were observed between subgroups for pso-
riasis type (Table 2).
E-selectin
The combined SMD for E-selectin was nearly twice as high in psoriasis compared to controls 
(d=1.78, 95% CI 1.32-2.25). Neither age, nor gender or psoriasis severity explained the high 
heterogeneity (I2=78%) between the studies. The measurement method had no influence on 
the heterogeneity because all 11 studies used the ELISA technique. Analyzing the forest plot, 
the study by Groves et al including 9 patients with erythrodermic psoriasis appears to have 
the highest SMD, indicating that patients in this study with severe disease have higher levels 
of E-selectin than healthy controls18 (Figure 2f ).
intracellular-Adhesion-Molecule-1
A total of 21 articles including 714 psoriasis patients and 601 controls yielded a significant 
positive association between psoriasis and ICAM-1 (d=1.77, 95% CI 1.15-2.39). Meta-regres-
sion and subgroup analyses did not show significant results. Interestingly the two largest 
studies including more than 100 therapy naïve psoriasis patients show SMDs varying from 
-0.09 (95% CI -0.50-0.31) to 6.25 (95% CI 5.57-6.92).19,20 The remaining studies have SMDs 
which lie in between (Figure 2g).
negative subgroups findings
The high level of heterogeneity between studies (all I2>75%), could not be explained by the 
subgroup analyses. These showed that the measurement method did not have a significant 
impact on the SMD for any of the studied markers of inflammation. There was also no sig-
nificant difference between studies with a higher and those with a lower quality assessment 
score, with the exception of IL-10, where nine studies with a higher score had a larger pooled 
effect size than the three studies with a lower score (Table 2).
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Publication bias
The funnel plots for IL-1β, TNFα, CRP and ICAM-1 showed evidence of asymmetry (Supple-
mentary Figures 2a, d, e, g). The addition of the “missing” studies imputed using the trim and 
fill method shifted the effect size for IL-1β and IL-10 towards significance with adjusted point 
estimates of -0.84 (-1.60-(-0.08)) and 1.96 (0.50-3.43) respectively. For CRP, TNFα, E-selectin 
and ICAM-1, the addition of the “missing” studies only increased the magnitude of the pooled 
effect sizes, which remained significant.
The Egger’s test confirmed the presence of publication bias for TNFα (6.09, 95% CI 1.42-
10.76) and ICAM-1 (5.58, 95% CI 0.003-11.17), however there also appeared to be publication 
bias for IL-6 (p=0.002).
DisCUssion
The current meta-analysis shows mild systemic inflammation in psoriasis patients compared 
to healthy controls with five of the six investigated pro-inflammatory serum markers being 
increased in psoriasis. The difference is nearly two points at the most and is overall inde-
pendent of age, gender, disease severity, psoriasis type, measurement methods and quality 
assessment for the different studies.
Contrary to expected, pooled anti-inflammatory IL-10 was not significantly decreased in 
psoriasis patients; of the 13 studies on IL-10, only 3 showed a significantly lower IL-10 in 
psoriasis. The literature on psoriasis suggests that IL-10 deficiency might play a role in its 
pathogenesis21 and a study even showed that antipsoriatic treatment lead to normalization 
of IL-10 values.20
The cytokines IL-1β, IL-6 and TNFα produced by the keratinocytes are key in the activation 
of innate immunity through activation of dendritic and T-cells (Figure 3 and Table 3).2 These 
pro-inflammatory cytokines are also produced in adipose tissue, hereby linking inflammation 
of the skin with obesity.6 In this meta-analysis, pooled serum IL-1β was the only marker to not 
be significantly elevated in psoriasis patients compared to healthy controls. This was contrary 
to expected because IL-1 triggers the production of IL-6 and TNFα in the molecular cascade 
and should therefore also be elevated.3 This result could be due to a limited number of stud-
ies on serum IL-1β. Age explained part of the heterogeneity between the studies for IL-6 and 
TNFα, indicating that the older the patients in the study, the smaller the SMD between the 
psoriasis patients and the controls. This could possibly be explained by decreasing immunity 
with increasing age.22
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IL-1β and IL-6 act together to enhance CRP.23 IL-6 was elevated in our analyses and can there-
fore explain the increased CRP obtained in psoriasis patients. In search of a novel biomarker 
to monitor disease progression and severity and improve cardiovascular risk prediction, CRP 
is also being used in other comorbidities.9,24,25 In the past decade, numerous meta-analyses 
have investigated the use of CRP in the prediction of CVD, concluding that CRP is at the most 
a moderate predictor of CVD compared to major established risk factors.9-11
figure 3. A simplified model, depicting the role of the inflammatory markers in this meta-analysis.
table 3. role of the selected inflammatory markers.
IL-1β IL-1 is a pro-inflammatory cytokine which activates neutrophils, monocytes, eosinophils and 
basophils and triggers production of TNFα, IL-6 by macrophages. Keratinocytes are the main 
source of IL-1β in the skin.
IL-6 IL-6 is a pro-inflammatory cytokine and is involved in the growth and differentiation of dermal 
and epidermal cells and can directly stimulate T-cell migration to the epidermis. IL-1 and TNFα 
activate keratinocytes to produce IL-6.
IL-10 IL-10 acts as an anti-inflammatory cytokine and can be produced by different cell populations, 
including keratinocytes, T-cell subsets, macrophages and monocytes and is capable of inhibiting 
synthesis of pro-inflammatory cytokines.
TNFα TNFα influences the proliferation, activation and differentiation of many cells and enhances the 
synthesis of IL-1, IL-6 and expression of adhesion molecules such as E-selectin and ICAM-1.
(hs)CRP CRP is a pro-inflammatory acute phase protein produced by the liver and a sensitive marker 
of systemic inflammation. Traditional assays for CRP are insufficiently sensitive for measuring 
the lower serum values associated with atherosclerotic disease. These can be measured by the 
newer hsCRP assays.
E-selectin E-selectin is a pro-inflammatory soluble cell adhesion molecule expressed on endothelial 
cells activated by cytokines. It is enhanced by TNFα and CRP through endothelial cells. During 
inflammation, E-selectin recruits leucocytes to the site of injury.
ICAM-1 The soluble intracellular adhesion molecule ICAM-1 is induced by TNFα, IL1 and CRP through 
endothelial cells. It is expressed by the vascular endothelium, macrophages and lymphocytes. It 
causes leucocytes to bind to endothelial cells and then to migrate into tissues.
Abbreviations: IL, Interleukin; TNF, Tumor Necrosis Factor; (hs)CRP, (high sensitivity) C-reactive protein; 
ICAM, Intracellular Adhesion Molecule.
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The soluble adhesion molecules E-selectin and ICAM-1, located at the end of the inflamma-
tory cascade, are enhanced by TNFα and CRP through endothelial cells.26,27 Of the inflamma-
tory markers studied in this meta-analysis, the SMD between psoriasis and controls was the 
highest for E-selectin and ICAM-1. These adhesion molecules have been available for several 
decades; however their clinical relevance is yet unclear. They can be involved in various condi-
tions, from infections, vasculitis, cancer to atherosclerosis and CVD.27,28 However, the evidence 
on adhesion molecules is contradictory, even within the same condition such as CVD.12,29
In other inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing 
spondylitis, there seems to be a general consensus that inflammatory markers are elevated in 
patients compared to healthy controls.30-32 This consensus is based on convenient individual 
studies rather than on meta-analysis. The concept that the elevation of inflammatory markers 
leads to systemic inflammation and comorbidities such as CVD seems to be logical, however 
there is a large gap between measuring systemic inflammation in the blood and the registra-
tion of events, and it is a further challenge to determine whether these events have a causal 
relationship to the exposure.26 This gap should be filled with hard evidence in order to prove 
a possible relationship between exposure and outcome. The present study confirms the 
elevation of markers in psoriasis, however does not investigate the link between this modest 
elevation and eventual metabolic diseases or cardiovascular events.
As to the clinical relevance of these markers of inflammation based on the results of this 
meta-analysis, we believe that they cannot be considered as markers of disease severity be-
cause they were only modestly increased in psoriasis patients compared to controls and the 
increase was independent of the PASI. However this does not exclude the fact that markers 
of inflammation could be important targets for therapy, such as is the case with TNFα, and 
recently IL-17.33
strengths and limitations
This is the first and largest meta-analysis on markers of inflammation in psoriasis combining 
78 studies with a psoriasis and comparative group of healthy subjects to pool information 
on seven different serum markers. We performed an extensive systematic search using three 
databases to retrieve articles. We limited selection bias of the articles by not restricting the 
language of the search and included foreign articles if the abstract and full text provided 
sufficient data. We included a considerably large number of studies, which were mainly 
observational in nature and consisted of small numbers of psoriasis patients. We not only 
investigated pro-inflammatory markers but also anti-inflammatory IL-10.
We analyzed baseline values of markers in treatment-naïve psoriasis patients and therefore 
could not draw conclusions on the use of serum markers in measuring disease progression. 
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Approximately two studies per outcome did not report the mean marker values completely 
and therefore could not be included in the meta-analysis, however we do not expect this to 
have influenced the obtained effect size because these studies showed varying results.34-42
We assume that most patients had moderate to severe disease (75% of studies had a 
PASI>10), possibly limiting the generalizability of our findings. On the other hand, the 
analyses showed that that the effect size for the serum markers was independent of disease 
severity.
In order to explain the high degree of heterogeneity between the studies, we conducted 
several meta-regression and subgroup analyses. The results should be interpreted cautiously 
because they were based on covariates at the level of the study in contrast to covariates from 
individual patient data, possibly leading to aggregation bias.
We used three different methods to assess publication bias and depending on the method 
used there seemed to be publication bias or not. This bias however did not change the direc-
tion of the association for any of the markers when using the trim and fill method.
The quality assessment scores were not high due to incomplete data on several items, the 
latter also influencing our selection of subgroup analyses. We acknowledge that REMARK 
is more a reporting device; nevertheless we did not expect the study quality to influence 
the studied outcomes because we compared objective measurements (serum marker levels) 
which are not dependent on factors such as blinding or allocation concealment. This was 
confirmed in the subgroup analysis showing no difference in pooled estimate between stud-
ies with a high and those with a low quality assessment score.
ConClUsion
Psoriasis patients show at the most mild systemic inflammation compared to controls. The 
elevation of the inflammatory markers is independent of psoriasis type and severity, ques-
tioning their use as biomarkers. In order to investigate the clinical relevance of this modest 
increase in inflammation, it would be interesting to conduct a review summarizing the 
evidence on the effect of antipsoriatic therapy on markers of inflammation.
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supplementary table 1. search strategy.
Database search string
PubMed psoriasis[tw] AND (interleukin-1[tw] OR il-1[tw] OR interleukin-10[tw] OR il-10[tw] OR 
interleukin-6[tw] OR il-6[tw] OR tumor necrosis factor*[tw] OR tnf[tw] OR c-reactive 
protein*[tw] OR crp[tw] OR icam[tw] OR sicam[tw] OR intercellular adhesion 
molecule*[tw] OR e-selectin*[tw] OR se-selectin*[tw] OR endothelial leukocyte adhesion 
molecule*[tw] OR elam[tw] OR selam[tw]) NOT (animals[mesh] NOT humans[mesh]) NOT 
(case reports[pt] OR letter[pt])
Embase (psoriasis/syn AND (((interleukin OR il) NEAR/1 (1 OR 6 OR 10 OR 1a* OR 1α OR 1b* 
OR 1β)):ti,ab,de OR (‘tumor necrosis’ NEAR/1 factor*):ti,ab,de OR tnf:ti,ab,de OR 
(‘c-reactive’ NEAR/1 protein*):ti,ab,de OR crp:ti,ab,de OR icam:ti,ab,de OR sicam:ti,ab,de 
OR (‘intercellular adhesion’ NEAR/1 molecule*):ti,ab,de OR ((e OR se) NEAR/1 
selectin*):ti,ab,de OR (‘endothelial leukocyte adhesion’ NEAR/1 molecule*):ti,ab,de OR 
elam:ti,ab,de OR selam:ti,ab,de) NOT ([animals]/lim NOT [humans]/lim)) NOT (‘case reports’ 
OR ‘case report’):ti,ab,de NOT [letter]/lim
web of science psoriasis AND (((interleukin OR il) SAME (1 OR 6 OR 10 OR 1a OR 1alpha OR 1alfa OR 1b OR 
1beta)) OR “tumor necrosis factor” OR tnf OR “c reactive protein” OR crp OR icam OR sicam 
OR “intercellular adhesion molecule*” OR “e selectin*” OR “se selectin*” OR “endothelial 
leukocyte adhesion molecule*” OR elam OR selam) NOT (animal* NOT human*) NOT “case 
report” NOT “case reports”
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supplementary figure 1. selected inflammatory serum markers based on a selection of markers ana-
lyzed in psoriasis and cardiovascular disease.
IL-1
IL-6
IL-8
IL-12
IL-17
IL-23
TNFα 
IFNγ
(hs)CRP
TNFα
IL-6
ICAM-1
VCAM-1
E-selectin
IFNγ
MCP-1
Psoriasis Cardiovascular 
disease
IL-1
IL-6
TNFα 
(hs)CRP
ICAM-1
E-selectin
IL-10 *
Selected 
markers
Abbreviations: IL, Interleukin; hsCRP, high sensitivity C-Reactive Protein; TNFα, Tumor Necrosis Factor alpha; 
ICAM-1, Intracellular Adhesion Molecule 1; IFNγ, Interferon gamma; MCP-1, Monocyte Chemoattractant 
Protein-1.
* Il-10 was deliberately chosen as an anti-inflammatory serum marker.
supplementary figures 2a to g. funnel plots identifying publication bias for all studied outcomes.
Abbreviations: Std diff in means, Standardized mean difference.
a. interleukin-1β
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b. interleukin-6
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e. C-reactive Protein
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f. E-selectin
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g. intracellular Adhesion Molecule-1
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AbstrACt
Psoriasis has been suggested to be an independent risk factor for cardiovascular disease, 
however available studies have shown inconsistent results. In this study, embedded within 
the population-based Rotterdam Study, we aimed to assess the association between psoria-
sis and cardiovascular outcomes.
Adjusted means were calculated for subclinical atherosclerosis using general linear models. 
Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time dependant 
variable, were calculated.
A total of 262 psoriasis (of which 24% had systemic or UV treatment) and 8,009 reference 
subjects were followed for a mean of 11 years. Psoriasis patients were significantly younger, 
smoked more and had higher diastolic blood-pressure and BMI levels. The adjusted carotid 
intima-media-thickness was 1.02±0.18mm for psoriasis and 1.02±0.16mm for reference sub-
jects. Similarly, crude and adjusted ankle-brachial index, pulse wave velocity and coronary 
artery calcium scores did not differ between the two groups. The risk of incident cardiovas-
cular disease was not increased in psoriasis (adjusted HR 0.73, 95% CI 0.50-1.06). The results 
were similar when coronary heart disease, stroke and heart failure were analyzed separately.
Psoriasis patients with predominantly mild disease from the general population are as 
likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.
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introDUCtion
Psoriasis is an inflammatory condition affecting the skin and, in approximately 10% of the 
patients, the joints.1,2 In the last decade, most observational studies on psoriasis have sug-
gested that the chronic inflammation in psoriasis is more than skin deep and results in a 
‘psoriatic march’ that can lead to endothelial dysfunction, atherosclerosis and eventually to 
cardiovascular disease.3 Case-control studies assessing the association between psoriasis 
and atherosclerosis are often based on patients from tertiary clinics with more severe and 
recalcitrant disease and a higher degree of impairment and are therefore not necessarily 
representative of the general psoriasis population.4-6 Studies based on routine databases 
or selected groups have shown an elevated risk of myocardial infarction (MI) in a specific 
subgroup, namely young psoriasis patients treated with systemic medication.7-10 Emerging 
research on cardiovascular disease in psoriasis in large population-based cohorts using re-
search and routine databases, report inconsistent results.7-27 Differences across studies can be 
explained by discrepancies in case ascertainment and definition of exposure and outcome, 
study-setting and design, adjustment for cardiovascular risk factors, inadequate statistical 
power and residual confounding.
There is no population-based study thus far, where all subjects receive the same examina-
tions independent of their health status, focussing simultaneously on atherosclerosis and 
hard cardiovascular outcomes, adjusting for several risk factors. Therefore the present study 
was designed to address subclinical atherosclerosis, coronary heart disease (CHD), stroke and 
heart failure in subjects diagnosed with psoriasis by a physician and reference subjects in 
the population-based Rotterdam Study, where detailed information on cardiovascular risk 
factors is available.28
MAtEriAls AnD MEtHoDs
study population
This study is embedded within the prospective population-based Rotterdam Study, de-
scribed elsewhere.28 All inhabitants of a suburb of Rotterdam aged 45 years and older were 
invited to participate. The baseline examination was completed between 1990 and 1993. In 
2000, the cohort was extended to include inhabitants who reached the age of 55 years or 
migrated to the research area. In 2005, a second expansion included all persons aged 45 and 
older. Participants have been followed since inclusion and examined every 4 years. The cur-
rent study using data from the original and first extended cohort comprised 10,994 subjects 
(participation rate of 75%). Information on non-participants was not available because they 
had not consented to participate in the study.
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The Rotterdam Study was approved by the Medical Ethics Committee of Erasmus Univer-
sity, Rotterdam, the Netherlands and adhered to the Helsinki Guidelines. All participants gave 
written informed consent.
Assessment of psoriasis
Psoriasis subjects in the Rotterdam Study were identified on a continuous basis. Medical 
record review was performed after a digital search for subjects with a diagnostic code for 
psoriasis by the GP (S91) and for participants with psoriasis medication according to the 
Anatomical Therapeutic Chemical Classification System.29 The GP records were searched 
for diagnosis of psoriasis in the GP notes, medical specialist reports and hospital discharge 
letters, registering the medical provider who diagnosed psoriasis. Patients were defined as 
having “possible” psoriasis if they had a prescription for one of the following medications: 
psoralens, dithranol, calcipotriol, calcitriol, coal tar, tacrolimus, pimecrolimus, fumaric acid, 
acitretin, methotrexate, ciclosporin, or biologicals. Definite psoriasis cases (n=277) were 
patients with a diagnosis of psoriasis by a dermatologist or rheumatologist, patients whose 
disease was mentioned twice or more by the GP, patients with a diagnosis of psoriasis based 
on psoriasis specific medication, and patients with psoriasis at the time of skin examination 
(Supplementary Figure 1). The latter was available in a subgroup of 1,551 of the 10,994 sub-
jects who were screened for dermatological conditions between August 2010 and November 
2011. For psoriasis patients from this group (n=47), the date of onset and Psoriasis Area and 
Severity Index (PASI) were recorded. The PASI was available in 14% of patients and ranged 
from 0.4-12.7.
We validated our algorithm using skin examination conducted in 1,551 subjects as the 
golden standard. The sensitivity and specificity were both 98%, with a positive predictive 
value (PPV) of 62% and negative predictive value of 99.9%. Accounting for patients who did 
not have psoriasis at skin examination, but during the interview reported having red, scaly 
plaques in the past, yielded a PPV value of 82%.
The date of psoriasis onset was the date of first diagnosis in the medical record (by the 
dermatologist, other medical specialist or the GP), the date of first antipsoriatic medication, 
or the self-reported date of onset (n=18), whichever came first. For the analyses, the “index 
date” for psoriasis was determined based on the date of psoriasis onset: this was the study 
entrance date for prevalent cases (with psoriasis onset before study inclusion) or a later date 
corresponding to the date of psoriasis onset for patients who developed psoriasis after inclu-
sion to the study.
Patients had mild psoriasis if they had only used topical treatment, had a PASI<10 at skin 
examination, or if they had not been treated at all, during follow-up. Patients with moderate 
to severe disease had been treated with UV therapy or systemic medication during follow-
up10,27 or had a PASI>10.
183
4.2 Atherosclerosis and cardiovascular events in psoriasis
reference population
The reference population consisted of 9,023 participants in the Rotterdam Study who did not 
use any of the above mentioned antipsoriatic medications during the follow-up and did not 
have a GP code for psoriasis. Their “index date” was the date of inclusion in the study.
subclinical measures of atherosclerosis
Atherosclerosis measurements were repeated at center visits. For psoriasis patients, the first 
available measurement after the date of onset was used in our analyses. If this was not avail-
able, measurements up to 6 months prior to the date of onset were included and otherwise 
psoriasis patients were excluded from the analyses. For reference subjects, the first available 
measurements after inclusion in the study were used. Carotid atherosclerosis and lower 
extremity atherosclerosis were assessed by measuring carotid intima-media thickness (IMT) 
and plaques and ankle-brachial index (ABI). Peripheral artery disease (PAD) was defined as ABI 
values of 0.9 or less.30 Coronary artery calcium (CAC) was assessed in the epicardial coronary 
arteries on CT scans. Carotid-femoral pulse wave velocity (PWV) measured aortic stiffness. 
The methods for these measurements are described in Supplementary Material and Methods 
and Supplementary Figure 2 depicts when they were performed. The measurements were 
not available for the entire population due to various reasons: no consent obtained, measure-
ments conducted after patients left follow-up and limited availability of ultrasonographers. 
Additionally, for psoriasis patients we only included measures of atherosclerosis after psoria-
sis onset in our analyses.
Cardiovascular outcomes
The clinical outcomes of this study are incident cardiovascular morbidity and mortality, 
described in detail previously.31 The medical records of all study participants were continu-
ously assessed for events. In brief, we investigated incident “hard” CHD defined as MI (fatal 
or non-fatal) and fatal CHD, excluding subjects with a history of MI or revascularization.32 
Stroke was defined as cerebral infarction diagnosed by CT scan, excluding stroke by intrace-
rebral haemorrhage, possibly caused by trauma and therefore not a cardiovascular event.33,34 
Heart failure was defined according to the European Society of Cardiology.35 Methods on 
assignment of prevalent and incident heart failure cases in the Rotterdam Study have been 
elaborated elsewhere.36,37
The primary outcome was incident cardiovascular disease (CVD); the secondary outcomes 
were the components of CVD, namely CHD, cerebral infarction diagnosed by CT, and heart 
failure. Median interquartile range (IQR) for follow-up was 9.11 (7.55, 16.03) years.
Cardiovascular risk factors
Information on traditional cardiovascular risk factors was collected: age, gender, smoking, 
body mass index (BMI), total and high-density lipoprotein (HDL) cholesterol, systolic and 
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diastolic blood pressure, use of lipid-lowering drugs, diabetes mellitus defined as the use of 
oral blood-glucose-lowering drugs or insulin or non-fasting glucose >11mmol/L or fasting 
glucose > 7mmol/L. Hypertension was defined as systolic pressure ≥140mm Hg or diastolic 
pressure ≥90mm Hg (mean of 2 measurements) or use of blood-pressure-lowering medica-
tion for the indication of hypertension.28
statistical analysis
The distribution of baseline characteristics was compared using t-test for continuous vari-
ables and Chi-Square for proportions. For atherosclerosis, we compared crude and adjusted 
means (± standard deviation [SD]) for IMT, ABI, and PWV and proportions for PAD and carotid 
plaques across the groups using general linear model analysis of variance. Two adjusted 
models were performed; once for age and gender, and the second model adjusting addition-
ally for BMI, systolic blood pressure, treatment of hypertension, total and HDL cholesterol, 
current smoking and diabetes mellitus.38,39 Due to the skewed distribution of CAC and to 
handle CAC scores of zero, we used the natural logarithm of (CAC+1) and back-transformed 
the results to obtain the geometric mean (95% confidence interval [CI]). We calculated crude 
and adjusted hazard ratio (HR) and 95% CI for developing incident CHD, stroke and heart 
failure using a time-dependant Cox regression analysis where psoriasis was treated as a time-
dependent variable using the index date. In this analysis the follow-up in years started from 
the date of inclusion to the Rotterdam Study until the first cardiovascular event, until death 
or the end of the follow-up period predetermined for the analyses, whichever came first. We 
adjusted these analyses according to the two above-mentioned models.
For all analyses, subjects with more than four missing covariates were excluded. For sub-
jects with less than four missing values, the covariates were imputed using multiple imputa-
tion (maximum missing values were 2.8%, for BMI).
sensitivity analysis
To assess the impact of psoriasis severity, the analyses were repeated for patients with mild 
and moderate to severe disease. In a Cox regression analysis we investigated whether patients 
with psoriasis onset prior to study inclusion (and therefore a longer duration of psoriasis) had 
an increased risk of CVD.
All analyses were conducted with SPSS version 17.0. (SPSS inc., Chicago, IL, USA).
rEsUlts
A total of 262 psoriasis patients and 8,009 reference subjects were followed for a median (IQR) 
of 11.1 (8.2; 16.5) and 9.1 (7.5; 16.0) years respectively. Of the 262 psoriasis patients, 44% were 
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diagnosed by the dermatologist, 2% by the rheumatologist, 32% by the GP, 16% based on 
antipsoriatic medication and 6% were diagnosed with psoriasis during skin examination. The 
gender distribution was comparable in both groups, but the psoriasis subjects were slightly 
younger (p<0.001) (Table 1). Almost a quarter of patients had received systemic medication 
or ultraviolet (UV) therapy. At study entry, psoriasis patients smoked significantly more (32% 
versus 22%), had a slightly higher BMI (27.1kg/m² versus 26.5kg/m²) and diastolic blood pres-
sure and used more cholesterol-lowering medication. There were no significant differences 
in total and HDL cholesterol, systolic blood pressure, antihypertensive treatment or diabetes 
mellitus between the two groups (Table 1).
subclinical measures of atherosclerosis
The crude mean carotid IMT for psoriasis was 1.00±0.20mm and 1.02±0.21mm for refer-
ence subjects (p=0.47; Table 2). Neither adjusting for age and gender alone nor adjusting 
table 1. Characteristics of psoriasis patients and reference population in the rotterdam study.
variable
Psoriasis
n=262
reference
n=8,009
p-value1
Age 64.32 ± 6.82 68.78 ± 9.47 <0.001
Male, n (%) 115 (43.9) 3,377 (42.2) 0.56
Psoriasis therapy2
topical therapy only, n (%) 158 (56.1) N/A
Uv therapy, n (%) 31 (14.8) N/A
systemic therapy, n (%) 46 (17.6) N/A
no therapy, n (%) 52 (19.8) N/A
systolic blood pressure, mm Hg 141 ± 21.92 140.7 ± 22.2 0.85
Diastolic blood pressure, mm Hg 76.7 ± 10.6 75.2 ± 11.8 0.05
Antihypertensive treatment, n (%) 85 (32.4) 2,515 (31.4) 0.72
Hypertension, n (%)3 157 (59.9) 5,036 (62.9) 0.33
body mass index, kg/m² 27.1 ± 3.9 26.5 ± 3.8 0.007
waist to hip ratio 0.91 ± 0.08 0.91 ± 0.09 0.32
total cholesterol, mmol/l 6.27 ± 1.24 6.37 ± 1.21 0.20
HDl cholesterol, mmol/l 1.34 ± 0.35 1.35 ± 0.36 0.63
Cholesterol-lowering medication, n (%) 23 (8.8) 403 (5.0) 0.007
Diabetes mellitus, n (%) 18 (6.9) 698 (8.7) 0.30
Current smoking, n (%) 85 (32.4) 1,773 (22.1) <0.001
Abbreviations: UV, Ultraviolet; HDL, High density lipoprotein; mmol/l, millimole per liter.
Data are mean ± standard deviation for continuous variables and proportions for dichotomous variables.
1 P-values were calculated with the t-test for continuous variables and with the Chi-square test for propor-
tions.
2 Percentages do not add up to 100% because some patients had UV and systemic therapy.
3 Hypertension: blood pressure ≥140/90 and/or antihypertensive medication.
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for all cardiovascular risk factors at the time of the IMT measurement, changed the mean 
IMT considerably for the two groups (fully adjusted mean 1.02±0.18mm for psoriasis and 
1.02±0.16mm for the reference population, p=0.62). Of the psoriasis patients, 72% had a 
carotid plaque compared to 65% of the reference population (p=0.09). When adjusting for 
age, gender and cardiovascular risk factors, psoriasis patients had 9% more plaques than 
the reference population (p=0.01). The mean ABI was not significantly different with a fully 
adjusted mean of 1.04±0.18 for psoriasis and 1.05±0.17 for reference subjects. There was no 
significant difference in presence of PAD between the two groups (p=0.26).
The crude geometric mean CAC score was 53.51 (95% CI 32.99-86.42) in psoriasis com-
pared to 55.98 (95% CI 51.26-61.12) in the reference group (p=0.86). The adjusted CAC scores 
table 2. subclinical measures of atherosclerosis in psoriasis patients after psoriasis diagnosis, com-
pared with the reference population.
Measure of 
atherosclerosis
n Crude mean 
± sD1
p-value Age and gender 
adjusted mean 
± sD1
p-value fully adjusted
mean ± sD1,2
p-value
Carotid intima-media thickness, mm
Psoriasis 143 1.00 ± 0.20 0.47 1.03 ± 0.19 0.49 1.02 ± 0.18 0.62
Reference 6,525 1.02 ± 0.21 1.02 ± 0.16 1.02 ± 0.16
Carotid plaque, %
Psoriasis 165 71.5% 0.09 75.5% 0.004 73.9% 0.01
Reference 6,519 65.1% 65.0% 65.0%
Ankle-brachial index
Psoriasis 139 1.06 ± 0.17 0.40 1.03 ± 0.19 0.21 1.04 ± 0.18 0.51
Reference 7,022 1.04 ± 0.20 1.05 ± 0.17 1.05 ± 0.17
Peripheral artery disease, %3
Psoriasis 139 14.4% 0.26 20.1% 0.48 19.0% 0.73
Reference 7,022 18.1% 18.0% 18.0%
Coronary artery calcium score4
Psoriasis 106 53.51
(32.99 – 86.42)
0.86 59.64
(38.50 – 92.04)
0.77 51.40
(33.59 - 78.41)
0.69
Reference 3,168 55.98
(51.26 – 61.12)
55.77
(51.50 – 60.41)
56.05
(51.89 - 60.55)
Pulse-wave velocity, m/s
Psoriasis 117 13.39 ± 3.14 0.54 13.61 ± 2.81 0.11 13.49 ± 2.60 0.24
Reference 4,551 13.21 ± 3.17 13.20 ± 2.77 13.20 ± 2.56
Abbreviations: SD, standard deviation; CI, Confidence Interval.
1 Means are estimated marginal means using general linear model analysis of variance.
2 Adjusted for age, gender, current smoking, body mass index, total cholesterol, HDL-cholesterol, systolic 
blood pressure, antihypertensive medication and diabetes mellitus.
3 Peripheral artery disease was defined as ankle-brachial values of 0.9 or less.
4 Coronary artery calcium score data were log transformed; we present back-transformed geometric means 
and 95% CI.
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did not change considerably and the difference between the two cohorts remained non-
significant. Carotid-femoral PWV was also not significantly different in the crude and fully 
adjusted models, with an adjusted PWV of 13.49±2.60m/s for psoriasis and 13.20±2.56m/s for 
the reference population (Table 2).
Cardiovascular disease
We followed 259 psoriasis patients and 7,931 reference subjects for incident cardiovascular 
events. There were a total of 1,613 cardiovascular events during more than 89,000 person 
years of follow-up, of which 28 occurred among psoriasis patients. The crude HR for psoriasis 
in developing the composite outcome CVD, treating psoriasis as a time-dependant variable, 
was borderline significant with a HR of 0.69 (95% CI 0.48-1.00) suggesting that psoriasis was 
protective for CVD. However, after adjusting for age and gender the association was no lon-
ger significant (HR 0.83, 95% CI 0.57-1.21) and this was comparable to the fully adjusted HR of 
0.73 (95% CI 0.50-1.06). When separating CVD into its components, the crude risk for incident 
CHD was not significantly different in psoriasis patients and reference subjects (HR 0.69, 95% 
CI 0.40-1.16) and remained similar after adjusting for age and gender and cardiovascular risk 
factors (Table 3). The fully adjusted risk of developing incident cerebral infarction was not 
significantly elevated in psoriasis (HR 0.69, 95% CI 0.36-1.34) nor was the risk for incident 
heart failure (HR 0.80, 95% CI 0.51-1.25).
sensitivity analysis
For subclinical measures of atherosclerosis, the subgroup analyses in mild psoriasis patients 
and in those with moderate to severe disease, each compared to the reference subjects 
showed no significant difference between the groups (data not shown). Patients with mild 
psoriasis (n=197), representing 76% of psoriasis cohort, showed no elevated adjusted risk of 
developing CHD (HR 0.85, 95% CI 0.49-1.47), cerebral infarction (HR 0.62, 95% CI 0.28-1.38) 
or heart failure (HR 1.01, 95% CI 0.64-1.59). The 62 patients with moderate to severe psoriasis 
had a fully adjusted HR for CHD of 0.21 (95% CI 0.03-1.50). The significantly decreased risk of 
heart failure of 0.12 (95% CI 0.02-0.83) and CVD of 0.37 (95% CI 0.15-0.89) for the subgroup 
of moderate to severe psoriasis was no longer significant after adjusting for age and gender 
(Table 3).
The fully adjusted risk of developing CVD was not elevated in patients with prevalent pso-
riasis at inclusion to the study compared to incident psoriasis cases and reference subjects 
(HR 0.64, 95% CI 0.37-1.10), indicating that patients with longer duration of psoriatic disease 
in our study did not have an increased risk of developing a cardiovascular event.
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DisCUssion
The present prospective population-based study with more than 10 years of follow-up, 
showed similar risk factor profile for CVD among subjects with psoriasis compared to those 
without psoriasis. Extensively examined psoriasis patients diagnosed by the dermatologist 
or the GP were not at a higher risk for subclinical atherosclerosis compared to the reference 
population and psoriasis was not an independent risk factor for incident cardiovascular 
events.
subclinical measures of atherosclerosis
Among approximately 140 psoriasis cases, none of the adjusted subclinical measures of 
atherosclerosis were higher compared to the reference population, with the exception of the 
binary outcome carotid plaque which was significantly elevated in psoriasis after adjustment. 
Carotid plaques could be actually increased in psoriasis patients compared to controls. How-
ever other reasons are likely to explain this finding. Because of the number of tests in our study 
(n=8), chance findings due to multiple testing may occur: the p-value for the fully adjusted 
model for plaque exceeded the Bonferroni corrected p-value of 0.006 (0.05/8). Furthermore, 
using a dichotomous variable might have affected our findings; when IMT was used as a 
continuous variable, no significant difference was seen between the two groups. Our findings 
are in line with a study observing no difference in endothelial dysfunction between psoriasis 
patients and healthy controls after exclusion of CVD and traditional cardiovascular risk fac-
tors.40 Other studies analyzing IMT, ABI, CAC and PWV in psoriasis patients compared to con-
trols are few, are relatively small case-control studies with a suboptimal selection of controls 
and are conducted in selected groups such as patients recruited from hospital dermatology 
outpatient clinics5,41-45 and dermatology inpatients with relatively severe disease.46,47 These 
factors could explain the discrepancy between the elevated measures of atherosclerosis in 
psoriasis patients compared to the controls in these studies and the absence of a significant 
difference in our study. The mean values for IMT in the Rotterdam Study are in the range of 
the mean IMT among psoriasis outpatients without cardiovascular risk factors or history of 
CVD in two studies.42,43 The control groups in these studies were much smaller, consisted of 
healthy individuals and had significantly lower IMT values, compared to the psoriasis group. 
The IMT studies and the only two other studies measuring PWV41,44 included patients who 
were 20 years younger on average than the Rotterdam Study population possibly explaining 
the lower IMT and PWV values obtained.
Only one other study analyzed CAC score in 32 patients with a long history of severe psoria-
sis, showing a higher mean CAC score (78±140) than in the Rotterdam Study, but with a CAC 
score range similar to our study. The controls, matched for cardiovascular risk factors, had a 
considerably lower CAC score than psoriasis patients, possibly because they were enrolled 
from a different source.47
4. Atherosclerosis, inflammation and cardiovascular disease in psoriasis
190
Coronary heart disease
Our results, based on hard endpoints of MI and CHD mortality, are in line with studies con-
firming the absence of association between psoriasis and MI.7,23,24,27 A German case-control 
study showed that psoriasis was associated with cardiovascular risk factors, but not with MI 
and stroke, with ORs of 1.14 (95% CI 0.81-1.62) and 0.97 (95% CI 0.61-1.54) respectively.23 A 
large Dutch cohort demonstrated that the adjusted risk of ischemic heart disease was compa-
rable between the psoriasis and reference population (HR 1.05, 95% CI 0.95-1.17).27 Another 
case-control study among Israeli inpatients showed that the association between CVD and 
psoriasis was no longer significant after adjusting for risk factors.24 In the PUVA Follow Up 
Study, psoriasis patients were not at an increased risk of CVD deaths (standardized mortality 
ratio 1.02, 95% CI 0.90-1.60), with the exception of patients with extremely severe disease.25
Of more than 20 original studies on the association between MI, CHD and psoriasis, the ma-
jority were based on secondary databases, limited by detection bias and where information 
on cardiovascular confounders was not always available. Although most studies have dem-
onstrated increased, but varying risks of cardiovascular events, a recent systematic review 
concluded that there was no consistency in the literature as to elevated cardiovascular risk 
factors in psoriasis patients.48 Even the studies investigating these outcomes using the same 
database (GPRD) resulted in varying risks owing to differences in study design, exposure and 
outcome definitions and depending on whether incident or prevalent cases of CVD were 
investigated.7,10,14,18,31 Initially, all psoriasis patients seemed to be at an increased risk of devel-
oping CVD, but now it is considered to be limited to young patients with severe disease.7-11 
Interestingly, in our study the risk estimates obtained for CVD in psoriasis patients, albeit not 
statistically significant, were consistently below one, suggesting a possible protective effect 
for which we have no explanation.
stroke
The risk of stroke in psoriasis has been investigated in several studies, but with different 
outcome definitions: ischemic, hemorrhagic, unspecified stroke, stroke confirmed or not 
by computed tomography (CT) to including all subtypes. In studies assessing CVD, stroke 
should be restricted to ischemic stroke excluding non-cardiovascular related subtypes to 
avoid overestimation of cardiovascular events. The impact of this outcome definition is nicely 
illustrated in two publications using the Taiwanese Health Insurance database: in one study 
psoriasis is not associated with stroke (OR 1.04, 95% CI 0.82-1.33)26 and in another psoriasis 
is associated with ischemic stroke (HR 1.27, 95% CI 1.05-1.52).12 A Danish population-based 
study showed that the adjusted risk for ischemic stroke was significantly higher in mild and 
severe psoriasis patients compared to the reference population.11 The disparity with our 
results may be explained by the difference in degree of adjustment for cardiovascular risk 
factors, measuring study outcomes independent of patients’ health status, the use of a nar-
row definition of stroke and assessment of incident versus prevalent stroke.13,14
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Heart failure
Only one other study analyzed heart failure using data from the Taiwan National Health Insur-
ance, adjusting for income, geographical region and level of urbanization of the patients’ 
community with an OR for psoriasis of 1.63 (95% CI 1.22-2.19).26 In this same study mild 
psoriasis patients did not have an elevated risk for heart failure, however a significant as-
sociation was found with psoriasis patients exposed to photo- or systemic therapy (OR 1.69, 
95% CI 1.24-2.30). The discrepancy with our results can be explained by missing adjustment 
for cardiovascular risk factors.
strengths and limitations
The Rotterdam Study is a detailed population-based study with a follow-up of more than 10 
years and a very high participation rate among the inhabitants of the same district in Rot-
terdam.28 Psoriasis subjects underwent the same examinations as the reference population 
every 4 years, irrespective of disease severity, health status and overall healthcare utiliza-
tion, minimizing selection and detection bias. Epidemiology of CVD being one of the main 
study objectives of the Rotterdam Study, this therefore reduces residual confounding on 
cardiovascular predictors and disease. In this study the standardized measures of atheroscle-
rosis are state-of-the-art and the identification of cardiovascular events (using clinical data, 
symptoms, ECG changes, echocardiography, X-rays, CT, diagnoses by medical specialists and 
not only ICD codes)31 limits possible non-differential misclassification bias. The present study 
used hard endpoints, such as hard CHD and CT-confirmed stroke, to minimize the effect of 
over-detection of softer endpoints, such as angina or transient ischemic attack, and therefore 
the outcomes are less likely to be affected by subject status or psoriatic disease. Psoriasis 
patients were identified using medical files, pharmacy data and, in a subset, clinical examina-
tions, resulting in the expected prevalence of 3% (of which 24% had moderate to severe 
disease), confirming the validity of the exposure definition.49,50 For all psoriasis patients a 
reliable date of onset of disease was available. To explore the cause-effect relationship of 
whether chronic psoriasis-related-inflammation would lead to atherosclerosis and CVD, we 
restricted the analyses to measurements and events occurring after psoriasis onset during an 
observation period of more than 10 years.
Subjects were only included in the Rotterdam Study if they were 55 years and older. This 
limits the generalizability of our findings to younger or non-Caucasian populations. In the 
studies that document increased risk of CVD, the greatest relative risk is in the younger 
population with severe disease; however due to the design of the Rotterdam Study, we were 
unable to investigate this risk in younger patients. Moreover the majority of the patients 
in our study had mild disease. We acknowledge the limited sample size of the psoriasis 
group; however this is inherent to a population-based-approach. We found no significant 
difference in risk of CVD between psoriasis and reference subjects. Although our study may 
have been underpowered for some of the endpoints, a larger sample size would most likely 
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lead to a narrower 95% CI but not alter the HR substantially. Moreover, for the subclinical 
measures of atherosclerosis, post hoc power analyses showed that our study had very high 
power to show a difference between the two groups (data not shown). The case definition 
of psoriasis may have resulted in the identification of false positive psoriasis cases, which 
could have diluted the effect of psoriasis on CVD, resulting in risk estimates closer to one (i.e. 
differential misclassification bias). This is the largest study to concurrently assess subclinical 
atherosclerosis and incident cardiovascular events adjusting for cardiovascular risk factors 
in the same population-based sample of psoriasis patients and reference subjects. The case 
definition of psoriasis was predominantly based on healthcare utilization (i.e., diagnoses by 
physicians and drug dispenses), not taking into account patients who had not sought care 
for their psoriasis. These would have most probably been mild psoriasis cases and we expect 
that including them would not have influenced our results considerably. In order to capture 
the entire range of psoriasis patients in the future, screening for skin conditions in Rotterdam 
Study participants is ongoing, independent of whether participants seek medical care from 
their GP or take antipsoriatic medication.
ConClUsion
Psoriasis patients from the general population with predominantly mild disease have a 
comparable cardiovascular risk profile to subjects without psoriasis and do not have a higher 
prevalence of subclinical atherosclerosis. In the present cohort, psoriasis did not appear to 
be an independent risk factor for incident cardiovascular events. Ultimately, a prospective 
cohort of incident psoriasis cases of substantial size, varying in age and disease severity could 
clarify the relationship between psoriasis, atherosclerosis and CVD.
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supplementary figure 1. Psoriasis case identification.
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supplementary figure 2. flowchart of the rotterdam study depicting measurements conducted at 
subsequent visits to the research center.
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sUPPlEMEntAry MAtEriAls AnD MEtHoDs: MEAsUrEMEnts of 
AtHErosClErosis.
Carotid atherosclerosis was assessed using the maximum common carotid intima-media 
thickness summarized as the average of the maximal measurements from the near and far 
walls of the left and right carotid arteries. Carotid plaques were defined as a focal widening 
relative to adjacent segments, with protrusion into the lumen composed either of only calci-
fied deposits or a combination of calcification and non-calcified material and assessed in the 
common carotid, bifurcation, and internal carotid arteries.1 Ultrasonography of the carotid 
arteries was performed with a 7.5 MHz linear array transducer (ATL UltraMark IV; Advanced 
Technology Laboratories, Bethel, Washington).
lower extremity atherosclerosis was measured using the ankle-brachial index (ABI) by 
computing the ratio of the systolic blood pressure at the ankle to the systolic blood pressure 
at the arm. ABI was calculated for each leg and the lowest ABI in either leg was used in the 
analysis.2,3 Values greater than 1.4 were excluded because high ABI may represent a different 
underlying pathology related to calcified, non-compressible arterial vessels.
Coronary artery calcium was assessed in the epicardial coronary arteries on scans obtained 
with either a C-150 electron beam computed tomography scanner (Imatron, South San 
Francisco, California) or a 16 or 64 slice multidetector computed tomography scanner (So-
matom Sensation 16 or 64; Siemens, Forchheim, Germany) and quantified using the Agatson 
method.4,5
Carotid-femoral pulse wave velocity was assessed with an automatic device (Complior; 
Artech Medical, Pantin, France) that measures the time delay between the rapid upstroke 
of the feet of simultaneously recorded pulse waves in the carotid and the femoral arteries in 
meters per second.6
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1. froM HEAltH rElAtED qUAlity of lifE to CliniCAl DEPrEssion: 
tHE DisEAsE sPECtrUM EvAlUAtED.
In this thesis we used a multifaceted approach to analyzing depression in psoriasis, by in-
vestigating Health Related Quality of Life (HRQoL), depressive symptoms, clinical depression 
and antidepressant use, using various data sources and statistical methods. These include a 
cross-sectional study, two population-based cohorts and a systematic review of the literature 
incorporated into a meta-analysis.
A total of 40% of psoriasis patients from dermatological outpatient clinics in Belgium re-
ported a substantial impact of psoriasis on their lives according to dermatology specific ques-
tionnaires (Chapter 2.1). The level of generic impairment of the quality of life was comparable 
to the level observed in other chronic diseases such as asthma, diabetes and rheumatoid 
arthritis and also comparable to the level found in prostate cancer patients and patients with 
hematological malignancies. Patients with moderate to severe disease reported higher qual-
ity of life scores than those with milder disease, regardless of whether dermatology specific 
or generic instruments were used.
According to a systematic review and meta-analysis of the literature on depression in 
psoriasis, one quarter of psoriasis patients manifest depressive symptoms and 12% are diag-
nosed with clinical depression (Chapter 3.1). Psoriasis patients are one and a half times more 
likely to manifest signs of clinical depression compared with their healthy peers. Depressive 
symptoms in psoriasis were assessed in mostly small studies based in tertiary centers. The 
relationship between psoriasis and clinical depression was investigated in large population-
based studies using administrative databases. The actual prevalence of depression according 
to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria is 
hard to estimate due to the scarcity of available studies. However it is definitely lower than 
the prevalence of depressive symptoms. This difference was also noted in the population-
based Rotterdam Study, where we demonstrated that symptoms of depression assessed ac-
cording to the Center for Epidemiologic Studies Depression Scale (CES-D) >16 were manifest 
in 8.5% of 236 psoriasis patients, however when the patients with an elevated CES-D score 
underwent clinical examination by the psychiatrist, only 3 patients were diagnosed with a 
major or minor depression according to the DSM-IV (Chapter 3.3).
According to the meta-analysis we conducted in chapter 3.1, the overall pooled proportion 
for antidepressant use in psoriasis in the literature was 9% (6-14%). Data on drug dispenses 
from the Dutch pharmacy database showed that psoriasis patients were one and a half times 
more likely to use an antidepressant compared to the reference group (after adjustment for 
age, gender and general healthcare consumption). The use of antidepressant medication 
peaked when patients sought medical care for their psoriasis and thereafter (Chapter 3.2).
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The effect of this increased healthcare seeking behavior was also reflected in the results 
from the Dutch General Practitioner (GP) database which show that psoriasis patients use 
significantly more medication of all therapeutic groups than patients without psoriasis of the 
same gender, age and GP practice (Chapter 2.2). Patients with moderate to severe psoriasis 
had more prescriptions for medication compared to patients with mild disease. In the Dutch 
GP database the odds of antidepressant use was 1.35, 95% confidence interval (CI) 1.26-1.45 
in psoriasis patients compared to controls without psoriasis, which is in in the range of the 
results from the data we obtained from the Dutch pharmacy database (odds ratio [OR] 1.47, 
95% CI 1.43-1.51), with a dose-response relationship for patients with moderate to severe 
disease in both studies.
The results of the studies conducted in this thesis lead to the chart in Figure 1, depicting the 
association between psoriasis, health related quality of life, depressive symptoms, clinical 
depression and antidepressant use. In the following, an attempt will be made to comment on 
the steps delineated in this figure.
Psoriasis
Clinical severity
PASI
BSA
SAPASI
Impaired 
Health Related 
Quality of Life
Depressive 
symptoms
Clinical 
depression
DLQI
Skindex
SF-36
BDI
HADS
CES-D
DSM-IV
ICD
Antidepressant use
figure 1. Potential pathways underlying the association between psoriasis and clinical depression.
Abbreviations: PASI, Psoriasis Area and Severity Index; BSA, Body Surface Area; SAPASI, Self-administered 
PASI; DLQI, Dermatology Life Quality Index; SF-36, Short Form-36; BDI, Beck Depression Inventory; HADS, 
Hospital Anxiety and Depression Scale; CES-D, Center for Epidemiologic Studies Depression Scale; DSM-IV, 
Diagnostic and Statistical Manual of Mental Disorders 4th edition; ICD, International Classification of Dis-
eases.
1.1 the link between Health related quality of life and depression
A structural equations modeling approach to test and estimate causal relations between 
objective disease severity, psoriasis symptoms, HRQoL and depressive symptoms, confirmed 
that psoriasis might first lead to problems in everyday life measured by a HRQoL instru-
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ment. One of the models showed that a very high proportion of the variability of depressive 
symptoms is explained by HRQoL impairment, demonstrating that it is directly related to the 
development of depressive symptoms.1
Although further studies in dermatological patients are lacking, an observational study in 
outpatients with depression showed that they had substantial and long-lasting decrements 
in multiple domains of functioning and well-being of the Short form 36 (SF-36).2 There is 
increasing interest in HRQoL as a measure of response to antidepressant treatment because 
it evaluates not only symptoms, but also physical, mental and social functioning and role 
performance. The Factors influencing Depression Endpoints Research (FINDER) study was 
designed to estimate HRQoL using the SF-36 and European Quality of Life-5 Dimensions (EQ-
5D) in more than 3,000 patients with a clinically diagnosed episode of depression at baseline 
and after commencing antidepressant treatment.3 A higher number of previous depressive 
episodes and a longer duration of the current depressive episode were associated with a 
poorer HRQoL outcome. Further, severity of depression measured by the Hospital Anxiety 
and Depression Score (HADS) at baseline was significantly associated with a worse SF-36 
Mental component summary. Outpatients with an untreated episode of depression expe-
rienced improvements in HRQoL after starting antidepressant medication. We can conclude 
that there is a reciprocal relationship between HRQoL and depression: impairment of HRQoL 
due to psoriasis can lead to depressive symptoms, and depression also impairs HRQoL.
1.2 influence of psoriasis severity
In chapter 2.1, Belgian psoriasis patients with more severe disease reported a higher impact 
of psoriasis on their lives. This was also confirmed by the fact that erythrodermic patients 
had the highest scores on the Dermatology Life Quality Index (DLQI) and Skindex-17 scales. 
However other studies have shown that the correlation between severity of psoriasis and 
impact on HRQoL is weak4 and that psoriasis caries a substantial burden even when disease 
severity is not extensive.5 According to an internet survey among psoriasis patients in the 
United States, lower self-administered Psoriasis Area and Severity Index (SAPASI) scores were 
associated with higher CES-D scores, after adjustment for HRQoL using the DLQI.1 An 11 year 
prospective study demonstrated a 25% decrease in the psychosocial impact of psoriasis 
on patients’ HRQoL. This suggests that patients either accommodate to the impact of their 
disease over time, or that they are adequately treated and the impact decreases when clinical 
disease severity is also reduced.6
1.3 Patient reported outcome measures in treatment evaluation
treatment dissatisfaction in psoriasis patients. More than 45% of patients with psoriasis 
and psoriatic arthritis participating in a survey from the National Psoriasis Foundation in 
the United States were dissatisfied with their treatment.7 At the time of the survey 50% of 
patients with mild, 24% with moderate and 9% with severe disease, were not receiving treat-
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ment for their psoriasis. 20% of patients with severe disease were using topical medication 
alone. The dissatisfaction was highest in the group of patients with moderate disease (Body 
Surface Area [BSA] of 3-10%), supporting the evidence that disease severity is not a good 
indicator to measure patient satisfaction. Some patients consider their psoriasis to be very 
debilitating despite low disease severity scores.5 Setting clear treatment goals in psoriasis can 
help to overcome impairment in HRQoL, high disease burden and treatment dissatisfaction 
that can lead to low treatment compliance.8 A review of generic and dermatology specific 
HRQoL instruments recommended the combination of SF-36 and Skindex-29 as instruments 
of choice.9 Involving psoriasis patients in the process of the choice of treatment is likely to 
improve their satisfaction with treatment and also clinical outcome.10
The question arises about the role patient reported outcome measures (PROMs) should 
play in daily practice and which instrument should be used. The choice of instrument de-
pends on the study setting, the disease and the purpose of its use. It is essential to distinguish 
between a clinical setting primarily benefiting the patient and a clinical trial setting. In the 
former setting (primary, secondary or tertiary), time constraint, practicality and the conse-
quences for treatment should be taken into consideration. In the context of a clinical trial 
investigating a new antipsoriatic therapy for example, it is essential to use a standardized 
instrument that enables to compare the results with studies on other treatments, to evaluate 
the impact of a treatment and to compare treatments costs. Standardized instruments are 
also used to compare HRQoL between different conditions.
Hrqol instruments for psoriasis. In the case of psoriasis, several instruments have been 
used: dermatology specific, disease specific and generic instruments measuring the HRQoL, 
but also conceptual questionnaires such as those assessing depressive symptoms. The DLQI 
was developed by Finlay and colleagues for use in clinical daily practice and was designed 
as a generic HRQoL tool.11 It was derived from answers to questions posed to dermatology 
patients on how their skin disease affected them. It is presently the most commonly used 
PROM in dermatology. In the United Kingdom, it is even required to use the DLQI to deter-
mine whether psoriasis patients are eligible to receive biological drugs, and in the European 
S3 guidelines, treatment goals are defined using the DLQI. However this questionnaire has 
several content and methodological limitations and does not meet the recent psychometric 
requirements for instruments assessing the HRQoL. It focusses more on physical limitations 
of skin disease and very few items address the psychological impact of the skin disease, 
which is important in psoriasis. It failed to fit the Rasch analysis and suffers from item bias 
because more than half of the questions are affected by external factors such as age, gender 
and diagnosis.12,13 The disease specific Psoriasis Disability Index (PDI) was developed to 
quantify the impact of psoriasis on patients’ lives, however with suboptimal subscales and 
psychometric properties.14,15
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which questionnaire to use? We suggest the use of an alternative dermatology-specific 
instrument such as the Skindex-29 or the Skindex-17, a Rasch reduced version of the Skin-
dex-29.16 This instrument has been extensively studied and refined in different population-
based samples and has been validated for psoriasis.17-19 It also contains more questions 
on the psychological impact of skin disease. Nevertheless, a disadvantage of dermatology 
specific instruments is that, due to the large number of dermatological diseases and their 
varying impact on HRQoL, it is unlikely that one single dermatology specific instrument could 
capture the variation of complaints for different dermatological conditions.
The generic SF-36 is the most commonly used instrument to assess HRQoL for all diseases 
and is very useful if physicians are interested in comparing QoL between different conditions. 
Because psoriasis has an impact on the psychological well-being of patients, questionnaires 
assessing depressive symptoms such as the Beck Depression Inventory (BDI) and the HADS 
are also commonly used.
overlap between Hrqol and depression questionnaires. HRQoL instruments partly 
measure concepts that are also contained in depression instruments. The mental compo-
nent of the generic SF-36 includes questions on emotional well-being, social functioning, 
energy and fatigue.20 Of the dermatology specific questionnaires, the Skindex focuses the 
most on elements that are also part of the depression questionnaires such as sleep, tiredness 
and depression and also addresses feelings of embarrassment, humiliation and frustration. 
Symptom severity and impact on everyday life seem closely correlated, which explains much 
of the correlation between HRQoL instruments and depression instruments in patients with 
psoriasis, and partly explains the overestimation of the prevalence of depressive symptoms 
based on depression questionnaires.
1.4 Clinical implications
It is a challenge to administer a questionnaire to psoriasis patients visiting the outpatient 
clinic, specifically due to shortage in time to administer it, and also to interpret the results. 
However addressing the impact of psoriasis on patients in everyday clinical practice is essen-
tial; it is an efficient way of assessing how patients feel about their skin condition which may 
aid to measure treatment success, to make therapeutic choices such as switching to another 
treatment or to determine the usefulness of starting a systemic treatment. An example of the 
usefulness of determining QoL is suggesting a more aggressive treatment for a patient with 
active psoriasis and signs of depression, but also patients with “only” nail psoriasis and no 
skin involvement may benefit from systemic treatment if they experience strong impairment 
of their QoL.
Physicians should use an empathic approach and not only address the physical aspects 
but also the psychosocial aspects of psoriasis. In practice, this could be accomplished by 
asking a general question such as how psoriasis affects their daily life, social activities or 
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relationships, which could be quantified using a visual analogue score. If there is a significant 
impact of psoriasis on daily life, a validated instrument could be used. This would preferably 
be a disease specific instrument of which only one has been developed for psoriasis.15 In this 
thesis we show that more than 25% of psoriasis patients from predominantly tertiary centers 
manifest signs of depressive symptoms, therefore these symptoms need to be addressed in 
the questionnaires. However, questions on sleeping pattern, changes in appetite, sadness 
and interest in life are not incorporated in the dermatology specific questionnaires. Until 
then, we recommend the use of the Skindex to measure the impact of psoriasis on patients’ 
QoL and if depression is suspected during medical consultation, we recommend the use of a 
depression questionnaire such as the BDI or HADS. The advantage of using for example the 
SF-36 or the Skindex is that these instruments have been validated for psoriasis,16,21,22 while 
validation studies for depression questionnaires such as the BDI, HADS or CES-D in psoriasis 
have yet to be conducted. On the other hand, we could consider the routine use of the 
Skindex questionnaire at baseline and during treatment, to monitor the effect of treatment 
and treatment satisfaction in combination with disease severity. The S3 guidelines propose 
a minimum efficacy goal at 10-16 weeks after initiation of systemic therapy, consisting of 
a PASI 50 and a DLQI of less than 5 points (no effect to moderate effect on patients’ life). 
The treatment should be regarded as inefficient and stopped if these goals are not met and 
an alternative treatment initiated.23 Although recommended in the S3 guidelines, presently, 
disease severity and QoL are mainly measured in the context of clinical trials, but seldom 
in regular patient care. If QoL instruments are to be used in outpatient clinics to monitor 
systemic treatment, the frequency of their administration and the influence of their outcome 
on the choice or modification of treatment should be clarified.
1.5 Educational interventions
The impact of psoriasis on the QoL of patients and the fact that it can lead to depressive 
symptoms and clinical depression, make it inevitable to address these aspects of this chronic 
and debilitating skin disease. Personalized antipsoriatic treatment for improvement of 
psoriasis clinical outcomes must go hand in hand with coping strategies and interventions 
to improve QoL, ascertain and treat possible depression. Several concepts of educational 
and behavioral interventions have been described for psoriasis and psychological interven-
tions enhance the effectiveness of standard treatments.24-27 Physicians in Ghent (Belgium) 
launched an educational program for patients with chronic diseases combining cognitive 
educational sessions, stress-reduction techniques and skin workshops facilitated by experts, 
with a significant improvement of QoL after the intervention.28 An internet survey showed 
that dissatisfaction with antipsoriatic treatment was higher in patients who had a higher 
likelihood of depression according to the CES-D score and less than half of the patients with 
psoriasis and depressive symptoms was receiving treatment for depression.1 Increasing pa-
tient’s knowledge about their skin disease and treatment can encourage participation in the 
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choice of treatment and can contribute towards patients satisfaction, treatment compliance 
and improvement of clinical outcome.29
1.6 the inflammation hypothesis in depression
Another hypothesis underlying the relationship between psoriasis and clinical depression 
could be chronic inflammation. Clinical studies have demonstrated that depression is associ-
ated with increased levels of serum cytokines.30-32 In the population-based Rotterdam Study, 
subjects with increased levels of interleukin 6 (IL-6) were more likely to have a depressive 
disorder.33 In a meta-analysis a significant association was seen between clinical depression 
and C-reactive protein (CRP), IL-1 and IL-6. The association was much higher when clinical 
interviews were used compared to using questionnaires assessing depressive symptoms.32 
The pro-inflammatory cytokine Tumor necrosis factor-alpha (TNFα) is also believed to be 
involved in depression.34 A randomized trial showed that 12 weeks of treatment of psoriasis 
with a TNFα inhibitor, reduces the symptoms of depression. However we should take into 
account the fact that in this study the majority of participants either did not have depressive 
symptoms or had predominantly mild depressive symptoms.35,36 This could be attributed 
to the improvement of clinical severity but also due to the anti-inflammatory effect of the 
drug. A concept finding (phase O) clinical study is being conducted to detect systemic in-
flammation and abnormality of cerebral glucose metabolism using PET/CT to determine the 
association with metabolic syndrome and major depressive symptoms in patients with pso-
riasis (ClinicalTrials.gov identifier: NCT01661127). We do not know whether the relationship 
between depression and inflammation is causal in nature and the biological plausibility is 
questionable. We doubt that the relationship between psoriasis and depression is mediated 
by systemic inflammation. It seems more logical to believe that psoriasis leads to depression 
through its impact on the emotional, social and physical aspects of an individual’s life, thus 
the HRQoL.
ConClUsion 1
Assessing the impact of psoriasis on a patients’ quality of life, setting treatment goals and 
expectations prior to initiation of therapy and evaluation of treatment using patient re-
ported outcomes are indispensable in the care of psoriasis, regardless of whether they are 
outpatients or participating in clinical trials. A holistic approach to psoriasis characterized 
by personalized treatment and the use of interventions to address the well-being of patients 
should become a pillar of antipsoriatic therapy.
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2. inflAMMAtion AnD CArDiovAsCUlAr DisEAsE: tHE PsoriAtiC MArCH 
DECoMPosED.
There is evidence in the literature that psoriasis could be triggered by risk factors such as 
smoking, obesity and weight gain.37-39 Inflammation of the skin or inflammation caused by 
risk factors leads to increased inflammatory serum markers. Systemic inflammation subse-
quently causes atherosclerosis and eventually leads to cardiovascular events such as myocar-
dial infarction and stroke. This “psoriatic march”40 seems biologically plausible, however it is 
not that straightforward.41 In this thesis we attempted to investigate and clarify the different 
steps depicted in Figure 2.
2.1 Cardiovascular risk factors
In the population-based Rotterdam Study, the risk factors smoking, body mass index, 
diastolic blood pressure and the use of lipid lowering agents, were significantly more el-
evated in the psoriasis group. There were no significant differences in total cholesterol and 
high-density lipoprotein (HDL) cholesterol, systolic blood pressure or diabetes between 
the psoriasis patients and the reference population (Chapter 4.2). These results are partly 
in line with those from a general-practice database from the United Kingdom, (The Health 
Improvement Network [THIN]), where obesity, raised triglyceride levels, hypertension and 
raised glucose levels were more common in psoriasis patients than in controls. Psoriasis was 
associated with the metabolic syndrome after adjustment for age, gender and follow-up, also 
in a “dose-response” manner.42 In chapter 2.2, based on prescription data from the Dutch GP 
database, we found similar results: psoriasis patients used more medication associated with 
the metabolic syndrome, namely lipid lowering agents, antihypertensive drugs and blood 
thinning agents, with higher prescriptions for moderate to severe than for mild psoriasis. 
However we noticed that psoriasis patients have an increased use of medication from all 
therapeutic classes, including medication we expected to be unrelated to psoriasis, such as 
antiemetics, spasmolytics, ophthalmologicals or antivertigo preparations. Based on these 
results, we conclude that psoriasis patients have increased overall drug utilization, regardless 
of whether the medication is associated with the metabolic syndrome or not. It is therefore 
uncertain if the presence of metabolic syndrome in psoriasis is real or a result of the increased 
health care utilization in this group of patients with chronic skin disease. Physicians should 
not screen these patients more than they would others, unless it is medically indicated.
2.2 Markers of inflammation
The hypothesis of a causal link between psoriasis and comorbidities based on systemic 
inflammation or common genetic predisposition has been suggested.40,43 Due to the vast 
amount of literature available on the subject of psoriasis, inflammation, metabolic syndrome 
and cardiovascular disease, it is always possible to find a logical explanation linking these 
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elements. However, when screening the available literature on serum markers of systemic 
inflammation in psoriasis, we noticed that the results were not consistent: some studies 
reported no difference in serum levels of markers between psoriasis patients and controls, 
while others showed an increase or decrease. We conducted a meta-analysis on the available 
translational research on serum markers of inflammation in psoriasis, just as has commonly 
been done in the case of research on CRP in cardiovascular disease.44-46 The studies were 
mainly laboratory research, their sample sizes were not based on a power calculation, the 
outcomes were hardly ever adjusted for confounders and often the most important outcome 
was whether the results were significant or not. Based on the nature of the studies and the 
modest difference in serum levels between psoriasis patients and controls ranging from 1,5 
to 2, it remains uncertain how clinically relevant this slight elevation could be.
Does inflammation lead to atherosclerosis? Would the chronic increase in serum inflam-
matory markers lead to atherosclerosis, then we would be interested to know, as from which 
marker levels the risk of developing atherosclerosis would increase. In the Framingham 
Heart Study, no significant association was found between a large selection of biomarkers 
of inflammation (including CRP, IL-6, Intercellular Adhesion Molecule 1 [ICAM-1]) and aortic 
atherosclerosis, in contrast to other studies conducted in the same Framingham cohort find-
ing associations between similar markers and carotid atherosclerosis,47,48 which are thought 
to represent a later stage of plaque burden. A systematic review of studies assessing the 
relationship of biomarkers with coronary calcium showed that the associations were no 
longer significant after adjustment for traditional risk factors.49 These results highlight that 
biomarkers are not necessarily useful in the identification of subclinical atherosclerosis and 
emphasize the importance of traditional risk factors.50 However, is also possible that markers 
of serum inflammation, such as shown for IL-18 in a large prospective study, are not associ-
ated with atherosclerotic burden, but directly associated with cardiovascular events.51
An interesting study to follow is the cardiovascular inflammation reduction trial (CIRT) which 
aims to test the inflammatory hypothesis in conditions associated with systemic inflam-
mation. More than 7,000 patients with prior myocardial infarction and type 2 diabetes or 
metabolic syndrome will be randomized to receive low-dose methotrexate or placebo for a 
period of 3 to 5 years. This is the first clinical trial to investigate whether targeting inflamma-
tion alone will reduce cardiovascular risk.52
2.3 subclinical measures of atherosclerosis
Measures of atherosclerosis such as intima media thickness (IMT), ankle-brachial index (ABI) 
and pulse wave velocity (PWV) have been shown to be strong predictors of coronary heart 
disease (CHD).53 Among 12 newer coronary heart disease risk markers, the addition of the 
coronary artery calcium (CAC) score provided the most statistically and clinically significant 
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improvement in Framingham risk predictions.54 In psoriasis many investigations have been 
conducted on the presence of subclinical measures of atherosclerosis. These are small 
case control studies on IMT, ABI, CAC and PWV, conducted in selected groups.55-62 In the 
population-based Rotterdam Study with a follow up of more than 10 years, where psoriasis 
subjects (n=262) underwent the same examinations as the reference population (n=8,009) 
irrespective of psoriasis severity or healthcare utilization, the IMT, ABI, CAC and PWV were not 
significantly different between the two groups after adjustment for age, gender and cardio-
vascular (CV) risk factors. This could be due to the predominantly mild severity of psoriasis in 
this population (76%). However a subgroup analysis in patients with moderate to severe dis-
ease from our study population also did not show significant differences between the groups 
(Chapter 4.2). This was the largest study to date where detailed information on standardized 
measures of atherosclerosis was available after diagnosis of psoriasis and  adjustment for 
cardiovascular risk factors was possible. According to our data, psoriasis patients do not have 
elevated measures of atherosclerosis compared to the general population, independent of 
disease severity. Based on these results, we cannot conclude psoriasis that patients are at 
increased risk of developing atherosclerosis, and therefore cardiovascular events. Moreover 
the traditional risk factors are more important predictors of cardiovascular disease.
2.4 Cardiovascular events
In the past decade, numerous articles have been published on the association between 
psoriasis and cardiovascular disease showing inconsistent results, which could be explained 
by the different databases used, the study design, case definition of exposure and outcome 
and residual confounding. Most of the studies were based on data from secondary databases, 
which were not designed for the study outcome, in this case cardiovascular disease (CVD), 
and therefore had limited information on important confounders such as CV risk factors.63,64 
The authors of these studies often listed residual confounding as one of their main limita-
tions.
Cardiovascular disease in the rotterdam study. We therefore decided to investigate the 
association between psoriasis and CVD in the Rotterdam Study, which was specially designed 
to investigate the epidemiology of CVD65 and represents a unique study population due to 
the fact that the examinations were conducted in all patients at the same period, limiting the 
effects of detection and surveillance bias. We studied incident hard cardiovascular endpoints 
such as hard CHD, computer tomography (CT) confirmed stroke and heart failure and the 
analyses were conducted on measurements occurring after psoriasis onset. These restrictions 
were not always made in other studies on this topic. We were able to dynamically adjust the 
analyses for cardiovascular risk factors determined at the examination rounds and not just 
once during the entire follow up of 10 years. Moreover, there have been very few publications 
on the risk of stroke and heart failure in psoriasis, which are also components of CVD. A total 
of 259 psoriasis patients and 7,931 reference subjects were followed for a mean of 11 years; 
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after adjustment for age, gender and CV risk, psoriasis was not associated with coronary 
heart disease, stroke or heart failure. All the hazard ratios were below 1 and not significant. 
In the stratified analyses for disease severity, psoriasis was also not associated with incident 
cardiovascular events (Chapter 4.2). We therefore conclude, based on the results from The 
Rotterdam Study, that psoriasis is not an independent risk factor for CVD. Other studies on 
this subject have shown at most a modest increment in CV risk in psoriasis, with significant 
ORs ranging around 1.5. The higher risk was found in a small subpopulation of mostly young 
patients with severe psoriasis.64 The results were based on routine care databases (General 
Practitioner Research Database and THIN), which have more limitations than data from a 
prospective cohort. In the Rotterdam Study we show that in a random selection of psoriasis 
patients from the general population it is unlikely that psoriasis represents an independent 
risk factor for subclinical atherosclerosis and incident hard cardiovascular events.
identifying a new risk factor for heart disease. In an editorial, Stern applies five criteria 
used by the US Preventative Task force for evaluating potential new risk factors for heart 
disease, showing that psoriasis is unlikely to be a clinically useful independent risk factor for 
CVD.66,67 A new risk factor should be easily and reliably measured. It should be an independent 
predictor of major CHD events in persons of intermediate risk who have no history of CHD 
(most of the studies to date did not look at incident CVD). When assessed in intermediate risk 
persons, the risk factor should reclassify a substantial proportion as high risk. Reclassified 
persons should be managed differently. If two or more risk factors provide similar prognostic 
information, then convenience, costs and safety may be important in choosing among them.
United states recommendations on screening for cardiovascular risk factors in pso-
riasis. Nevertheless, the American Journal of Cardiology in the United States advises that 
psoriasis patients with moderate to severe psoriasis and patients with mild psoriasis and 
increased CV risk factors should be informed that they may be at risk for coronary artery 
disease and should therefore undergo appropriate evaluation screening for CV risk factors.68 
We believe that these measures are not justified and are based on studies which are not 
population-based, and where surveillance bias is an important limitation. These measures 
will lead psoriasis patients with moderate to severe disease to believe that their psoriasis 
increases their risk of metabolic syndrome or CVD, whereas it is possible that the real cause 
of their risk increase is either impairment of QoL leading to stigmatization, isolation and 
depressive symptoms, resulting in risk factors such as obesity and smoking, or even positive 
family history for CVD.
risk factors and antipsoriatic treatment. The increased risk for CVD in moderate to severe 
psoriasis could also be confounded by antipsoriatic treatment such as cyclosporine, which 
can lead to hypertension or acitretine, which can cause hyperlipidemia, both risk factors for 
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CVD. Therefore the choice of an antipsoriatic treatment should take into account the pres-
ence of pre-existent risk factors. On the other hand, addressing risk factors might also con-
tribute to better treatment responses. In a recent trial, overweight mild to moderate psoriasis 
patients randomized to a hypocaloric diet achieved significant weight loss after 16 weeks 
and a higher mean PASI change compared to the group with a normal diet.69 According to 
data from the Psocare study in Italy, psoriasis patients with lower BMIs responded better to 
systemic therapy than obese patients.70 These results suggest that life-style change could 
lead to a better control of psoriasis and response to antipsoriatic therapy.
framingham risk score in psoriasis. The present guidelines for the prevention of coronary 
heart disease recommend the use of risk scores such as the most widely used Framingham 
risk score (FRS) to identify adults at higher risk of CHD, who would benefit from preventive 
therapy.71 This has led to publications on the 10-year FRS in psoriasis patients, most of them 
were small studies conducted in tertiary centers72-75 and one study assessing the 10 year 
risk was a phase III study with more than 2,800 patients.76 They show that approx. 3-10% of 
psoriasis patients with moderate to severe disease are at high risk. Interestingly, in the article 
by Fernandez Torrez, the risk was independent of disease severity measured by the PASI. 
However we should be cautious when interpreting FRS in psoriasis because the risk depends 
on the presence of risk factors and not on the presence of psoriasis. As previously mentioned, 
psoriasis patients seem to have more risk factors for the metabolic syndrome, and therefore 
their FRS is higher than in controls.
2.5 surveillance bias
Chapter 2.2 demonstrates that overall drug utilization is elevated in psoriasis patients 
compared with controls, also for drugs unrelated to psoriasis, independent of psoriasis 
disease severity. Moreover, there have been innumerable publications on comorbidities of 
psoriasis, other than CVD, associating psoriasis with several, not always obviously related, 
chronic diseases such as chronic obstructive pulmonary disease, osteoporosis and Crohn’s 
disease.77-79 It is likely that increased healthcare utilization by psoriasis patients, also affects 
their risk of being diagnosed with other comorbidities. Possibly, the reason why we found 
that psoriasis was not associated with CVD in the Rotterdam Study, was because there was 
a minimal amount detection bias in this population and because all patients of a suburb of 
Rotterdam were invited to participate regardless of comorbidities with a high participation 
rate of approximately 75%.
2.6 the choice of systemic therapies to prevent cardiovascular outcomes
We are concerned about the continuing trend of upgrading psoriasis to a systemic inflamma-
tory disease and therewith introducing a compelling reason for more aggressive treatment. 
Plaque psoriasis does not cause irreversible organ damage and while psoriatic arthritis can 
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lead to destructive joint damage, there is no evidence available that it affects the organs. 
We should acknowledge that the management of psoriasis patients could be influenced by 
the claim that psoriasis is a dangerous disease due to increased CVD and mortality, and the 
emphasis on the severe HRQoL impairment. This could lead to overtreatment of psoriasis and 
consequently push health insurance companies to reimburse costly treatments. Physicians 
should be cautious when wanting to treat psoriasis more aggressively in order to prevent 
possible cardiovascular events. Especially after one of the recent biological drugs, the IL-12/23 
antagonist briakinumab, was withdrawn from the market due to concerns about the increased 
incidence of major adverse cardiac events.80 Moreover, TNFα inhibitors are contraindicated in 
patients with stages III to IV heart failure according to the New-York Heart Association.
Effect of antipsoriatic therapy on cardiovascular events. Several studies have looked at 
the effect of systemic psoriasis therapies on the incidence of myocardial infarction but did 
not find consistent results. A cohort study using administrative and pharmacy claims data 
from a large insurance company in the United States, found no difference in MI risk in the 
systemic treatment group compared with psoriasis patients receiving UVB phototherapy.81 
Data from more than 8,000 psoriasis or psoriatic arthritis patients enrolled in the Kaiser 
Permanente Southern California (KPSC) health plan, among which more than 1,600 patients 
were treated with TNFα inhibitors adalimumab, etanercept or infliximab, showed that the 
risk of developing MI halved in patients using TNFα inhibitors compared to patients on topi-
cal treatment (adjusted for age and gender HR 0.50, 95% CI 0.32-0.81). This could be due to 
selection bias of healthy patients in the TNFα group, leading to confounding by indication. 
However, longer duration of TNF inhibitor therapy (>685 days) was not associated with sig-
nificantly lower risk of MI with a HR of 1.36, 95% CI 0.64-2.90.82 In a Danish psoriasis cohort, 
results varied between the composite outcome death, MI and stroke (lower risk in patients 
with systemic treatment) and the composite outcome cardiovascular death, MI and stroke 
(no significant reduction of risk).83 A recent meta-analysis of short term randomized clinical 
trials evaluated the effect of anti-IL12 and IL23 on CVD, noticing no significant difference 
in the rate of a composite CVD endpoint in patients treated with biologics compared with 
those treated with standard care or placebo therapies.84 There are more studies on their way 
assessing intermediary cardiovascular outcomes in patients with moderate to severe disease 
treated with biologic agents measuring coronary calcium score, serum cytokines and tradi-
tional risk factors (ClinicalTrials.gov identifier: NCT01356758). A head to head comparison of 
a biological agent and fumaric acid for cardiovascular and metabolic risk factors is on its way 
(ClinicalTrials.gov identifier: NCT01088165). In the meantime, psoriasis registries such as the 
PSONET,85 the industry funded PSOLAR86 and long term post marketing studies will provide 
valuable information on efficacy and adverse events of antipsoriatic treatments. Presently 
there is no convincing evidence supporting the use of systemic therapies in psoriasis for 
other reasons than treating psoriasis itself.
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ConClUsion 2
The results presented in this thesis support the multifactorial nature of the association 
between psoriasis, cardiovascular risk factors, atherosclerosis and cardiovascular events, 
refuting the hypothesis of a straight march. There is a need for a large prospective cohort of 
incident psoriasis cases, varying in age and disease severity, with a long follow-up to clarify 
the relationship between psoriasis, atherosclerosis and cardiovascular disease. Until then, 
caution is warranted when interpreting results from large database studies with limitations 
inherent to their design. Nevertheless, physicians and specifically dermatologists are not only 
expected to treat a skin condition, but also have a responsibility towards safeguarding the 
general health of their patients.
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6. Summary
1. introDUCtion AnD AiMs of tHis tHEsis
We gave a general introduction to this thesis in chapter 1. Psoriasis is a chronic skin condition 
that affects approximately 2% of the European population. Environmental factors such as 
stress, medication, trauma or smoking and genetic factors trigger the production of pro-
inflammatory cytokines and chemokines and maintain inflammatory processes in the skin. 
The most common form is plaque psoriasis and can be present in combination with psoriatic 
arthritis, which can also be considered as its own entity. The treatment options for psoriasis 
are vast and range from topical treatment, phototherapy to systemic therapy and the more 
recent biological drugs. Apart from assessing the success of antipsoriatic treatment using 
severity scores, measuring and addressing the health related quality of life (HRQoL) using 
patient reported outcome measures has become an important part of treatment evaluation. 
In the introduction, we give an insight on psoriasis comorbidities. Observational studies in 
the past decade have focused on the investigation of the metabolic syndrome and cardio-
vascular disease in psoriasis, mainly in routine and secondary databases often developed for 
other purposes. The question remains whether the association between psoriasis and these 
comorbidities is causal in nature. In this thesis, we show the complexity of this association 
and mainly focus on the study of HRQoL, depression and cardiovascular disease in psoriasis 
patients using various data sources: pharmacy and general practitioner databases and data 
from a prospective population-based cohort.
2. CHArACtEristiCs of PsoriAsis PAtiEnts
In chapter 2.1, we describe psoriasis characteristics, clinical severity and their impact on 
quality of life (QoL) of patients diagnosed with psoriasis by more than 190 Belgian derma-
tologists. Of the 3,629 psoriasis patients, more than three quarters had plaque psoriasis for 
more than 16 years. Plaque psoriasis involved most commonly the scalp, extensor sites of 
the extremities and lower back. One fifth of patients had nail involvement, 16% had affected 
genitals, 15% suffered from severe joint pain, 6.4% reported psoriatic arthritis diagnosed by 
a rheumatologist. Despite the fact that 80% of patients were receiving current therapy, the 
clinical psoriasis severity was relatively high with a mean Psoriasis Area and Severity Index 
(PASI) of 8.5, Body Surface Area (BSA) of 12% and 37% of patients with moderate to very se-
vere disease according to the Physician’s Global Assessment (PGA). 40% of patients reported 
a substantial impact of psoriasis, according to the Dermatology Life Quality Index (DLQI) and 
Skindex-17. The mean European Quality of Life-5 Dimensions (EQ-5D) score was comparable 
to the level of impairment observed in other chronic diseases such as asthma, diabetes and 
rheumatoid arthritis. Patients with moderate to severe disease reported a higher impact of 
psoriasis on their QoL than patients with mild disease. Based on these results we concluded 
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that psoriasis patients consulting dermatologists have relatively severe disease and often 
report a high impact of psoriasis on their QoL.
In chapter 2.2 we investigated drug utilization in psoriasis patients compared with controls 
in the Dutch General Practitioner (GP) database. We followed 17,627 psoriasis patients and 
17,627 controls matched for age, gender, GP and follow-up for a mean duration of more 
than 4 years. We investigated all drug prescriptions (therapeutic groups and chemical sub-
stances) and categorized the prescriptions into groups: (1) drugs for psoriasis symptom relief 
(painkillers and emollients), (2) drugs for psoriasis treatment (topical and systemic), (3) drugs 
associated to comorbidities such as metabolic syndrome, and (4) drugs which we expected 
to be unrelated to psoriasis. Approximately 20% of psoriasis patients received no treatment 
for psoriasis and 8% had moderate to severe disease. The rest only used topical antipsoriatic 
drugs. During the follow-up, a mean of 9 unique drugs was prescribed in psoriasis patients; 
this was significantly higher than in controls (mean of 7). The number of annually prescribed 
drugs did not vary over time and was stable in the period up to a decade after psoriasis 
diagnosis. All of the most commonly prescribed therapeutic groups were significantly more 
often prescribed in psoriasis patients than in controls. Drugs related to symptoms of psoriasis 
were significantly higher in psoriasis patients compared with controls (odds ratio (OR) 2.17, 
95% confidence interval [CI] 2.07-2.28), with higher ORs in patients with moderate to severe 
disease compared with those with mild disease. The OR of medication related to psoriasis 
comorbidities was 1.46 (95% CI 1.39-1.53) and was similar to the OR of drugs, which were a 
priori not expected to be associated with psoriasis (OR 1.49, 95% CI 1.42-1.57), such as oph-
thalmologicals (OR 1.33, 95% CI 1.26-1.40), nasal preparations (OR 1.29, 95% CI 1.22-1.36) and 
laxatives (OR 1.29, 95% CI 1.14-1.45). This study shows that all types of medication are more 
often prescribed in psoriasis patients and this increased drug use is not limited to medica-
tion associated with psoriasis comorbidities, indicating an increased healthcare utilization in 
psoriasis patients compared with controls.
3. DEPrEssivE syMPtoMs AnD CliniCAl DEPrEssion in PsoriAsis
In chapter 3.1 we give a systematic overview of the literature on depression in psoriasis. Our 
goal was to determine the pooled prevalence and odds of depressive symptoms and clinical 
depression in psoriasis in controlled and uncontrolled studies. The majority of the eligible 
studies were conducted in tertiary centres, without a control group. The prevalence of de-
pressive symptoms was 28% using questionnaires and the prevalence of clinical depression 
was 12% using International Classification of Diseases (ICD) codes, 19% using Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria and 9% of psoriasis pa-
tients used antidepressants. Psoriasis patients had significantly more depressive symptoms 
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(standardized mean difference [SMD] 1.16, 95% CI 0.67-1.66) and population-based studies 
showed that they were at least one and a half times more likely to experience depression and 
used four times more antidepressants than controls. Based on the meta-analysis we conduct-
ed, we can say that psoriasis patients not only suffer from impaired HRQoL, but more than 
10% suffer from clinical depression, and more than a quarter have depressive symptoms. The 
high prevalence of depressive symptoms in this meta-analysis is likely to be affected by the 
tertiary study populations and the use of questionnaires, where psoriasis-related symptoms 
may be detected as depressive symptoms.
Chapter 3.2 represents a cohort study where we used pharmacy and hospitalization 
data from 1998 to 2008 for more than 2.5 million Dutch residents to investigate the use 
of antidepressant drugs in psoriasis patients and a reference population. A total of 25,691 
psoriasis and 128,573 reference subjects were followed for more than 9 years. The incidence 
of antidepressant use was more than twice as high in the psoriasis group, and the hazard 
ratio (HR) adjusted for age, gender and healthcare consumption was 1.55 (95% CI 1.50-1.61). 
Psoriasis patients had more than twice as many episodes of antidepressant use than the 
reference population, with an adjusted HR of 1.47 (95% CI 1.43-1.51). Antidepressant use 
was already increased before psoriasis patients sought medical treatment for their skin and 
peaked around the time of treatment initiation and remained increased thereafter. Within 
the psoriasis cohort, psoriasis patients were 7% more likely to receive antidepressant drugs 
after the initiation of antipsoriatic therapy. This study shows that psoriasis patients use more 
antidepressant drugs than the general population, specifically at the time when they seek 
medical care for their psoriasis and in the period after antipsoriatic treatment.
In chapter 3.3 we evaluate whether psoriasis patients have more depressive symptoms and 
signs of a clinical depression compared to reference subjects in a population-based sample. 
Participants of the Rotterdam Study were screened for depressive symptoms using the 
Centre for Epidemiological Studies-Depression scale (CES-D), independent of other comor-
bidities. Subjects with a score above 16 (cut off for depressive symptoms according to the 
questionnaire), were interviewed, and depression was categorized according to the DSM-IV. 
A total of 296 psoriasis and 7,733 reference subjects were included. Psoriasis patients had 
predominantly mild disease and approximately one quarter had used systemic medication 
or UV-therapy. The median CES-D score and number of subjects with a score above 16 did 
not differ significantly between the groups. Psoriasis was not associated with a CES-D≥16 (OR 
0.99, 95% CI 0.62-1.58). A total of 20 psoriasis subjects had a CES-D≥16 and 15 underwent 
a clinical interview. A total of 3 subjects had a major or minor depression and 6 subjects 
had depressive symptoms according to the DSM-IV criteria. Psoriasis patients with depressive 
symptoms assessed by the CES-D tool were not significantly more likely to develop a clinical 
depression compared to subjects from the reference group. In this population-based sample, 
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psoriasis subjects with predominantly mild disease manifest as much depressive symptoms 
and clinical depression as patients without psoriasis.
4. AtHErosClErosis, inflAMMAtion AnD CArDiovAsCUlAr DisEAsE in 
PsoriAsis
In chapter 4.1 we performed a systematic review of the literature and a meta-analysis to 
determine the extent to which systemic inflammation is elevated in patients with psoriasis 
compared with healthy controls. We included studies comparing the serum inflammatory 
markers interleukin (IL)-1β, IL-6, IL-10, C-reactive protein (CRP), intracellular adhesion mol-
ecule (ICAM)-1, E-selectin and Tumour necrosis factor-alpha (TNFα) in patients with psoriasis 
and healthy controls. Differences in serum marker levels between patients and controls were 
pooled as SMD using a random-effects model. We included 78 studies, comprising a total of 
7,852 individuals of which 3,085 had psoriasis. 64% of psoriasis patients had plaque psoriasis. 
The overall mean PASI was 17.7, indicating that the majority of the studies included patients 
with severe psoriasis. The pooled SMDs were higher in patients with psoriasis than in healthy 
controls for IL-6 (1.32), CRP (1.83), TNFα (1.32), E-selectin (1.78) and ICAM-1 (1.77). The SMD 
between cases and controls for IL-1β and IL-10 was not significant. Age had a significant ef-
fect on the SMD for IL-6 and TNFα; the older the patients in the study, the smaller the SMD 
between psoriasis patients and controls, possibly explained by decreasing immunity with 
increasing age. For IL-6 the effect size was higher for plaque psoriasis studies (1.98). The effect 
size was not influenced by the PASI. This meta-analysis suggests modest but significantly 
elevated levels of the proinflammatory cytokines in the serum of psoriasis patients with 
predominantly severe disease compared with controls. The difference is two points at the 
most and is overall independent of age, gender, disease severity and psoriasis type.
In chapter 4.2 we investigated whether psoriasis is associated with cardiovascular outcomes 
using data from the population-based Rotterdam Study. In this study, risk factors for cardio-
vascular disease (CVD) and subclinical measures of atherosclerosis were regularly assessed 
and hard cardiovascular outcomes were registered for all participants, regardless of comor-
bidities. A total of 262 psoriasis and 8,009 reference subjects were followed for a mean of 11 
years. 24% of psoriasis patients had used systemic treatment or phototherapy for their pso-
riasis. Psoriasis patients were significantly younger, smoked more, and had higher diastolic 
blood pressure and body mass index (BMI) levels compared with the reference subjects. All 
analyses were adjusted for age, gender, current smoking, BMI, total cholesterol, high-density 
lipoprotein cholesterol, systolic blood pressure, antihypertensive medication and diabetes 
mellitus. The crude and adjusted carotid intima-media thickness, ankle-brachial index, pulse-
wave velocity, and coronary artery calcium scores did not differ between psoriasis patients 
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and reference subjects. The risk of incident CVD was not increased in psoriasis (adjusted HR 
0.73, 95% CI 0.50-1.06) in the Cox regression analysis where psoriasis was the time-dependent 
variable. When analysed separately, the risk of coronary heart disease, cerebral infarction and 
heart failure was also not elevated in psoriasis patients compared to controls. The results of 
this population-based study suggest that psoriasis patients with predominantly mild disease 
are not at a higher risk for subclinical atherosclerosis and psoriasis is not an independent risk 
factor for cardiovascular disease.
5. GEnErAl DisCUssion AnD PErsPECtivEs
In chapter 5 we discuss the findings of this thesis and offer our insights on clinical implica-
tions and future perspectives.
Firstly we analysed the relationship between psoriasis, health related quality of life, de-
pressive symptoms and clinical depression and conclude that addressing psoriasis patients’ 
well-being should become a part of psoriasis treatment.
The second part of the discussion is dedicated to the complexity of the association be-
tween cardiovascular risk factors, systemic inflammation, subclinical atherosclerosis and 
cardiovascular events, showing the need of a well-designed large prospective cohort in order 
to investigate the multifactorial nature of this association. We conclude that it is unnecessary 
that psoriasis patients undergo standard screening for cardiovascular risk factors and cardio-
vascular disease. Nevertheless, it is important that medical practitioners and dermatologists 
not only address the skin, but also the general health, comorbidities and well-being of their 
patients.
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1. inlEiDinG En DoElEn vAn Dit ProEfsCHrift
In hoofdstuk 1, beginnen we een met een algemene introductie van dit proefschrift. Pso-
riasis is een chronische huidaandoening die bij ongeveer 2% van de Europese bevolking 
voorkomt. Naast genetische factoren, beïnvloeden ook omgevingsfactoren waaronder 
stress, medicatie, trauma’s en roken de productie van pro-inflammatoire cytokines en 
chemokines en zo ook de inflammatoire processen in de huid. De meest voorkomende 
presentatie is plaque psoriasis en kan ook gepaard gaan met arthritis psoriatica, welke soms 
ook beschouwd wordt als een aparte entiteit. Er zijn verschillende therapieën voor psoriasis; 
variërend van topicale behandeling, lichtbehandeling tot systemische middelen waaraan de 
biologicals als laatste zijn toegevoegd. Het bepalen van de kwaliteit van leven van patiënten 
is, naast het effect van een behandeling op de ziekte-ernst, een belangrijke uitkomstmaat 
geworden bij de evaluatie van een therapie. In de introductie, geven we een overzicht van 
de comorbiditeiten van psoriasis. De afgelopen tien jaar is observationeel onderzoek bij 
psoriasis voornamelijk gericht geweest op het onderzoeken van comorbiditeiten zoals het 
metaboolsyndroom en hart- en vaatziekten met name in secundaire databases die vaak voor 
andere doeleinden zijn ontwikkeld. De vraag of het verband tussen psoriasis en deze como-
rbiditeiten causaal is, is echter nog niet beantwoord. In dit proefschrift laten we de com-
plexiteit van deze associatie zien en richten onze aandacht met name op het onderzoeken 
van de kwaliteit van leven, depressie en hart- en vaatziekten bij psoriasis patiënten met data 
van verschillende bronnen: apothekersdata, huisartsendata en data van een prospectieve 
populatie-gebaseerde studie.
2. kEnMErkEn vAn PsoriAsisPAtiëntEn
In hoofdstuk 2.1 beschrijven we de kenmerken van psoriasis, de ziekte-ernst en de invloed 
hiervan op de kwaliteit van leven van psoriasispatiënten op basis van gegevens van meer 
dan 190 Belgische dermatologen. Meer dan driekwart van de 3,629 psoriasispatiënten had 
plaque psoriasis gedurende meer dan 16 jaar. Bij een vijfde van de patiënten waren de nagels 
aangedaan, bij 16% waren de genitaliën aangedaan, 15% had gewrichtsklachten en 6.4% 
van de patiënten rapporteerde arthritis psoriatica, gediagnosticeerd door een reumatoloog. 
Ongeveer 80% van de patiënten werd ten tijde van de studie behandeld voor psoriasis, en 
toch was de ziekte-ernst relatief hoog met een gemiddelde Psoriasis Area and Severity Index 
(PASI) van 8.5, een Body Surface Area (BSA) van 12% en matig tot zeer ernstige ziekte volgens 
de Physician’s Global Assessment (PGA) in 37% van de patiënten. Een wezenlijke impact van 
psoriasis op de kwaliteit van leven, volgens de Dermatology Life Quality Index (DLQI) en 
de Skindex-17 werd door 40% van de patiënten gerapporteerd. De gemiddelde European 
Quality of Life-5 Dimensions (EQ-5D) score was vergelijkbaar met de score van patiënten 
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met chronische aandoeningen zoals astma, diabetes en reumatoïde artritis. Patiënten met 
matig tot ernstige ziekte rapporteerden een hogere impact van psoriasis op hun kwaliteit 
van leven vergeleken met patiënten met milde ziekte. Op basis van deze resultaten, kunnen 
we concluderen dat psoriasispatiënten die bij de dermatoloog komen, relatief ernstige ziekte 
hebben en een hoge impact op hun kwaliteit van leven rapporteren.
In hoofdstuk 2.2 hebben we medicatiegebruik vergeleken tussen psoriasispatiënten en con-
troles zonder psoriasis in het Databestand van Nederlandse Huisartsen. We hebben 17,627 
psoriasispatiënten en 17,627 controles gematched voor leeftijd, geslacht en follow-up tijd, 
gevolgd voor een gemiddelde duur van meer dan 4 jaar. We hebben alle medicatievoorschrif-
ten (therapeutische groepen en chemische stoffen) onderzocht en hebben de voorschriften 
in categorieën ingedeeld: (1) medicatie voor symptomen van psoriasis (pijnstillers en emol-
lientia), (2) medicatie voor de behandeling van psoriasis (topicale en systemische middelen), 
(3) medicatie met een verband tot de comorbiditeiten zoals het metaboolsyndroom en 
depressie, en (4) een groep met geneesmiddelen die a priori ongerelateerd zijn aan psoriasis.
Ongeveer 20% van de psoriasispatiënten werd er niet voor behandeld en 8% had matig 
tot ernstige ziekte. De resterende patiënten gebruikten alleen topicale middelen voor psori-
asis. Psoriasispatiënten kregen gemiddeld 9 verschillende geneesmiddelen voorgeschreven 
gedurende de follow-up; dit was significant hoger dan het gemiddelde aantal voorschriften 
bij de controles, namelijk 7. Het aantal jaarlijks voorgeschreven middelen veranderde niet in 
de tijd en was stabiel tot 10 jaar na de psoriasis diagnose. De meest voorgeschreven thera-
peutische hoofdgroepen werden significant vaker voorgeschreven aan psoriasispatiënten. 
Middelen die gerelateerd zijn aan symptomen van psoriasis waren significant hoger bij 
psoriasispatiënten dan bij de controles (odds ratio [OR] 2.17, 95% betrouwbaarheidsinterval 
[BI] 2.07-2.28), met een hogere OR voor psoriasispatiënten met matige tot ernstige ziekte 
vergeleken met patiënten met milde ziekte. De OR van geneesmiddelen gerelateerd aan 
psoriasis comorbiditeiten was 1.46 (95% BI 1.39-1.53) en kwam overeen met de OR van 
geneesmiddelen waarvan a priori verwacht werd dat ze niet geassocieerd zouden worden 
met psoriasis (OR 1.49, 95% BI 1.42-1.57), zoals ophthalmologica (OR 1.33, 95% BI 1.26-1.40), 
neuspreparaten (OR 1.29, 95% BI 1.22-1.36) en laxeermiddelen (OR 1.29, 95% BI 1.14-1.45). 
Deze studie laat zien dat de voorschriften voor heel veel geneesmiddelen verhoogd zijn bij 
psoriasispatiënten. Het verhoogde geneesmiddelgebruik beperkt zich niet tot geneesmidde-
len dit te maken hebben met de behandeling van psoriasis en eventuele comorbiditeiten. Dit 
wijst op een algeheel verhoogde gezondheidsconsumptie bij psoriasispatiënten vergeleken 
met controles.
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3. DEPrEssiEvE syMPtoMEn En klinisCHE DEPrEssiE bij PsoriAsis
In hoofdstuk 3.1 geven we een systematisch overzicht van de literatuur over depressie bij 
psoriasis. Het doel van dit hoofdstuk is om de prevalentie en odds van depressieve sympto-
men en klinische depressie in psoriasis te bepalen in studies met en zonder een controle-
groep. De meerderheid van de geschikte studies werd uitgevoerd in tertiaire centra, zonder 
een controle groep. Uit de vragenlijsten bleek dat depressieve symptomen voorkomen bij 
28% van de psoriasispatiënten. De prevalentie van klinische depressie was 12% volgens de 
International Classification of Diseases (ICD) codes, 19% volgens de Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition (DSM-IV) en 9% van de psoriasispatiënten gebruikte 
antidepressiva. In studies met een controle groep, hadden psoriasispatiënten significant 
meer depressieve symptomen (standardized mean difference [SMD] 1.16, 95% BI 0.67-1.66) 
en populatie-gebaseerde studies toonden aan dat psoriasispatiënten anderhalf keer waar-
schijnlijker te maken krijgen met depressie en vier keer zo vaak antidepressiva gebruiken dan 
controles. Op basis van de uitgevoerde meta-analyse kunnen we concluderen dat psoriasis 
niet alleen invloed heeft op de kwaliteit van leven van patiënten, maar dat 10% van de 
psoriasispatiënten aan een klinische depressie lijdt en meer dan een kwart aan depressieve 
symptomen. De hoge prevalentie van depressieve symptomen in deze meta-analyse kan 
beïnvloed zijn door de tertiaire studiepopulaties en het gebruik van vraaglijsten, waarmee 
psoriasis gerelateerde symptomen als depressieve symptomen worden gedetecteerd.
Hoofdstuk 3.2 is een cohortstudie waarin we apothekersdata en data van ziekenhuisop-
names van meer dan 2.5 miljoen Nederlanders van 1998 tot 2008 hebben gebruikt om 
antidepressivagebruik bij psoriasispatiënten en een referentiepopulatie te onderzoeken. 
25,691 psoriasispatiënten en 128,573 referentiepatiënten werden gevolgd gedurende meer 
dan 9 jaar. De incidentie van antidepressivagebruik was meer dan twee keer zo hoog in de 
psoriasisgroep en de hazard ratio (HR) aangepast voor leeftijd, geslacht en gezondheids-
zorgconsumptie was 1.55 (95% BI 1.50-1.61). Psoriasispatiënten hadden twee keer zoveel 
episodes van antidepressivagebruik vergeleken met de referentiepopulatie, met een aan-
gepaste HR van 1.47 (95% BI 1.43-1.51). Antidepressivagebruik was reeds verhoogd voordat 
psoriasispatiënten medische hulp zochten voor de behandeling van de huid, en bereikte een 
piek rondom de tijd van aanvang van de behandeling van psoriasis. Nadien bleef antidepres-
sivagebruik verhoogd. Binnen het psoriasiscohort hadden psoriasispatiënten 7% meer kans 
om een antidepressivum te krijgen na hun eerste behandeling voor psoriasis. Deze studie 
laat zien dat psoriasispatiënten meer antidepressiva gebruiken dan de algemene bevolking, 
met name rondom de tijd waar zij medische zorg zoeken voor psoriasis en de periode na start 
van de psoriasisbehandeling.
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In hoofdstuk 3.3 onderzoeken we of psoriasispatiënten meer depressieve symptomen en kli-
nische depressie hebben vergeleken met controles afkomstig uit een populatie-gebaseerde 
studie. Deelnemers van de Rotterdam Study werden onafhankelijk van comorbiditeiten ge-
screend voor depressieve symptomen met de Centre for Epidemiological Studies-Depression 
vraaglijst (CES-D). Deelnemers met een score hoger dan 16 (afkapwaarde voor depressieve 
symptomen volgens de vraaglijst), werden geïnterviewd, en depressie werd gecategoriseerd 
volgens de DSM-IV. In totaal werden 296 psoriasis en 7,733 referentiepatiënten geïncludeerd. 
De psoriasispatiënten hadden overwegend milde ziekte en ongeveer een kwart had systemi-
sche- of lichtbehandeling. De mediaan CES-D score en het aantal deelnemers met een score 
boven de 16 was niet verschillend tussen de twee groepen. Er was geen associatie tussen 
psoriasis en een CES-D≥16 (OR 0.99, 95% BI 0.62-1.58). In totaal hadden 20 psoriasispatiënten 
een CES-D≥16 en daarvan ondergingen 15 een interview. Uiteindelijk hadden 3 deelnemers 
een “major” of “minor depressive disorder” en 6 deelnemers hadden depressieve symptomen 
volgens de DSM-IV criteria. Psoriasispatiënten met depressieve symptomen volgens de 
CES-D ontwikkelden niet significant meer klinische depressie vergeleken met deelnemers 
van de referentie groep. In deze populatie-gebaseerde studie, hebben psoriasispatiënten 
met overwegend milde ziekte net zo vaak depressieve symptomen en klinische depressie als 
patiënten zonder psoriasis.
4. ArtEriosClErosE, inflAMMAtiE En CArDiovAsCUlAirE ZiEktE bij 
PsoriAsis
In hoofdstuk 4.1 hebben we de literatuur systematisch doorzocht en een meta-analyse 
uitgevoerd om te bepalen in welke mate systemische inflammatie verhoogd is bij psori-
asispatiënten vergeleken met gezonde controles. We hebben studies geïncludeerd die 
de inflammatoire serum markers interleukin (IL)-1β, IL-6, IL-10, C-reactive protein (CRP), 
intracellular adhesion molecule (ICAM)-1, E-selectin en Tumour necrosis factor-alpha (TNFα) 
hebben onderzocht bij psoriasispatiënten en gezonde controles. Het verschil in gemiddelde 
concentratie van serum markers tussen patiënten en controles, ook standardized mean dif-
ference (SMD) genoemd, werd gepooled voor alle studies volgens het random-effects model. 
78 studies met 7,852 individuen werden geïncludeerd, waarvan 3,085 met psoriasis. 64% van 
de psoriasispatiënten had plaque psoriasis. De geincludeerde patiënten hadden een gemid-
delde PASI van 17.7, en betreft dus een subgroep met ernstig psoriasis. De gepoolde SMDs 
waren hoger in psoriasispatiënten dan in gezonde controles voor IL-6 (1.32), CRP (1.83), TNFα 
(1.32), E-selectin (1.78) en ICAM-1 (1.77). De SMD tussen psoriasis en controles voor IL-1β 
en IL-10 waren niet significant. Leeftijd had een significant effect op de SMD voor IL-6 en 
TNFα; hoe ouder de patiënten in de studie, hoe kleiner de SMD tussen psoriasis en controles, 
mogelijk te verklaren door vermindering van immuniteit met de leeftijd. Bij IL-6, was de SMD 
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hoger voor studies met plaque psoriasis (1.98). De SMD was onafhankelijk van de PASI. Deze 
meta-analyse laat zien dat de proinflammatoire cytokines in de serum van psoriasispatiënten 
met voornamelijk ernstige ziekte, significant, maar alleen licht verhoogd zijn vergeleken met 
controles. Het verschil tussen de serumwaarden bij psoriasis en controles bedraagt hooguit 
2 punten, en is over het algemeen onafhankelijk van leeftijd, geslacht, ziekte-ernst en type 
psoriasis.
In hoofdstuk 4.2 hebben we onderzocht of psoriasis geassocieerd is met hart- en vaat-
ziekten in de populatie-gebaseerde Rotterdam Study. In deze studie worden regelmatig 
cardiovasculaire risicofactoren en maten van subklinische atherosclerose gemeten en 
hart- en vaatziekten geregistreerd, onafhankelijk van comorbiditeiten. In totaal werden 
262 psoriasispatiënten en 8,009 referentiepersonen gevolgd gedurende gemiddeld 11 jaar. 
Van de geïncludeerde psoriasispatiënten had 24% een systemische- of lichtbehandeling. 
Psoriasispatiënten waren significant jonger, rookten meer en hadden hogere diastolische 
bloeddruk en Body Mass Index (BMI) dan de controles. Alle analyses werden aangepast voor 
leeftijd, geslacht, roken, BMI, cholesterol, high-density lipoproteïne, cholesterol, systolische 
bloeddruk, antihypertensiva en diabetes mellitus. De ruwe en aangepaste intima-media 
dikte van de arteria carotis communis, enkel-arm-index, polsgolfsnelheid, en scores voor 
coronaire calcium waren niet verschillend tussen psoriasispatiënten en referentiepersonen. 
Het risico voor incidente hart- en vaatziekte was niet verhoogd voor psoriasis (aangepaste 
HR 0.73, 95% BI 0.50-1.06) volgens de Cox regressie analyse met psoriasis als tijd-afhankelijke 
variabele. Ook het risico van verschillende manifestaties van hart- en vaatziekten, namelijk 
coronaire hartziekte, beroertes, en hartfalen, was niet verhoogd in psoriasispatiënten verge-
leken met controles. De uitkomsten van deze populatie-gebaseerde studie suggereren dat 
psoriasispatiënten met een overwegend milde ziekten geen verhoogd risico hebben op het 
krijgen van subklinische atherosclerose, en dat psoriasis geen onafhankelijke risicofactor is 
voor hart- en vaatziekten.
5. AlGEMEnE DisCUssiE En toEkoMst
In hoofdstuk 5 worden de bevindingen van dit proefschrift besproken en wordt er inzicht 
gegeven in klinische implicaties en toekomstig onderzoek.
In het eerste deel hebben we de relatie tussen psoriasis, kwaliteit van leven, depressieve 
symptomen en klinische depressie onderzocht en concluderen we dat het welzijn van pati-
enten deel moet uitmaken van de behandeling van patiënten met psoriasis.
Het tweede deel van de discussie is gewijd aan de complexiteit van de associatie tussen 
cardiovasculaire risicofactoren, systemische inflammatie, subklinische atherosclerose en 
cardiovasculaire aandoeningen, en laat zien dat we een grote prospectieve cohort studie 
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nodig hebben om de multifactoriële natuur van deze associatie te kunnen doorgronden. We 
concluderen dat het niet noodzakelijk is dat psoriasispatiënten standaard gescreend worden 
op cardiovasculaire risicofactoren en hart- en vaatziekten. Het is echter wel van belang dat 
behandelaars en dermatologen naast aandacht voor de huid, zich bewust zijn van de alge-
mene gezondheid, comorbiditeiten en het welbevinden van hun patiënten.
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HADS, Hospital Anxiety and Depression Scale
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ICAM-1, Intracellular adhesion molecule-1
ICD, International Classification of Diseases
IL-1β, Interleukin-1 beta
IL-6, Interleukin-6
IL-10, Interleukin-10
IMT, Intima-media thickness
MADRS, Montgomery Asberg Depression Rating Scale
MINI, Mini International Neuropsychiatric Interview
PASI, Psoriasis Area and Severity Index
PDI, Psoriasis Disability Index
PGA, Physician’s Global Assessment
PROM, Patient Reported Outcome Measures
PWV, Pulse wave velocity
SAPASI, Self-administered Psoriasis Area and Severity Index
SF-36, Short Form with 36 questions
SSRI, Selective Serotonin Reuptake Inhibitor
TCA, Tricyclic antidepressant
TNFα, Tumor necrosis factor-alpha
Zung-SDS, Zung Self-rating Depression Scale
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